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Zusammenfassung  I 
Zusammenfassung 
 
Die Entwicklung und die funktionelle Charakterisierung von Immunglobulin (Ig) Präparaten, die 
aus menschlichem Blutplasma gewonnen werden, sind von hoher klinischer Relevanz für die Therapie 
von Patienten, die an Antikörpermangel, Autoimmun- oder an Entzündungserkrankungen leiden. 
Gegenwärtig werden hauptsächlich intravenös verabreichte Immunglobulin G (IgG) Präparate (IVIgs) 
zur Behandlung eines breiten Spektrums pathologischer Zustände, wie primärer und sekundärer 
Immundefekte (PID; SID), aber auch zur Immunmodulation eingesetzt. Dennoch besteht die 
Notwendigkeit, eine effizientere Ausnutzung des Plasmas zu erreichen sowie die Wirksamkeit 
polyklonaler Ig-Präparate zu verbessern, ohne den Plasmabedarf zu erhöhen. Insbesondere Fraktionen, 
die IgA- und IgM-Moleküle enthalten, können aufgrund ihrer vielseitigen pharmakologischen Effekte 
vorteilhaft sein und therapeutisch genutzt werden.  
Trimodulin (Wirkstoffname, welcher der Abgrenzung zu einem Standard-IVIg-Präparat dient) ist 
ein neues Ig-Präparat aus menschlichem Blutplasma, für die intravenöse Anwendung und ist in seiner 
Zusammensetzung einzigartig, da es im Vergleich zu den bisher auf dem Markt verfügbaren Standard-
IVIg-Präparaten neben IgG auch definierte Mengen an IgM- sowie IgA-Molekülen enthält. Es wurde für 
die Behandlung von Patienten mit schweren Infektionen entwickelt und bereits in einer klinischen 
Phase II Studie (CIGMA Studie) getestet, in der ein vielversprechendes Potenzial für die Therapie von 
Patienten mit schwerer ambulant erworbener Lungenentzündung (sCAP) nachgewiesen werden konnte. 
Aufgrund der Neuheit und der Komplexität des Ig Präparates, das neben IgG auch IgM und IgA Moleküle 
enthält, besteht jedoch Bedarf an einem detaillierteren Verständnis der komplexen Wirkungsweise von 
Trimodulin, sowohl hinsichtlich seiner antimikrobiellen als auch seiner immunmodulatorischen 
Eigenschaften. Insbesondere das Komplementsystem ist ein wichtiges Werkzeug des humoralen 
Immunsystems, da seine Aktivierung über verschiedene Effektorfunktionen zur Abtötung eindringender 
Krankheitserreger führt. Es kann allerdings auch schädlich für den Wirt sein, wenn das Immunsystem 
überaktiviert ist und zu Gewebeschäden sowie zu multiplem Organversagen führen. Daher ist es wichtig, 
dass die Aktivierung sowie die Hemmung des Komplementsystems ausbalanciert sind. Es wurde die 
Hypothese aufgestellt, dass Trimodulin eine ambivalente Wirkung hinsichtlich der 
Komplementaktivierung aufweist, um die Neutralisierung eindringender Mikroorganismen zu 
gewährleisten, aber auch um den Wirt vor Entzündungsreaktionen zu schützen, die durch ein 
überaktiviertes Immunsystem verursacht werden können.  
Um zu überprüfen, ob die Aktivierung des Komplementsystems gehemmt werden kann, wurde die 
Bindung von Trimodulin an aktivierte Komplementfaktoren (C3b, C4b, C5a und C3a) in ELISA Tests 
untersucht. Es wurde gezeigt, dass Trimodulin sowohl mit C3b- als auch mit C4b-Molekülen interagieren 
kann, indem es diese bindet sowie überlagert. Die Zugabe einer IVIg-Kontrolle (Intratect) zeigte nur 
geringe Effekte und die Abnahme der C3b sowie C4b Detektion war nach Gabe des IgM- und IgA-
angereicherten Präparats deutlich erhöht. Darüber hinaus zeigte sich ein Trend zur Verringerung der 
C5a Detektion nach Trimodulin Gabe, wohingegen keine Interaktion von Trimodulin mit aktivierten 
C3a-Molekülen nachgewiesen werden konnte. Des Weiteren wurde mit Hilfe eines 
komplementabhängigen Zytotoxizitätstests (CDC) untersucht, ob Trimodulin die Aktivierung des 
Komplementsystems auch funktionell verhindern kann. Daher wurde die komplementabhängige 
Zytotoxizität von Zielzellen (Ramos-Zelllinie) nach Zugabe von Trimodulin gemessen, wobei eine 
deutliche Reduktion der Zytotoxizität von Ramos-Zellen festgestellt werden konnte. Diese Ergebnisse 
zeigten erstmalig, dass Trimodulin dazu in der Lage ist, aktivierte Komplementfaktoren zu hemmen, was 
zur Verhinderung von Entzündungsreaktionen bei Patienten mit einer überstimulierten Immunantwort 
eingesetzt werden könnte. Darüber hinaus zeigten die Ergebnisse ebenfalls deutlich die Vorteile der 
Verwendung von Trimodulin zur Reduzierung der Überstimulation des Komplementsystems, gegenüber 
einem Standard-IVIg-Präparat auf, welches keine verminderte Zytotoxizität in diesem Test bewirkte. 
Weiterführend wurden zwei Opsonophagozytose-Tests (OPAs) entwickelt, um zu analysieren, ob 
Trimodulin, welches neben IgG und IgA auch ⋲ 23% IgM enthält, dazu in der Lage ist, das 
Komplementsystem zu aktivieren und die Opsonophagozytose von Krankheitserregern zu induzieren. 
Generell können IgM Moleküle das Komplementsystem im klassischen Weg deutlich effektiver aktivieren 
als IgG Moleküle. Der Opsonophagozytose-Test, der mit lebenden E. coli Bakterien durchgeführt wurde, 
  
 
II Zusammenfassung 
war allerdings nicht dazu geeignet die Aktivierung des Komplementsystems und die damit verbundene 
Einleitung der Opsonophagozytose durch Trimodulin zu zeigen. Es wurde ausschließlich die IgG-
vermittelte Phagozytose der Bakterien detektiert. Weiterhin wurde vermutet, dass dies auf eine starke 
unspezifische Abtötung durch die verwendete Komplementquelle zurückzuführen ist, die auch in 
Abwesenheit von Trimodulin eine große Anzahl an E. coli Bakterien neutralisierte. Aus diesen Gründen 
wurde ein zweiter Opsonophagozytose-Test unter Verwendung von S. aureus Biopartikeln etabliert und 
die Fähigkeit von Trimodulin Opsonophagozytose einzuleiten, in einem Durchflusszytometer (FACS) 
evaluiert. Die Analyse zeigte, dass Trimodulin dazu in der Lage war, das Komplementsystem 
konzentrationsabhängig zu aktivieren und dadurch die Opsonophagozytose von S. aureus Biopartikeln 
durch Effektor Zellen (HL-60-Zelllinie) in niedrigen Konzentrationen auszulösen. Zusätzlich wurde 
festgestellt, dass Trimodulin in hohen Dosen auch im Opsonophagozytose-Test das Komplementsystem 
hemmte.  
Die Ergebnisse dieser Doktorarbeit unterstützen die Theorie, dass Trimodulin eine ambivalente 
Wirkung hinsichtlich der Komplementaktivierung besitzt und stehen im Einklang mit verschiedenen 
Studien, die ebenfalls duale Mechanismen von Ig-Präparaten hinsichtlich der Aktivierung und der 
Hemmung des Komplementsystems zeigen. Darüber hinaus wird vermutet, dass die Behandlung mit 
Trimodulin dazu beitragen könnte, Entzündungsreaktionen, die durch eine Überstimulation des 
Komplementsystems verursacht werden, zu reduzieren und gleichzeitig die Neutralisierung schädlicher 
Krankheitserreger sicherzustellen. Des Weiteren gibt die Arbeit durch die Bestätigung der Aktivierung 
sowie Inhibierung des Komplementsystems durch Trimodulin neue Einblicke in dessen Wirkungsweise 
und zeigt entscheidende Vorteile der Verwendung eines IgM- und IgA-angereicherten Präparats im 
Vergleich zu einem Standard-IVIg-Präparat auf.  
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Abstract 
 
The development and the functional characterization of human plasma-derived immunoglobulin 
(Ig) preparations are of high clinical relevance for the therapy of patients who suffer from antibody 
depletion, autoimmune or inflammatory disorders. Currently, mainly intravenous immunoglobulin G 
(IgG) preparations (IVIgs) are in use to treat a broad range of pathological conditions, like primary and 
secondary immunodeficiencies (PID; SID), but also for immunomodulation. Nevertheless, there is a need 
to improve the exploitation of the plasma as well as the efficacy of polyclonal Ig preparations without 
an increase in plasma demand. Especially fractions containing IgA and IgM molecules may be 
advantageous, because of their versatile pharmacological effects that could be exploited therapeutically. 
Trimodulin (name of the active substance, for differentiation from a standard IVIg preparation) is 
a new plasma-derived Ig preparation for intravenous application and is unique, as it contains besides 
IgG also defined amounts of IgM as well as IgA molecules compared to currently available standard IVIg 
preparations. It was developed for the treatment of patients with severe infections and was already tested 
in a phase II clinical trial (CIGMA study), where a promising potential in the therapy of patients with 
severe community-acquired pneumonia (sCAP) could be demonstrated. Based on the novelty and 
complexity of this Ig preparation that contains besides IgG also IgM as well as IgA molecules, there is 
still a need for a detailed understanding of the complex mode of action (MoA) of trimodulin regarding 
its antimicrobial as well as its immunomodulatory mechanisms. Particularly the complement system is 
an important tool of the humoral immune system, because its activation leads to the killing of invading 
pathogens via various effector functions. Nevertheless, it can also be harmful to the host when the 
immune system is over-activated and can lead to tissue damage as well as multiple organ failure. 
Therefore, it is important that the complement system is balanced between activation and inhibition. It 
was hypothesized that trimodulin exhibits an ambivalent effect regarding complement activation to 
ensure the neutralization of invading microorganisms but also to protect the host against inflammation 
caused by a hyper-activated immune system.  
In order to evaluate the ability to inhibit complement activation, the binding of trimodulin to 
activated complement factors (C3b, C4b, C5a and C3a) was analyzed in ELISA settings. It was 
demonstrated that trimodulin is able to interact with C3b as well as C4b molecules by binding and an 
overlay of these complement factors. The addition of an IVIg control (Intratect) showed only slight 
effects and the decrease in the detection of C3b as well as C4b was obviously stronger with the IgM- and 
IgA-enriched preparation. Moreover, a trend in reducing the detection of C5a with trimodulin was 
revealed, whereas no interaction of trimodulin with activated C3a molecules could be demonstrated. 
Furthermore, a complement-dependent cytotoxicity (CDC) assay was used to analyze if trimodulin can 
even functionally prevent complement activation. Therefore, the CDC of target cells (Ramos cell line) 
was measured after addition of trimodulin and an obvious reduction in the CDC of Ramos cells was 
detected. This demonstrated for the first time that trimodulin is able to inhibit activated complement 
factors, which could be used to prevent inflammation in patients with an over-stimulated immune 
response. Furthermore, the results clearly showed the benefit of using trimodulin to prevent the over-
stimulation of the complement system, over a standard IVIg preparation that was not able to reduce the 
CDC in this assay. 
In order to analyze if trimodulin, which contains besides IgG and IgA also ⋲ 23% IgM, is able to 
activate the complement system and to induce the opsonophagocytosis of pathogens, two 
opsonophagocytosis assays (OPAs) were developed. In general, IgM molecules are able to activate the 
complement system via the classical pathway more effectively than IgG molecules. The OPA using living 
E. coli bacteria unfortunately did not depict the opsonophagocytic capacity of trimodulin, but showed 
only the IgG-mediated phagocytosis of the bacteria. This was assumed to be due to a high non-specific 
killing of the used complement source, which destroyed high amounts of E. coli bacteria even in the 
absence of trimodulin. For this reason, a second OPA was established by using S. aureus bioparticles and 
the opsonophagocytic capacity of trimodulin was evaluated in a fluorescence-activated cell sorter 
(FACS). The analysis showed that trimodulin was able to activate the complement system concentration-
dependently and thereby to trigger the opsonophagocytosis of S. aureus bioparticles by effector cells 
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(HL-60 cell line) in low concentrations. Additionally, it was detected that even in the OPA setting 
trimodulin was able to inhibit the complement system in high doses. 
The results of this PhD thesis obviously support the theory that trimodulin exhibits an ambivalent 
effect regarding complement activity and are in accordance with various studies that also show dual 
mechanisms of Ig preparations in activating and inhibiting the complement system. Moreover, it is 
assumed that the treatment with trimodulin could help to reduce inflammation caused by an over-
stimulation of the complement system and simultaneously ensuring the neutralization of harmful 
pathogens. Furthermore, the PhD thesis gives new insights in the MoA by confirmation of the 
complement activating as well as inhibitory capacity of trimodulin and emphasizes the crucial 
advantages of using an IgM- and IgA-enriched preparation compared to a standard IVIg preparation.  
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Introduction   1 
1. Introduction 
 
1.1. The human immune system  
 
The primary function of the immune system is to protect the host against invading pathogens that 
are harmful to the body, like bacteria, viruses, parasites and fungi. It is a network of cells, tissues and 
organs to control and eliminate such disease-causing organisms. By using a complex array of protective 
mechanisms, it is able to detect specific structural features (antigens) of the pathogens and can therefore 
distinguish between self and non-self. This is a very important function, to avoid excessive damage to 
the body’s own tissues and cells1,2. Generally, the immune system is divided into the innate and the 
adaptive immune responses. Both parts stay in constant interaction by using an elaborate communication 
network. The innate immune response is the early first line of defense against invading microbes. 
Involved cell types react quickly and include macrophages, dendritic cells, natural killer cells, 
granulocytes and mast cells. They are able to recognize pathogenic structures in an unspecific way and 
react to signaling molecules released by the body. Epithelial barriers, soluble proteins and bioactive small 
molecules (e.g. complement proteins or cytokines) also belong to the innate immune system. It causes 
inflammation by eliminating infectious agents, but also helps to activate the cells of the adaptive arm. 
This part of the immune system exhibits highest specificity for its targets, but reacts slower than the 
innate response. The main cell types of the adaptive immune system are B and T lymphocytes, which 
express antigen-specific receptors on their surfaces. The major functions of the T cells are the killing of 
pathogens and infected cells as well as the control of the adaptive response. B cells primarily secrete 
antibodies that attach to the infectious agents. Once exposed to an antigen, the adaptive arm forms 
immunological memory, ready to remember specific pathogens for the next infection3. 
The two arms of the immune system are often described as distinct mechanisms, but they usually 
act together. An important example of the elaborate collaboration of the innate and adaptive arm is the 
clearance of immune complexes by the complement system and antibodies that bind specifically to a 
certain pathogen. The synergy of both parts of the immune system is a fundamental process that is 
necessary for a functional immune response4,5. 
 
1.2. The complement system 
 
The complement system is a tightly regulated network of more than 30 soluble and membrane-
associated proteins that provides a first-line defense against invading microorganisms6,7. It was 
discovered as heat-sensitive component of normal plasma that complements the antibacterial activity of 
antibodies. However, today it is well established that it can be activated early in infection even in the 
absence of antibodies. As part of the non-specific humoral immune response, it is rapid and efficient in 
protecting the host through the immediate activation of components that are present in the blood as 
inactive proenzymes, called zymogens. Although it belongs to the innate immunity, it influences the 
adaptive arm by the interaction with cell surface receptors of immune cells as well as by augmenting the 
opsonization of bacteria through antibodies. Therefore, it is an important effector component of both, 
the innate and the adaptive immune system8–11.  
The complement proteins react in a cascade like manner with one another and are activated by 
proteolytic cleavage at site of infection, where they induce inflammatory events to help immune cells 
fighting pathogens and maintain homeostasis. This enzymatic cascade proceeds by the cleavage of a 
zymogen precursor, which becomes an active enzyme by itself and goes on with the activation of the 
next complement zymogen in the pathway. Hence, the cascade amplifies itself and leads to a large 
cytolytic and inflammatory response to infectious organisms12. This is caused by the generation of 
proinflammatory mediators like C3a and C5a, so-called anaphylatoxins, by opsonization of pathogenic 
surfaces with complement opsins, like C3b and C4b and by the formation of the membrane attack 
complex (MAC), which is the terminal component of the cascade and leads to the lysis of targeted cells13. 
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1.2.1. Mechanisms of activation 
 
The complement system can be activated via three different pathways: the classical, lectin and 
alternative pathway (Figure 1)7,12.  
The classical pathway is antibody dependent and starts with the recognition of a pathogen or a 
foreign antigen by IgG or IgM. This emerging immune complex triggers the activation of the first 
complement component, the C1 complex11. It consists of one C1q molecule as well as two molecules of 
the serine proteases C1r and C1s and binds to the Fc portion of the Igs attached to pathogenic surfaces. 
Thus, the serine proteases are autocatalytically activated and in turn cleave their substrates C4 and C2 
into the fragments C4b, C4a and C2b, C2a. C4b, which is covalently bound to the surface of the pathogen, 
assembles with the serine protease C2b and leads to the generation of the C3 convertase. The consequent 
cleavage of the C3 molecule forms the opsonin C3b and the anaphylatoxin C3a and marks the point at 
which the three complement pathways converge. With the production of C3b molecules and their 
deposition on the pathogenic surface, the microorganisms are effectively opsonized and further 
complement activation takes place. In contrast, the generation of C3a leads to local inflammatory 
responses13,14. The C3b molecule then interacts and assembles with the C3 convertase and therefore 
induces a change in the specificity regarding the cleavage preferences. It is now able to bind and cleave 
the C5 molecule and therefore generates the C5b fragment and the anaphylatoxin C5a. C5b is responsible 
for the recruitment of the terminal factors C6, C7, C8 and C9 of the cascade. All these components build 
together the MAC C5b-9 that forms pores into the membrane of the pathogens, leading to subsequent 
lysis15. It is well established that IgM is more efficient in activating the complement system than IgG. In 
general, C1q needs two or more IgG molecules in a specific distance to each other for activation of the 
complement cascade, because of low binding affinity to some IgG subclasses. The energy that is required 
for C1q activation is only achieved by the binding of two or more IgG molecules. Compared with this, 
just one pentameric IgM molecule, comprising 10 antigen-binding sites, bound to the surface of a 
microorganism, is sufficient for classical pathway activation. IgA, IgD and IgE have not the ability to 
activate the complement system via the classical effector arm12.  
As the classical pathway needs C1q for activation, the lectin pathway requires a similar molecule, 
called mannose-binding lectin (MBL), which is composed of globular lectin domains and collagen-like 
arms. This protein binds directly to foreign cells and recognizes mannose residues on microorganism 
surfaces. It is also capable of binding to IgA on the surface of microorganisms, thereby activating the 
lectin pathway16. In addition, ficolins resemble C1q and can activate the lectin pathway as well. The 
MBL-associated serine proteases (MASP), MASP-1 and MASP-2, can in turn bind to MBL and ficolin 
molecules and autoactivate when these complexes bind to a foreign cell. This in turn leads to the cleavage 
of classical pathway components. Homologous to C1s, MASP-2 is responsible for the C4 and C2 
fragmentation, while MASP-1 cleaves C38,17,18. After that, the following steps of the complement cascade 
are indistinguishable from the classical effector arm.  
In comparison to the activation of the classical and lectin pathway, the alternative pathway does 
not require specific binding to a foreign protein. The pathway starts with the spontaneous hydrolysis of 
factor C3 to C3(H2O) that associates with the serine protease complement factor B. Another component, 
factor D, then proteolytically cleaves factor B to Bb and Ba. Bb stays in complex with C3(H2O) and is a 
serine protease. It cleaves C3 into C3b, which binds to factor B and generates more C3 convertases. This 
amplification loop is stabilized by the serum protein properdin, which also enhances the reaction. The 
generation of more C3b fragments then leads to the assembly of the C5 convertase, C3bBbC3b. After 
that, the progress of the alternative pathway is homologous to the MAC formation in the classical 
pathway15,19. In addition, Hiemstra et al. described the formation of a C3/C5 specific convertase after 
the incubation of alternative pathway components C3, factor B and D as well as Properdin with deposited 
IgA. These results revealed that IgA is also capable of activate the complement pathway via the 
alternative arm20. 
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Figure 1 Overview of the complement cascade. The complement system can be activated via the classical, lectin and alternative 
pathway. The binding of C1q to its ligands, such as immune complexes, triggers classical pathway activation. The lectin pathway 
is activated by the binding of MBL ficolins or collectins to a pathogen. Activation of the alternative pathway occurs 
spontaneously and is initiated by the hydrolysis of factor C3 to C3(H2O). All pathways converge at the point of C3 activation 
that is cleaved into the opsin C3b and the anaphylatoxin C3a. C5 convertases lead to the formation of C5a as well as C5b. The 
latter generates together with C6-9 the MAC, which in turn forms pores into the membrane and lyses the target cells21. CR = 
complement-receptor; FI = factor I; MAC = membrane attack complex; MASP = MBL-associated serine proteases; MBL = 
mannose-binding lectin; PAR = protease-activated receptor. 
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1.2.2. The complement system and inflammation 
 
The activation of the complement cascade leads to a variety of antimicrobial functions to protect 
the host from pathogens that are harmful to the body6,9,11,22,23. However, this activation can also induce 
inflammatory reactions due to the generation of powerful immune effectors, like the anaphylatoxins C5a 
and C3a. Already low concentrations of these factors are enough to induce acute inflammation and 
anaphylactic reactions24. C3a and C5a are released after the cleavage of C3 and C5 with their specific 
convertases and are able to activate immune cells and non-myeloid cells that express the specific 
anaphylatoxin receptors (C3aR and C5aR) on their surfaces23. These receptors can be found on 
leukocytes, macrophages, mast cells, hepatocytes, lung epithelial cells, endothelial cells, astrocytes and 
microglial cells25. C3a and C5a are the most extensively studied anaphylatoxins and show a great array 
of biological activities22. They induce the chemotaxis of phagocytes (neutrophils, eosinophils and 
monocytes) to the site of infection, thereby activating the effector cells and inflammatory mediators, like 
cytokines, lysosomal proteases and reactive oxygen species (ROS) are released6,26. These events lead to 
smooth muscle contraction, increased vascular permeability and cause inflammatory cell migration. 
Moreover, C3a and C5a can induce histamine release by mast cells, leading to vasodilation and 
extravasation of fluid23,27. In addition, the binding of the anaphylatoxins to effector cells (e.g. 
macrophages, mast cells, B and T lymphocytes) leads to the generation of cytokines, which in turn 
induces an amplification of the inflammatory response. This interplay between the complement system 
and proinflammatory cytokines can also lead to an enhanced anaphylatoxin receptor expression on 
inflammatory cells27,28. In case of excessive complement activation, all the indicated mechanisms can be 
harmful to the host and lead to tissue damage and multiple organ failure9,24,26,29.  
The anaphylatoxins show differences in their biological activity: C5a is the most active and stable 
anaphylatoxin, whereas C3a is up to 200-times less potent12. In addition, C5a exhibits a stronger 
chemotactic influence on phagocytic cells at already very low concentrations. Both anaphylatoxins are 
quickly converted into C3a-desArg and C5a-desArg after generation in plasma. This is performed by 
carboxypeptidase N and B, which cleave the C-terminal arginine. Differences to C3a and C5a are a 
weaker proinflammatory activity of C5a-desArg and the inability of C3a-desArg to bind to the C3aR22,23. 
Furthermore, there are evidences that C3a can also exhibit anti-inflammatory activities as an antagonist 
to C5a. It seems that C3a can react dichotomous to an injury or inflammatory infections, depending on 
particular conditions. On the one hand, C3a is able to prevent neutrophil migration and accumulation 
in an acute setting of inflammation, thus leading to reduced inflammation. On the other hand, in chronic 
phases of inflammation, the proinflammatory actions of C3a are triggered. This dual role of C3a seems 
also to be dependent of the involved cell types and is important for the development of 
therapeutics23,30,31. Nevertheless, deregulated complement activity contributes to the pathogenesis of a 
number of chronic inflammatory diseases. Excessive activation or insufficient control are key mediators 
for an immune imbalance between inflammatory cells, complement system and tissue damage that lead 
to hypersensitivity reactions, respiratory distress syndrome, neurodegenerative diseases, endotoxic shock 
and multiple organ failure24,26,32–34. 
 
1.2.3. Inhibition of the complement system 
 
The complement system has to be tightly regulated, in order to prevent undesired as well as 
indiscriminated effects that are harmful to host cells. Pro-inflammatory mechanisms mainly induced by 
anaphylatoxins can damage host tissues and cells, when the immune system is over-stimulated, due to 
uncontrolled activation of the complement system. Therefore, it is necessary to control complement 
activation by a variety of membrane-bound and soluble inhibitors. This ensures that healthy host surfaces 
are not affected by uncontrolled attacks of the complement system, but at the same time permits the 
efficient activation to defense foreign targets35. An important modulator of the complement response is 
the C1 inhibitor (C1INH), which is able to bind and to inactivate the two molecules C1r and C1s of the 
classical pathway. It can also inhibit MASP-1 and MASP-2 of the lectin pathway irreversibly. The key 
regulators for the alternative pathway are complement factor H (CFH) and complement factor I (CFI) 
that interact with the factors C3b as well as C4b. As a plasma serine protease, CFI degrades C3b to iC3b 
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and further into C3dg as well as C3c, with the help of specific cofactors. It is also able to cleave C4b and 
the C3 convertase C4b2a, whereas CFH induces the dissociation of the C3bBb convertase into C3b and 
Bb and therefore downregulates the alternative pathway. The regulation of the terminal MAC is 
controlled by vitronectin (protein S), which inhibits the polymerization of C5b-7 and clusterin that 
prevents the insertion of this complex into cell membranes. Moreover, CD59 is the key modulator of the 
terminal pathway, which prevents the C5b-9 formation by blocking the C9 incorporation into C5b-836–
38.  
However, insufficient regulation of the complement cascades can lead to a number of 
inflammatory and autoimmune diseases39. Therefore, it is important to discover new drugs that are not 
only able to activate but also to inhibit as well as modulate the complement system. The development 
of drug candidates can be divided into different categories regarding their function: protease inhibitors, 
soluble complement regulators, therapeutic antibodies, complement component inhibitors and receptor 
antagonists. In general, it is important to specifically target particular factors for each indication and to 
preserve immunomodulatory as well as defensive mechanisms of complement40. 
 
1.3. Immunoglobulins 
 
Igs are heterodimeric glycoproteins, produced and secreted by plasma cells41,42. They can be 
divided into natural and adaptive antibodies, due to their different origin42. Natural antibodies (mostly 
IgM) are spontaneously produced without antigen exposure, are polyreactive and the first line of defense 
in a newborn organism. Compared to this, adaptive Igs are produced by B2 B-cells after the binding of 
an antigen to a B-cell receptor (BCR) and are specific to this certain antigen43. 
In general, Igs are roughly Y-shaped molecules, consisting of two large heavy and two small light 
chains connected by disulfide bonds as well as noncovalent interactions (Figure 2). Moreover, they are 
separated in a NH2-terminal variable domain, where antigen binding occurs and COOH-terminal 
constant regions for effector functions, like complement activation or Fc receptor binding41. The region, 
where the antigen binding takes place, is also called Fab-domain and differs from the Fc-domain, where 
the effector functions are triggered. A flexible polypeptide chain, called the hinge-region, joins the Fab 
and the Fc domain. In addition, the light chains consist either of a kappa or lambda chain and contain 
one variable (VL) and one constant domain (CL), whereas the heavy chains exhibit one variable (VH) 
and three or four constant regions (CH)44. The five different Ig isotypes with their specific functions are 
determined by the structure of the heavy chains (alpha, gamma, delta, epsilon or mu) and can be divided 
into IgA, IgG, IgD, IgE and IgM45. 
 
Figure 2 Basic structure of an Ig, depicted by IgG. Igs consist of two heavy (dark blue) and two light chains (light blue). Each 
chain has amino terminal variable regions (Fab-domain), where antigen binding occurs and carboxyl terminal constant regions, 
where effector functions are triggered (Fc-domain). The light chain has one variable region (VL) and one constant region (CH), 
whereas the heavy chain is composited of one variable region (VH) and three constant regions (CH1-3). The Fab and the Fc 
domain are linked by a flexible hinge-region with disulfide bonds. Light and heavy chains are also connected by disulfide 
bonds41,44.  
COOHCOOH
Fc-domain
Fab-domain
Hinge-region
CH2
CH3
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1.3.1. Immunoglobulin G 
 
IgG is the predominant isotype found in human serum and the most extensively studied Ig class. 
The molecular weight of IgG is approximately 150 kDa and the serum concentration amounts to 
9 mg/mL. Moreover, it has the longest half-life among all Ig isotypes. Due to differences in the structure 
and function of the heavy chains, it is divided into four subclasses (IgG1, IgG2, IgG3 and IgG4), each 
triggering specific responses to an antigen42,46. In general, the most important effector functions of IgG 
are caused by the activation of the complement system and the binding to Fc-γ receptors (FcγR). FcγRs, 
which are found on B cells as well as most innate immune cells, are distinguished by their structure in 
FcγRIII (CD16), FcγRII (CD32) as well as FcγRI (CD64) and specifically bind to the Fc-domain of IgG47. 
The subclasses IgG3 as well as IgG1 bind to all Fc-γ receptors. IgG4 is able to bind to FcγRII and III and 
IgG2 exclusively to FcγRII41. Concerning complement interaction, IgG4 is the only subclass that is not 
able to activate the complement system, whereas the affinity for C1q of the classical complement 
pathway is highest for IgG3, followed by IgG1 and IgG2. Moreover, the most well-known effector 
functions, mediated by the Fc-domain of IgG are antibody-dependent cell-mediated cytotoxicity (ADCC), 
antibody-dependent cellular phagocytosis (ADCP) and CDC, which also link the innate and the adaptive 
immune responses48. IgG1 is the most abundant antibody subclass and the primarily isotype that reacts 
to soluble and membrane-bound protein antigens. In addition, a deficiency of IgG1 causes 
hypogammaglobulinemia, where the level of total IgG is decreased49. The main function of IgG2 is the 
binding to bacterial capsular polysaccharide antigens, whereas IgG3 induces mainly effector functions 
and is a pro-inflammatory antibody with a relatively low half-live. Additionally, viral infections mostly 
cause the production of IgG3 and IgG1. Finally, IgG4 antibodies are often generated after repeated or 
long-term exposure to an allergen and are the primarily isotype that responses due to therapeutic 
proteins (e.g.FVIII)46,50. Next to the induction of effector functions, IgG molecules are also able to 
neutralize toxins as well as viruses directly and are therefore potent mediators of host protection41.  
  
1.3.2. Immunoglobulin A 
 
IgA is the predominant antibody found in secretions on mucosal surfaces. It is produced in high 
amounts by a remarkable energy consumption, which suggests that it is of high relevance for the immune 
defense51. Monomeric IgA, which is divided into the subclasses IgA1 and IgA2 in humans, is located in 
the serum and has a molecular weight of approximately 160 kDa. With a concentration of 2-3 mg/mL, 
it is the most abundant Ig in serum, after IgG. The secretory form of IgA is mainly dimeric, stabilized 
through disulfide linkages as well as a joining chain (J-chain) and has approximately 385 kDa42. It is 
transported to mucosal surfaces by the binding to the polymeric Ig rector (pIgR), which is expressed on 
the basolateral surface of epithelial cells, thereby receiving the extracellular part of the pIgR, known as 
secretory component52. The main function of IgA is to protect the mucosal barrier from pathogens like 
bacteria as well as viruses and exhibits strong anti-inflammatory properties in the secreted form53. It is 
able to prevent the attachment to host cells by the direct binding to pathogens and the associated 
neutralization as well as blocking of their activation. Moreover, secretory IgA can also inhibit the 
entrance of pathogens to the intestinal lumen by immune exclusion, a process by which the accessibility 
of epithelial receptors is prevented54. In addition, the pIgR can transport immune complexes composed 
of polymeric IgA and the specific pathogen that are formed in the lamina propria by transocytosis into 
the lumen52. However, IgA can also lead to inflammatory mechanisms, by its immune activating 
functions and the binding to specific receptors55. The Fcα receptor I (FcαRI), also known as CD89, is a 
mediator of effector functions induced by the binding of clustered IgA on the surface of a pathogen. It is 
expressed on neutrophils, monocytes, eosinophils as well as some macrophages and dendritic cells56,57. 
The binding can lead to the phagocytosis of target cells, the release of cytokines, the production of 
activated oxygen species and the initiation of ADCC52. Moreover, IgA does not activate the complement 
system via the classical pathway. It can only induce activation by triggering the lectin and the alternative 
pathway, but this does not seem to be a major effector mechanism of IgA16,20. In general, it is a poor 
activator of the complement system and there is evidence that IgA can even inhibit complement 
activation induced by IgG or IgM antibodies in an environment with less antigen58.  
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1.3.3. Immunoglobulin M 
 
IgM is the first antibody that is produced in response to infectious antigens. The monomeric form 
of IgM is present on naïve B lymphocytes and serves as B cell receptor with a molecular weight of 
180 kDa. Compared to this, the secreted form is found mainly as a pentamer and occasionally as a 
hexamer, has a molecular weight of approximately 970 kDa and an average serum concentration of 
1.5 mg/mL42,59. The pentamer is composed of 5 monomers linked by disulfide bonds and a J-chain. This 
specific structure leads to the availability of 10 antigen binding sites that exhibit a relatively low affinity, 
but a wide range of avidities. Additionally, the high valency allows IgM to bind to pathogens more 
efficiently than other Igs and this facilitates agglutination, which is an important mechanism for antigen 
neutralization by providing phagocytosis and the clearance of pathogens. Moreover, the majority of IgM 
is polyreactive60. In general, IgM is able to block pathogens from binding to targets cells (direct 
neutralization), but not as effective as IgG or IgA. However, the polymeric character makes IgM a potent 
activator of complement, because one single molecule is able to activate the classical pathway61. 
Compared to this, C1q needs two or more IgG molecules in a specific distance to each other, to become 
activated. This is an important function of IgM, because complement activation links the innate and the 
adaptive immune response and leads to pathogen opsonization as well as neutralization. IgM can also 
modulate effector functions by binding to its recently discovered Fcµ receptor (FcµR). This receptor is 
expressed on B, T as well as natural killer cells (NK cells), but is not present on monocytes, granulocytes, 
erythrocytes, and platelets62. In general, FcµR binds IgM attached to membrane components by its Fab 
domain more efficiently than free IgM. Furthermore, it is assumed that the Fcµ receptor activated by 
IgM, plays a role in B and T cell regulation63–65. In addition, IgM is able to contribute to the mucosal 
immunity, by binding to the pIgR and the associated transport to mucosal surfaces66. Due to its multiple 
functions, IgM plays an important role in early immunity but also in the long-term protection against 
various pathogens60. 
 
1.4. Immune effector cells  
 
It is essential for the host immunity to recognize and neutralize pathogens that are harmful to the 
body. Effector functions caused by the activation of specific immune cells (e.g. phagocytes, NK cells, 
mast cells) are of high relevance, besides the direct inhibition by antibodies or the cellular cytotoxicity 
caused by the activation of the complement system in response to invading microorganisms. Immune 
effector cells exhibit the potential to capture and destroy pathogens by mechanisms like phagocytosis, 
degranulation or intracellular degradation, but can also mediate inflammation. They are attracted by a 
stimulus and actively respond to it2,67.  
 
1.4.1. Neutrophil granulocytes 
 
Neutrophils are the major pathogen-fighting immune cells and the most abundant cell type in the 
blood68–70. Besides eosinophils and basophils, they are one type of granulocytes, which belong to the 
white blood cells and are also known as polymorphonuclear cells (PMNs). Their primarily function is 
the killing of pathogens and the protection of the host as first line of defense of the innate immune 
system. During a bacterial infection, they are generated at a rate of 1012 per day68. Neutrophils exhibit 
three antimicrobial functions, thereby linking the innate and the adaptive immunity: phagocytosis, 
degranulation as well as the release of extracellular neutrophil traps (NETs). Phagocytosis is the process 
by which an opsonized pathogen is ingested into the vacuole of a phagocyte and is destroyed at low pH 
and by specific enzymes, after the formation of a phagolysosome. In neutrophils this process is very 
rapid, compared to the phagocytosis induced by other immune cells (e.g. macrophages)70. Additionally, 
ROS are generated by the activation of a NADPH oxidase during phagocytosis by neutrophils. They are 
released into the phagolysosome as well as to the outside of the neutrophils, where they can also affect 
neighboring cells. ROS is suggested to kill pathogens directly and therefore supports the antimicrobial 
functions of neutrophils68,71. A further effector function is the degranulation of neutrophils that destroys 
pathogens by the release of granules, which contain proteinases as well as antimicrobial peptides. After 
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the fusion of the neutrophil granulocyte with a plasma membrane the release of the granules occurs, 
which are classified in three different types due to their specific function. Moreover, NETs are used to 
bind and kill bacteria as well as fungi extracellularly, when the ingestion of large foreign particles is 
inhibited. For this purpose, long chromatic fibers that contain also granules of the neutrophils, are 
ejected after the membrane breaks and trap the microorganisms68. This process is known as NETosis. It 
is a form of active cell death, distinct from apoptosis and necrosis, which requires the generation of ROS 
as well as NADPH72. However, neutrophils can also mediate inflammation by the production as well as 
release of pro-inflammatory cytokines73. Due to their numerous functions, neutrophils play an essential 
role for pathogen destruction and are important effector cells of the immune system. 
 
1.5. Antibody mediated effector functions 
 
The immune system exhibits various functions to respond to and destroy invading pathogens. One 
mechanism is the direct binding and the neutralization of microorganisms by antibodies. Moreover, there 
are also indirect mechanisms, known as antibody mediated effector functions, by which the killing of a 
pathogen is mediated. These functions are mainly triggered by the interaction of complement or Fc 
receptors with the Fc-part of an antibody and link the innate and the adaptive immune system. This 
leads to the activation or inhibition of specific pathways in various immune effector cells. ADCC, ADCP 
as well as CDC are the best-known effector functions induced by the binding of Fc receptors to 
antibodies48. In the following paragraphs, direct as well as indirect mechanisms (Figure 3) of pathogen 
destruction triggered by Igs are described in detail.  
 
 
Figure 3 Antibody mediated functions to destroy pathogens. Antibodies exhibit direct and indirect mechanisms to mediate the 
destruction and clearance of invading microorganisms. (i) Direct binding and neutralization prevents the infection of the cell by 
pathogens. (ii) CDC induces the formation of the MAC and leads to the lysis of bacteria. (iii) Opsonization and phagocytosis 
induces the ingestion of a microorganism covered with specific opsonins on its surface (antibodies and complement factors) by 
an activated phagocytic cell. (iv) ADCC occurs when the Fc part of an antibody is bound by Fc receptors on an effector cell, which 
induces the lysis of a pathogen48.  
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1.5.1. Direct neutralization  
 
Antibodies are able to prevent invading pathogens from infecting host cells in the absence of 
effector cells or molecules (e.g. complement) by direct binding. This process is known as neutralization 
and is caused by Igs that block the attachment of the microorganisms to host tissues (see Figure 3)74. It 
is an important function for viral protection, by binding the virus particle, which sterically hinders the 
interaction of the pathogen with host receptors75. Therefore, the elimination of the pathogen can be 
induced before a serious infection develops. Moreover, bacteria can cause damage to the host by the 
release of specific toxins. A toxin operates by the attachment to receptors on the target cell. Neutralizing 
antibodies prevent this attachment by rapidly binding to the receptor-binding site of the toxin with high 
affinity. In general, IgA neutralizes toxins mainly on mucosal surfaces, whereas IgG is responsible for 
toxin neutralization in tissues45. In addition, the adhesion of bacteria to host surfaces is a critical step in 
the pathogenesis of bacterial infections. Molecules, called adhesins, cause the binding to the cells and 
are therefore targets of neutralizing antibodies76. 
 
1.5.2. Complement-dependent cytotoxicity 
 
CDC is an important effector function to eliminate pathogens and neoplastic cells that can be 
harmful to the body. It is initiated by the activation of the complement system that leads to the formation 
of the MAC and target cell death (see Figure 3). The classical, the lectin as well as the alternative pathway 
can induce CDC77,78. CDC is also an important function of therapeutic antibodies that can activate the 
classical pathway, triggered by immune complexes consisting of IgM, IgG1, IgG3 and to a lesser extent 
IgG2 as well as the pathogen. This leads to the binding of C1q and to the opsonization of the foreign cell 
with activated complement components79,80. By the terminal insertion of the MAC, ions and water can 
enter the cell and cause a lethal colloid-osmotic swelling. The CDC affects the cell organelles by dilation 
of the rough endoplasmic reticulum, disruption of the Golgi complex, swelling of mitochondria and lysis 
of the plasma as well as nuclear membranes. In addition, ROS are generated and a number of 
intracellular signals were triggered. Nucleated cells require the presence of multiple MACs because 
otherwise, they can endocytose the MAC and the damage will be repaired78,81,82. When complement 
activation is dysregulated, many malignancies can occur. Under specific conditions, the system can 
destroy normal tissues and cellular debris, which is unsuccessfully removed, accumulates. This 
dysfunction can lead to autoimmune diseases as well as inflammatory pathologies. Therefore, it is 
important to find agents that inhibit CDC as well as antibodies that activate the complement system83.  
 
1.5.3. Opsonization and phagocytosis 
 
Opsonization is an antimicrobial process that promotes the covering of pathogen surfaces with 
opsonins, like antibodies or complement factors. It is a mechanism by which the phagocytosis of foreign 
particles is induced as well as facilitated45,84,85. In general, opsonins create a bridge between the particle 
being ingested and the phagocytic cell. They bind to antigens on the pathogens and are recognized by 
complement as well as Fc receptors on effector cells, like neutrophils or macrophages. This in turn 
induces the phagocytic process45. Phagocytosis mediates the clearance of microbial particles as well as 
apoptotic cells (see Figure 3)48. The effectivity of this process is increased by the engagement of multiple 
ligands on the opsonized cells with multiple receptors on the phagocytes as well as by the aggregation 
(also known as crosslinking) of phagocytic receptors that are capable of lateral membrane diffusion. 
After recognition of the immune complexes, signaling pathways are activated by which the actin skeleton 
of the effector cell is regulated and the plasma membrane is able to engulf the pathogen. A new vesicle, 
the phagosome is built, which matures and transforms. Fusion as well as fission reactions of the 
phagosome with early endosomes, late endosomes and finally lysosomes take place. The mature 
condition of the phagosome is called phagolysosome, which contains a different composition of the 
membrane with an acidic and degenerative environment inside for the digestion of the internalized 
contents84,85 . Opsonization and phagocytosis (opsonophagocytosis) are important effects that regulate 
and control tissue homeostasis and the immune response. Nevertheless, it can also mediate inflammation 
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by the release of cytokines through phagocytes and this attracts further effector cells as well as plasma 
proteins to the site of infection73. 
 
1.6. Antibody mediated immunomodulation 
 
As mentioned in the previous chapters, the activation of the hosts’ immune system by direct 
mechanisms or indirect effector functions is a fundamental process for the killing and destruction of 
pathogens that are harmful to the body. Nevertheless, a permanent stimulation, autoimmune reactions 
or a hyper-responsiveness of immune cells lead to an excessive activation of the whole immune system 
and to strong reactions that may be directed against the host86. A higher production and the uncontrolled 
release of cytokines cause the up-regulation of inflammatory reactions and this contributes to the 
emergence of pathological pain. Moreover, it can lead to tissue damage, hemodynamic changes, organ 
failure and finally to death87. There is evidence that administered polyclonal or monoclonal antibody 
preparations exhibit a therapeutic effect by initiation of the immune response, but also by the down-
regulation of harmful effects caused by inflammation, autoimmunity and hypersensitivity88–91. 
 
1.6.1. Anti-inflammatory mechanisms of Ig preparations  
 
In general, Ig preparations are used as replacement therapy in immunosuppressed patients and in 
high doses as anti-inflammatory therapeutics in autoimmune diseases. The letter is mediated by various 
molecular mechanisms that affect the innate as well as the adaptive immune response92. Igs are able to 
block Fc receptors on effector cells for antibody recognition. These receptors are important for the 
opsonophagocytosis of pathogens that enter the hosts’ immune system. By preventing the binding to Fc 
receptors, the Fc-mediated phagocytic process is inhibited, which is an important effect regarding 
autoimmune diseases93. Moreover, Ig preparations can inhibit the complement cascade by binding to 
activated complement factors and preventing their deposition on tissues and cells94–96. This mechanism 
will be described in detail in paragraph 1.6.2. Further effects are the modulation of pro-inflammatory as 
well as anti-inflammatory cytokine production, the neutralization of autoantibodies as well as an 
increased expression of the inhibitory Fc-receptor (FcγRIIB)89,91–93.  
 
1.6.2. Neutralization of complement factors by Ig preparations  
 
The activation of the complement system is not always beneficial for the host and can lead to a 
number of severe diseases under inappropriate circumstances. Despite the protective function of the 
complement system in immunity, it can induce autoimmune reactions or the over stimulation of the 
innate immune system that is harmful and cause self-damaging as well as inflammation11,17,94,97. The 
neutralization of the components of the complement system is therefore of high clinical relevance.  
It has been postulated, that high-dose IVIgs as well as IgM-enriched and IgA-enriched preparations 
can affect the complement system in an anti-inflammatory manner, by blocking its activation95,98–101. 
Basta et al. described the interaction of IVIgs with C3b and C4b molecules, as well as with C3a and C5a 
in the fluid phase. Fc-specific binding of opsins and F(ab)´2-mediated binding of the anaphylatoxins, 
that inhibited the complement cascade directly, could be shown in in vitro experiments11,17,96. Moreover, 
Rieben et al. examined the complement inhibitory capacity of different IVIgs as well as IgM- and IgA-
enriched Ig preparations and could show that the inhibitory effects regarding C3 and C4 were best for 
an IgM- and IgA-enriched preparation in comparison to pure IVIgs, but also IgG-dependent effects were 
revealed. These results were confirmed in an in vivo rat model99. Additionally, Miletic et al. showed a 
higher capacity of IgM and IgA in inhibiting complement C4 uptake onto sensitized sheep erythrocytes 
as target cells than IgG102. Furthermore, Roos et al. analyzed IVIg preparations for their capacity to block 
complement activation in pig xenografts, transplanted into primates. They showed a dose-dependent 
inhibition by the preparations as well as a stronger inhibitory capacity of IgM compared to IgG98. The 
study of Mollnes et al. focused on the inhibition of complement-mediated red cell lysis by Igs and they 
concluded that this was mainly due to the binding and blocking of the C1q molecule, which is dependent 
on the IgG isotype. Furthermore, they reported that IgG3 proteins were the most potent inhibitors, 
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followed by IgG1, whereas IgG2 and IgG4 did not exhibit inhibitory capacity103. The inhibitory effect of 
IVIgs regarding complement was also tested in an experimental stroke setting in mice. After the 
administration of IVIg, complement-mediated neuronal cell death was prevented and the general 
functional outcome in murine stroke improved, leading to the hypothesis that this was due to the efficacy 
of IVIgs to bind activated complement components104. In addition, Esen et al. demonstrated 
neuroprotective effects of IVIgs in a rat model of sepsis by complement inhibition. These effects were 
ascribed to a reduction of the C5a anaphylatoxin and a resulting inhibition of inflammation as well as 
apoptosis105.  
The previously described studies show a strong influence of different Ig preparations on 
complement inhibition in settings simulating an over-stimulated immune system. This inhibitory effect 
was due to the direct binding of complement factors by Igs. Moreover, the results indicated a stronger 
effect of IgM- and IgA-enriched preparations on complement inhibition compared to IVIgs. 
 
1.7. Acute lower respiratory tract infections 
 
Acute lower respiratory tract infections (LRIs) are a substantial public health problem worldwide. 
In 2015, approximately 2.74 million people died, because of infections of the lower respiratory tract106. 
The mortality caused by these infections is still high and the burden of disease even increased in the last 
years in people older than 70. LRI include pneumonia, but also croup, tracheobronchitis, as well as 
bronchiolitis107,108. In general, the patients’ outcome is dependent on the virulence of the organism, 
which is responsible for the infection as well as the inflammatory response in the lung. Inflammation of 
the pulmonary system develops when high amounts of virulent microbes colonize the lung and the 
immune system is overstimulated. This in turn can finally lead to lung injury as well as abnormal 
pulmonary function109.  
 
1.7.1. Severe Community-Acquired Pneumonia 
 
One of the most common causes of death within LRIs is the community-acquired pneumonia 
(CAP)110,111. Generally, a pneumonia is described as an infection of the lung parenchyma, where the 
immune system is overwhelmed with the defense of invading pathogens. The main pathogen is 
Streptococcus pneumoniae followed by Haemophilus influenzae and Staphylococcus aureus. Symptoms like 
fever, cough with purulent sputum, dyspnea and pleuritic chest pain are common 112,113. An overall 
increased progress of disease and a higher mortality rate is called sCAP, where patients require admission 
to an intensive care unit (ICU) and often have to be ventilated114. Despite the availability and the 
improvement of pneumococcal polyvalent vaccine-based immunization strategies as well as of antibiotic 
treatment, the morbidity and mortality in sCAP is still high115,116. Challenges of the therapy against 
pneumonia are the increasing resistance of the bacteria to antibiotics as well as the development of new 
contagious and deadly pathogens115,117. In addition, patients with severe infections often suffer from 
transient antibody depletion. It was shown that the antibody serum concentrations correlate with disease 
severity and that there is a need for replacement therapy118. In general, it is of high relevance for sCAP 
patients to obtain an effective treatment that activates the immune system and destroys relevant 
pathogens because, high bacterial load that cannot be cleared completely as well as a resulting over-
activation of the hosts’ immune defense can lead to harmful effects for the patient. Activation of the 
complement cascade as well as the release of cytokines and the subsequent recruitment of effector cells 
that in turn secrete cytokines, are key events that trigger inflammation116. Pneumolysin, a virulence 
factor of Streptococcus pneumoniae activates the classical complement pathway, whereas the alternative 
pathway is triggered by teichnoic acid, a polymer component of the pneumococcal cell wall119. 
Unsuccessful treatment with antibacterial agents together with antibody depletion can therefore 
aggravate the situation and lead to the development of a hyper-inflammation, which causes the systemic 
spread of the disease, pulmonary damage and at worst sepsis and multi-organ failure. Because of these 
difficulties in antimicrobial therapy, mortality in sCAP remains high and there is a need for adjunctive 
therapies that also target inflammatory responses115,120–122. One mechanism of agents that are able to 
reduce inflammation is the inhibition of activated complement factors. There is evidence that 
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neutralization of complement component C5a by specific inhibitors protects the patient against lung and 
extrapulmonary organ injury in pneumonia-induced sepsis123. Therefore, it may improve the patient 
outcomes by targeting directly the host response rather than the microorganisms. Related to this, various 
Ig preparations have been examined for their potential as add-on therapies in patients with sCAP. It 
could be shown that such preparations can prevent nonspecific complement activation, besides the 
improvement of pathogen opsonization as well as the neutralization of endotoxins and 
superantigens96,98,99,12411,98,99,124. 
 
1.8. Coronavirus Disease 2019 
 
The outbreak of the coronavirus disease 2019 (COVID-19) was caused by the novel severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2)125,126. It was primarily identified in China, has rapidly 
spread all over the world and finally caused a pandemic127–129. In the past, coronaviruses were 
responsible for the severe acute respiratory syndrome (SARS) pandemic of 2003 as well as for the Middle 
East respiratory syndrome in 2012 (MERS)117,130,131. SARS-CoV-2 is an RNA viruses that is comprised of 
an envelope, is non-segmented and rapidly trasmitted128. The symptoms of COVID-19 are fever, cough, 
myalgia, fatigue as well as headaches, hemoptysis and diarrhea132. Most patients show a mild to a 
moderate progress of the disease, but in 5-10% of the cases severe diseases like pneumonia, respiratory 
failure or acute respiratory distress syndrome (ARDS) develope133. It is also known that the virus invades 
the lung parenchyma and causes severe interstitial inflammation of the lungs, seen in computer 
tomography images134. This is due to the over-stimulated immune responses that trigger mediator 
cascades (complement, coagulation and cytokine storm) as well as to the lytic effects of the virus, which 
is harmful to host cells125,135,136. High levels of pro-inflammatory cytokines, like tumor necrosis factor 
(TNF), interleukin-1β (IL-1β) as well as interleukin-6 (IL-6) were found in patients with SARS-CoV-2132. 
These pro-inflammatory cytokines are mainly produced by immune cells and are able recruit other 
immune cells to the site of inflammation. When the immune system is permanently activated and a loss 
of negative feedback occurs, pro-inflammatory cytokines are excessively produced and lead to an 
exponential growth of inflammation. This can result in a cytokine storm, which causes increased vascular 
hyperpermeability and at worst multiple organ failure.137 There is evidence that cytokine storm is a major 
cause for lung injury and ultimately for ARDS in critically ill COVID-19 patients132. Therefore, it is 
important that the treatment of SARS-CoV-2 positive patients include a therapeutic reduction of the 
uncontrolled and excessive immune response to save the patient’s lives. Moreover, various studies 
described that complement activation in COVID-19 patients can also cause inflammatory responses and 
an inhibition of the complement system could have positive effects for the disease progression. Gralinski 
et al. already analyzed the role of the complement system in SARS-CoV infections of 2003. By using a 
model with SARS-CoV infected mice he was able to demonstrate a direct activation of the complement 
system in the lung at day 1 of infection. It was suggested that this activation mediates systemic pro-
inflammatory responses like the recruitment of neutrophils and inflammatory monocytes as well as the 
release of cytokines and chemokines138. Additionally, the activation of the complement system was also 
analyzed by Gao et al. relating to SARS-CoV, MERS-CoV as well as to the new SARS-CoV-2 infections. It 
was reported that the nucleocapsid (N) proteins of the analyzed coronaviruses, are all able to bind to 
MASP-2 of the lectin pathway and thereby aberrantly activating the complement system that leads to 
inflammatory lung injury139. Moreover, first clinical studies in patients with mild and severe COVID-19 
infections detected increased levels of complement factor C5a compared to healthy individuals, which 
was suggested to contribute to lung as well as endothelial damage140. In addition, Magro et al. detected 
thrombotic microvascular injury in patients infected with SARS-CoV-2 accompanied by the deposition of 
complement (C5b-9, C4d, MASP-2), which was associated with an increased activation of the clotting 
pathway leading to hypercoagulability141. These findings leads to the assumption that uncontrolled 
complement activation by SARS-CoV-2 plays a major role in the development of inflammation as well as 
multiple organ failure. Additionally, the complement system is also able to interact and activate the 
coagulation system. It was shown that C5a for e.g. can increase the activity of tissue factor, which is an 
important coagulation protein and that the inhibition of complement is associated with a reduced 
expression of this factor142,143. In COVID-19 patients, excessive intravascular coagulation as well as 
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thrombus formation was detected144. It was assumed that the increase in coagulation was caused by an 
increased complement activity141. For the described reasons, it could be a promising treatment, to reduce 
or inhibit complement activation by monoclonal antibodies or plasma derived Ig preparations next to 
the standard antiviral therapies that directly neutralize aberrantly activated complement factors. 
Therefore, the effects of complement inhibition in COVID-19 patients should be evaluated in future 
studies145–148. 
 
1.9. Plasma derived immunoglobulin preparations  
 
Plasma-derived Igs are of high relevance for e.g. the destruction and clearance of pathogens, the 
therapy of autoimmune diseases and for immunomodulation. By exhibiting multiple effector functions, 
they protect the host against infections and control the immune response in order to prevent over-
stimulatory processes149. Moreover, the development of plasma-derived Ig preparations that contain 
highly purified antibody molecules, which are isolated and pooled from thousands of healthy donors, 
are used as replacement therapy in immunodeficient patients as well as for the treatment of 
inflammatory disorders150–152. Due to the pooling, the preparations contain a considerably higher amount 
of Igs that contain various specificities compared to one individual149. Plasma-derived Ig preparations 
are produced by chromatographic purification and the removal of potential pathogens and impurities is 
ensured by various processes as well as by controls during manufacturing153,154. The products are either 
administered by intravenous, intramuscular or subcutaneous infusion. Currently, mainly IVIgs are in use, 
but there is a need for the better exploitation of the plasma, which contains additionally fractions of IgA 
and IgM. The production of alternative Ig preparations with other compositions is an important step for 
new indications and therapies149. 
 
1.9.1. Intratect 
 
Intratect is a human plasma-derived polyvalent IVIg preparation developed as replacement therapy 
for PID and SID. Meanwhile, IVIgs are used for autoimmune and inflammatory diseases as well155–
157.Therefore, new indications for Intratect like chronic inflammatory demyelinating polyneuropathy 
(CIDP) and multifocal motor neuropathy (MMN) were approved. IVIg preparations in general, contain 
>95% IgG, exhibit a distribution of the IgG subclasses that is comparable to the composition in normal 
serum and have a minimal amount of aggregates. It is a critical step in the manufacturing process of 
IVIgs that the functionality of the IgG molecules as well as the safety of the product is maintained. 
For Intratect production, the method of Cohn (fractionated precipitation) was modified for the 
separation of the precipitates by using filter instead of centrifugation techniques116. The efficacy, safety 
as well as the pharmacokinetic profile of Intratect was tested in clinical trials in patients with PID, SID 
and autoimmune disorders. The data suggests that the preparation is well tolerated, safe and effective 
for this indications with mild and transient adverse reactions158–160. Moreover, the immunomodulatory 
effects of Intratect were also examined regarding its complement inhibitory capacity. Spycher et al. 
analysed the complement inhibitory capacity of different IVIg preparations in an ELISA system and 
confirmed that Intratect was able to inhibit the deposition of C3b as well as iC3b concentration-
dependently. Nevertheless, the product was not as effective in inhibiting complement as the other IVIg 
preparations that were tested in this study100.  
 
1.9.2. Trimodulin 
 
Trimodulin (name of the active substance) is a human plasma-derived polyvalent Ig preparation 
for intravenous administration (IV) and comprises ⋲ 23% IgM, ⋲ 21% IgA and ⋲ 56% total IgG. It was 
specifically developed for the treatment of severe infections and already tested in a phase I and II clinical 
trial. Due to the three antibody isotypes that are present in the product, three relevant mode of actions 
are described, divided in antimicrobial and immunomodulatory functions: on the one hand, trimodulin 
can initiate the opsonization and clearance of pathogens as well as the neutralization of their virulence 
factors. On the other hand, it is able to modulate the host inflammatory responses.  
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The three Igs of trimodulin show a large variety of activities and are important for antimicrobial 
activities. IgM is the first Ig that arises in a humoral immune response following infection or 
immunization by an antigen and can be divided into natural and immune IgM161. Both forms have 
specific functions regarding pathogen-associated infections. Natural IgM is able to facilitate the removal 
of apoptotic cells, bacterial debris, dead virus particles and their toxins. In the pentameric structure, IgM 
exhibits 10 antigen binding sites and has therefore a higher valency than other Igs. A single IgM 
pentamer can activate the complement system via the classical pathway, whereas IgG needs two and 
more molecules. This high valency makes IgM more efficient in antigen binding than other Igs, although 
it has a lower affinity60. In addition, the activation of the complement system increases the pathogen 
lysis via CDC23. IgA, secreted on mucosal surfaces and in plasma, protects against microorganisms and 
toxins as well as prevents their attachment to mucosal surfaces58. Its receptor is expressed on neutrophils 
that can be activated to mediate phagocytosis. The secretory form of IgA (sIgA) has a polymeric character 
and is more effective than monomeric IgA in preventing bacterial or viral infection41,51. It induces 
complement activation via the alternative and the lectin pathway, therefore mediating pathogen lysis 
via CDC16,20. IgG shows highest specificity for its targets and induces phagocytosis as well as ADCC of 
pathogens by binding to their specific receptors on effector cells41,46. Moreover, it has various immune 
modulating activities in autoimmune and inflammatory disorders155,162.  
In the CIGMA study, which was a randomized, placebo-controlled, double-blind, multicenter, 
phase II trial, the efficacy and safety of trimodulin as add-on therapy in mechanically ventilated sCAP 
patients was evaluated. In post hoc analyses, it could be shown that the mortality of the patients was 
significantly reduced in subsets with elevated baseline C-reactive protein (CRP) levels and/or reduced 
IgM levels163. CRP is an acute-phase inflammatory protein that increases up to 1000-fold in response to 
bacterial infections164. The advantages shown in the trimodulin-treated patients are an indicator for the 
important antimicrobial as well as immunomodulatory functions of the product and support its mode of 
action.  
Several studies done in the past, showed the pharmacological effect of trimodulin: the product is 
able to bind to the first complement component of the classical pathway, C1q, therefore activating the 
proteolytic cascade and leading to opsonization of pathogens. Moreover, it can bind bacterial and viral 
pathogen-associated molecular patterns (PAMPS) to restrict dysregulated inflammatory responses. This 
antimicrobial functions support the host immune system, especially in immune-compromised patients. 
In addition, trimodulin shows important immunomodulatory effects: it can affect the cytokine 
network165, influences the toll-like receptor (TLR) expression on monocytes165 and interacts with 
activated complement components, which can prevent or correct systemic hyper-inflammatory responses 
as well as infection-related tissue damage166.  
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2. Aim of the thesis 
 
The aim of this PhD thesis was to functionally analyze the new IgM- and IgA-enriched Ig 
preparation trimodulin, for an improved understanding of its complex MoA of not only IgG, but also IgM 
and IgA. In general, plasma-derived Ig preparations exhibit a variety of functions that can help people 
who suffer from antibody-depletion, inflammatory or autoimmune diseases155–157,167,168. For this reason, 
there is strong interest in the development, characterization and the clinical uses of such preparations149.  
Trimodulin is being developed for the treatment of severe infections and was already tested in a 
phase II clinical trial with sCAP patients. It was seen that the 28-day mortality of subsets with elevated 
CRP and/or reduced IgM levels could be obviously reduced after trimodulin addition163. Currently, 
trimodulin is also tested in a multinational phase II clinical trial for the treatment of severe COVID-19 
patients. Moreover, pre-clinical in vitro as well as in vivo studies investigated various pharmacological 
effects of this Ig preparation. On the one hand, trimodulin shows antimicrobial functions: it is able to 
bind C1q, the first component of the classical complement pathway, induces the opsonization of gram-
positive and gram-negative bacteria, viruses and fungi and is able to trigger the IgG-mediated 
phagocytosis of pathogens (data not published). On the other hand, trimodulin can also operate via its 
immunomodulatory mechanisms: it reduces the production of pro-inflammatory cytokines165, is able to 
modulate the phenotype of monocytes165, inhibits T cell activation165 and was shown to interact with the 
complement system166. These mechanisms are caused by the individual functions of the IgM, IgA and 
IgG molecules, which are present in trimodulin.  
Nevertheless, there is still a need for a better understanding of the correlation between the 
antimicrobial and immunomodulatory effects to obtain detailed insights in the MoA of trimodulin. 
Therefore, this PhD thesis pursued the aim to analyze the ambivalent effects of trimodulin that are 
responsible for balancing the activation and the inhibition of the immune system. Moreover, it was also 
important to analyze the influence of the enriched IgM and IgA proportion in trimodulin and to compare 
it with a normal IVIg preparation. For this reason, Intratect was used in this PhD thesis as IVIg control.  
Initially, it was analyzed if trimodulin is able to bind and inhibit the activated complement factors 
C3b, C4b, C3a and C5a. The opsonins (C3b and C4b) as well as the anaphylatoxins (C3a and C5a) play 
an important role in the activation of the complement system and in the defense against invading 
pathogens12. However, they can also be harmful to the host, when the complement system is over-
activated. Especially C5a and C3a can trigger various inflammatory effects that can lead to tissue damage 
and multiple organ failure24. Due to the interactions of trimodulin with activated complement factors 
that were seen in ELISA experiments of Rieben et al.166, it was hypothesized that trimodulin is also able 
to functionally inhibit activated complement factors. The ability of trimodulin to decrease the activation 
of the complement system would be beneficial for patients with autoimmune diseases or inflammatory 
disorders that attack the bodies’ own cells and tissues. Particularly in diseases like sCAP or COVID-19, it 
is known that the immune system can be over-stimulated, which leads to systemic inflammation and can 
promote mortality125,135,136,169. In order to prove the hypothesis that trimodulin can inhibit activated 
complement factors, the binding of the Ig preparation to the various complement components was tested 
and subsequently, the functional effect determined by using a CDC assay. This was the first time that 
trimodulin was functionally analyzed concerning complement system inhibition.  
Certainly, the activation of the immune system in order to destroy invading pathogens is also an 
important MoA of Ig preparations. It is known that IVIgs are able to induce the phagocytosis of 
microorganisms, by binding to effector cells like neutrophils or macrophages and to trigger their 
clearance48. The IgG-mediated phagocytosis of trimodulin could already be shown in pre-clinical 
experiments (data not published). Nevertheless, there is a need to analyze the ability of trimodulin, to 
additionally activate the complement system, which triggers effector functions like opsonophagocytosis 
or CDC of pathogens and therefore facilitates their neutralization48. In general, IgM molecules are better 
activators of the classical complement pathway than IgG molecules, whereas IgA does not have the ability 
to induce this pathway12. In order to analyze, if trimodulin is able to trigger the opsonophagocytosis of 
pathogens, an OPA was developed. It was hypothesized that trimodulin, which contains high amounts 
of IgM and IgA molecules, is a better complement activator and therefore induces a stronger 
opsonophagocytosis than Intratect that is only compromised of IgG molecules.  
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This PhD thesis analyzed for the first time the dual role of trimodulin regarding complement 
activation and therefore gave new insights in the MoA of this preparation.  
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3. Material  
 
3.1. Chemicals and reagents 
 
Product Manufacturer Order number 
0.4% Trypan Blue Solution Corning 25-900-CI  
All Blue Prestained Protein Standards Bio-Rad 1610373 
Aqua B. Braun 0082479E 
Bond-Breaker TCEP solution Thermo Scientific 77720 
Bovine serum albumin Sigma-Aldrich A9647 
Carbonate-Bicarbonate Buffer (capsule)  Sigma-Aldrich C3041-50CAP 
Dulbecco’s PBS (w/o Ca2+ w/o Mg2+ ) Life technologies 14190144 
Gelatin  Sigma-Aldrich 48723-500G-F 
Gelatin Veronal Buffer with Mg2+ and Ca2+ 
(GVB++) 
Boston Bio Products IBB-300X 
Hanks’ Balanced Salt Solution (10x) with Mg2+ 
and Ca2+ 
Thermo Scientific 14065056 
HEPES Buffer Solution (1 M) Life technologies 15630-056  
Methanol Merck 1.06009.1011 
NuPage Antioxidant Thermo Scientific NP0005 
NuPage LDS Sample Buffer (4x) Thermo Scientific NP0007 
NuPage MOPS SDS Running Buffer (20x)  Thermo Scientific  NP0001 
NuPage Transfer Buffer Thermo Scientific NP0006 
PBS (10x), pH 7.4 Thermo Scientific 70011044 
Propidium iodide  Invitrogen P1304MP 
Odyssey Blocking Buffer Li-Cor 927-40000 
TBS-T concentrate (20x) In-house preparation 1083 
TMB substrate In-house preparation  1077 
TMB substrate buffer In-house preparation  1076 
TMB substrate stopping solution In-house preparation 1078 
Triton X-100 Sigma-Aldrich T8787-50ML 
Tween 20  Sigma-Aldrich P1379-25ML 
Zymosan A (from Saccharomyces cerevisiae) Sigma-Aldrich Z4250-250MG 
 
3.2. Consumables 
 
Product Manufacturer Order number 
15 mL conical tube Falcon 352096 
50 mL conical tube Falcon 352070 
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24 well F-bottom plate Corning 353047 
Bolt Bis-Tris Plus Gels, 15 well (8%) Thermo Scientific NW00085BOX 
Cell culture flask T-25 Eppendorf 0030710029 
Cell culture flask T-75 Eppendorf 0030711025 
Cell culture flask T-175 Eppendorf 0030712013 
Cluster tubes, 1.2 mL, 96 well, PP Corning  CLS4401-960EA 
Combitips advanced, 5 mL Eppendorf 0030089456 
Combitips advanced, 10 mL Eppendorf 0030089464 
Counting Chamber Neubauer Improved C-Chip Carl Roth PK36.1 
Deep well plate, 96 square well VWR 732-3323 
Drigalski spatula  VWR 612-2688 
epT.I.P.S. Biopure, 0.1-20 μl Eppendorf 0030075323 
epT.I.P.S. Biopure, 2-200 μl Eppendorf 0030075021 
epT.I.P.S. Biopure, 50-1000 µL Eppendorf 0030075358 
Inoculation loop VWR 612-9352P 
Micro cuvette VWR 634-0675 
Microplate, 96 well, Nunc MaxiSorp, PS, F-
Bottom 
Thermo Scientific  44-2404-21 
Microplate, 96 well, PS, U-bottom Greiner 650101 
Microplate, 96 well, PS, V-bottom Greiner 651101 
Microplate sealing tape VWR 319-1250 
Mini orbital shaker VWR 444-0270 
Pierce Nitrocellulose Membrane Thermo Scientific 88013 
Pierce Western Blot Filter Paper Thermo Scientific 84783 
Safe-Lock Tubes, 1.5 mL Eppendorf  0030120086 
Serological pipette, 5 mL VWR 612-5523P 
Serological pipette, 10 mL VWR 612-5827P 
Serological pipette, 25 mL VWR 612-5828P 
Serological pipette, 50 mL VWR 612-5546P 
 
3.3. Devices 
 
Product Manufacturer 
Amersham Typhoon 5 Imager GE Healthcare 
Axiovert 40c Zeiss 
Cell Freezing Container Cool Cell LX Corning 
Clean bench Herasafe Thermo Scientific 
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Thermomixer Comfort  Eppendorf  
FACS Canto II BD 
HERACell 240i CO2 Incubator  Thermo Scientific 
Heraeus Multifuge 3S Plus Thermo Scientific 
Heraeus Multifuge X3R Thermo Scientific 
Ice Basin , 4 L NeoLab 
Infinite F200 Tecan  
Low Speed Orbital Shaker Corning 
Magnetic stir bar  VWR 
Magnetic stirrer VWR 
Microcentrifuge 220 R Hettich 
Microplate shaker VWR 
Microplate washer 405TSUVS Biotek 
Multipette Eppendorf 
Olympus IX53 microscope Olympus 
Power Supply  Bio-Rad 
Research pipette (12-channel) 30-300 µL Eppendorf 
Research plus pipette 0.5-10 µL Eppendorf 
Research plus pipette 1-20 µL Eppendorf 
Research plus pipette 10-100 µL Eppendorf 
Research plus pipette 20-200 µL Eppendorf 
Research plus pipette 100-1000 µL Eppendorf 
Spectral Photometer UV-3100PC VWR 
Ultrasonic bath VWR 
Vortex shaker IKA 
Water Bath Grant 
X Cell II Blot Module Thermo Scientific 
X Cell SureLock Mini-Cell Electrophoresis 
Chamber 
Thermo Scientific  
 
3.4. Software  
 
Product Manufacturer 
Amersham Typhoon Control Software GE Healthcare 
BD FACSDiva BD 
FlowJo X Tree Star 
GraphPad Prism GraphPad Software 
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Image Quant TL  GE Healthcare 
 
3.5. Cell culture reagents 
 
Product Manufacturer Order number 
Dimethylformamide  Sigma-Aldrich 227056-100ML 
Dimethyl sulfoxide  Sigma-Aldrich D2650-100ML 
Fetal bovine serum Life technologies 10270106 
RPMI-1640 Medium ATCC ATCC 30-2001 
Penicillin-Streptomycin Sigma-Aldrich P0781-100ML 
 
3.6. Bacteria culture reagents  
 
Product Manufacturer Order number 
Glycerol, pure, 83.5-88.5% aqueous solution Acros organics 277360010 
LB agar plates (Miller) VWR 102502ZA 
LB broth (Miller)  Alfa Aesar H26676.36 
 
3.7. Buffer protocols 
 
Formulation Buffer Intratect pH 5.0 
0.32 M glycine 
In distilled water 
 
Formulation Buffer trimodulin pH 4.3 
0.32 M glycine 
In distilled water 
 
TBS-T Washing Buffer  
1x TBS-T concentrate (20x) 
In distilled water  
 
Western Blot Buffer  
10% methanol 
0.1% antioxidant  
1x Transfer Buffer 
In distilled water 
 
 
 
   
Material   21 
3.8. Kits 
 
Product Supplier Order number 
Human C3a ELISA Kit BD 550499 
Human C5a ELISA Kit BD 557965 
 
3.9. Cell lines 
 
Product Supplier Order number 
HL-60 cells ATCC ATCC CCL-240 
Ramos Cells ATCC ATCC CRL-1596 
 
3.10. Bacteria  
 
Product Supplier Order number 
E. coli (K12) ATCC ATCC 10798 
Staphylococcus aureus bioparticles, Alexa Fluor 
488 conjugate  
Thermo Scientific S23371 
 
 
3.11. Antibodies 
 
Product Manufacturer Order number 
CF488A Donkey Anti-Goat Antibody Biotium 20016. 
CF555 Donkey Anti-Mouse Antibody Biotium 20037. 
CF640R Donkey Anti-Rabbit Antibody Biotium 20178. 
Goat anti-human IgG/IgA/IgM antibody mix Abcam 102416 
Goat anti-rabbit antibody (HRP) Agilent P044801-2 
Mouse anti-human CD11b (Pacific Blue) BD 558123 
Mouse anti-human CD16 (V500) BD 561393 
Mouse anti-human CD20 (APC) BD 559776 
Mouse anti-human CD32 (PE) BD 550586 
Mouse anti-human CD35 (FITC) BD 555452 
Mouse anti-human CD64 (Alexa Fluor 700) BD 561188 
Mouse anti-human CD71 (APC) BD 561940 
Mouse anti-human IgM antibody (clone AF6) 2BScientific 2BS-SM100101 
Mouse IgG1 κ Isotype Control (Alexa Flour 
700) 
BD 557882 
Mouse IgG1 κ Isotype Control (FITC) BD 555748 
Mouse IgG1 κ Isotype Control (Pacific Blue) BD 558120 
Mouse IgG1 κ Isotype Control (V500) BD 560787 
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Mouse IgG2a κ Isotype Control (APC) BD 555576 
Mouse IgG2b κ Isotype Control (APC) BD 555745 
Mouse IgG2b κ Isotype Control (PE) BD 555743 
Rabbit anti-human C3c antibody  Agilent  F020102-2 
Rabbit anti-human C4c antibody  Agilent F016902-2 
Rabbit anti-human C5a antibody Thermo Scientific PA5-35000 
Rabbit anti-human IgG antibody Abcam ab97156 
Rabbit anti-mouse IgG antibody (HRP) Abcam ab6728 
 
3.12. Serum and complement 
 
Product Manufacturer Order number 
EDTA-plasma In-house preparation n/a 
Purified C5a Sigma-Aldrich 204902 
Normal human serum In-house preparation n/a 
Human serum IgG/IgM depleted Pel-Freez 34014 -10 
 
3.13. Antibody preparations 
 
Product Manufacturer PZN  
MabThera (Rituximab, 100 mg)  Roche Pharma AG 08709896 
 
3.14. Plasma products 
 
Product Manufacturer Lot  
Intratect Biotest AG B791256 
trimodulin Biotest AG B588016 
B588026 
B588036 
B588039 
 
Intratect (50 g/L) is a normal human IVIg preparation containing ⋲ 96% IgG. Trimodulin (50 g/L) 
is an IgM/IgA-enriched Ig preparation with ⋲ 23% IgM, 21% IgA and ⋲ 56% total IgG. 
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4. Methods 
 
4.1. Cell culture techniques 
 
All cells were cultured under controlled conditions, at 37 °C and 5% CO2 in a humidified incubator. 
Every 3-4 days they were subcultured, thereby transferred to a new culture bottle and fresh medium was 
added.  
 
4.1.1. Determination of cell count 
 
For determination of the cell count, a Neubauer chamber was used. The counting grid of this 
chamber consists of 3 x 3 large squares, each with an area of 1 mm2. The central large square, which is 
divided into 5 x 5 medium squares and each of them again divided into 4 x 4 smaller squares, is used 
for the counting of platelets as well as red blood cells. The four large squares in the corners of the 
chamber comprises a volume of 0.0001 mL, are divided into 16 smaller squares with 0.25 mm side length 
and used for the counting of white blood cells as well as most cell-line derived cells. In order to determine 
the cell count, samples were 2-fold diluted in 0.2% trypan blue solution. This dye exclusively labels dead 
cells, because it cannot pass the membrane of intact cells and cannot enter the cytoplasm. Samples with 
higher cell densities were pre-diluted in phosphate-buffered saline (PBS). After dilution, 10 µL of the 
sample was added to the chamber and the cells counted using a light microscope. The bright viable cells 
were excluded from the dark blue labeled dead cells and the cell concentration, the absolute cell number 
as well as the viability determined by the following formulas: 
 
Cell concentration [cells/mL] = 
Number of viable cells ∙ Dilution factor 
Number of squares ∙ 0.0001 mL
 
 
Absolute cell number = Cell concentration ∙ total volume 
 
Viability [%] = 
Number of viable cells
Number of total cells
∙100 
 
4.1.2. Cryopreservation 
 
For long-term storage, cells of a low passage number were centrifuged at 350 x g for 5 min and 
adjusted to 1∙106 cells/mL in cryopreservation medium, containing 95% culture medium and 5% 
Dimethyl sulfoxide (DMSO). 1 mL aliquots were generated and frozen for 24 h at -80 °C in a cell-freezing 
container, to ensure a temperature decrease of 1 °C per min. After that, the cells were transferred to 
a -150 °C refrigerator. 
  
4.1.3. Ramos cells 
 
The Ramos cell line is a human B lymphocytic cell line that originates from Burkitt’s lymphoma 
and express the surface antigen CD20170–172. Ramos cells were routinely used to analyze antibodies to 
induce cell death by binding to CD20173,174. In the CDC assay, the cells were used to evaluate the effects 
of trimodulin on CDC of the Ramos cells, caused by the activation of the complement cascade through 
binding of the chimeric monoclonal antibody Rituximab to CD20.  
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4.1.4. Cultivation of Ramos cells 
 
Frozen cryovials were rapidly thawed in a 37 °C water bath and the cells transferred to a 15 mL 
conical tube, containing 9 mL of pre-warmed RPMI-1640 medium, supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin-streptomycin. After centrifugation of the cells at 350 x g for 5 min, they 
were resuspended in 10 mL supplemented RPMI-1640 medium and transferred to a T-25 cell culture 
flask. The cells were incubated in a 37 °C humidified incubator, containing 5% CO2 and subcultured 
every 3-4 days. They were counted and 1.5∙105 cells/mL were transferred to a new T-75 cell culture 
flask.  
After thawing, cells were subcultured at least three times prior to their first use in the CDC assay 
and a maximum of 25 passages was performed.  
 
4.1.5. HL-60 cells 
 
The HL-60 cell line is a human leukemia cell line, with a neutrophilic promyelocytic morphology 
and was obtained from peripheral blood175. The cells differentiate to mature granulocytes by the addition 
of DMSO or retinoic acid to the culture medium176,177. Moreover, the treatment with 12-O-
tetradecanoylphorbol-13-acetate (TPA) leads to monocytic, macrophage-like and eosinophil 
phenotypes178. These characteristics have made the cell line an attractive model for myeloid cell 
differentiation and for cytokine research179. In this study, HL-60 cells were used as effector cells in the 
OPA after differentiation to mature neutrophil-like granulocytes.  
 
4.1.6. Cultivation of HL-60 cells 
 
In order to cultivate the HL-60 cells, frozen cryovials were rapidly thawed in a 37 °C water bath. 
After thawing, the cells were transferred to a 15 mL conical tube, containing 9 mL of pre-warmed IMDM 
medium, supplemented with 20% FBS and 1% penicillin-streptomycin. Subsequently, the cells were 
centrifuged at 350 x g for 5 min and transferred to a T-25 cell culture flask. They were incubated for 3-
4 days at 37 °C and 5% CO2 in a humidified incubator. For subculturing, they were counted and set to 
2∙105 cells/mL by transferring the required amount of cell suspension to a new T-75 cell culture flask 
and adding supplemented IMDM medium.  
After thawing, cells were subcultured at least three times prior to their first use in the OPA assay 
and a maximum of 25 passages was performed.  
 
4.2. Bacterial culture of E. coli (K12) 
 
In order to use the gram-negative bacterium E. coli (K12) in the OPA assay, the microorganisms 
were cultured under controlled conditions. E. coli are rod-shaped, facultative anaerobe bacteria with 
peritrichous flagella for motility or are non-motile180. They colonize the lower intestine of endothermic 
organisms, as part of the normal microbiota, where they can suppress the growth of pathogenic bacteria 
and synthesize vitamins181,182. However, harmful serotypes can lead to various infections of the enteric, 
urinary, pulmonary and the nervous system183. The reference strain K12 was one of the first 
microorganisms targeted for genome sequencing and therefore helped to understand the genetics, 
molecular biology, physiology and biochemistry of this bacterium184. In the present study, E. coli 
(K12) was used as a model-organism for the phagocytosis of microorganisms by trimodulin in the 
OPA assay. 
All steps, described in the following paragraphs (inoculum, master stock and assay stock 
preparation) were performed under a clean bench.  
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4.2.1. Inoculum preparation  
 
To dissolve the lyophilized pellet of E. coli (K12), the vial was opened and 5-6 mL lysogeny broth 
(LB) medium were pipetted to a 15 mL conical tube. 1 mL was taken out to resuspend the bacteria and 
transferred to the tube, containing the residual medium. The tube was incubated for 24 h at 37 °C and 
shaking (⋲ 140 rpm).  
 
4.2.2. Master stock preparation  
 
A master stock preparation is used as an internal reference standard and is directly made from the 
reference culture vial (ATCC). It is stored as liquid suspension at -150 °C and used for the production of 
assay stocks. The assay stocks in turn are used in the individual tests.  
In order to produce master stocks of the E. coli culture, the liquid over-night inoculum was mixed 
with 80% glycerol. 500 µL of the suspension was distributed to 1.5 mL safe-lock tubes and stored in 
a -150 °C freezer.  
 
4.2.3. Assay stock preparation 
 
For assay stock preparation, a small piece of ice was removed from the frozen master stock vial 
and was distributed on a LB agar plate with a Drigalski spatula, which was streaked out onto a 2nd and 
3rd LB agar plate. The plates were incubated upside-down at 37 °C overnight. After that, 20 colonies 
were harvested by using a sterile inoculation loop and were transferred to a 50 mL conical tube, 
containing 50 mL LB medium. The tube was incubated in a 37 °C water bath for 3-8 h until an optical 
density (OD), measured at a wavelength of 600 nm, between 0.5 and 0.8 was reached. 10 mL of the 
suspension were removed from the top of the tube and were transferred to a new 50 mL conical tube. 
Subsequently, 5 mL of 80% glycerol were added as well as 10 mL fresh LB medium, resuspended and 
0.5 mL distributed to 1.5 mL safe-lock tubes. The aliquots were stored at -150 °C. 
 
4.3. Purification of blood components and activity testing 
 
Whole blood is a mixture of various components that can be separated by centrifugation due to 
their different relative density and gravities. The components are divided into plasma, platelets and 
leucocytes as well as red blood cells (RBCs) (Figure 4)185. Blood plasma is the liquid protein-rich fraction 
of whole blood and serves as solution in which the cells as well as the platelets are suspended. Serum is 
collected after clotting of whole blood and remains as fluid after centrifugation. In comparison to plasma, 
it is free of fibrinogens and clotting factors186.  
Since complement components can be found in plasma and serum, the collection of these blood 
components is an important method for the analysis of the factors in different in vitro tests.  
 
 
Figure 4 Purification of blood components by centrifugation of whole blood. Due to their different gravities, plasma, white 
blood cells and platelets as well as RBCs can be separated after centrifugation of whole blood. In comparison to plasma, serum 
is devoid of fibrinogens as well as coagulation factors185,186.    
Blood Plasma Serum
Plasma
White blood cells
and platelets
Red blood cells
With
coagulation 
factors
Without
coagulation 
factors
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4.3.1. Ethylenediaminetetraacetic acid (EDTA)-plasma collection 
 
The plasma was collected by using EDTA-treated tubes for blood sampling. EDTA is an 
anticoagulant, which has the ability to chelate calcium ions necessary for the coagulation cascade, 
thereby preventing blood from clotting187. Whole blood, collected from 10 different donors, was 
centrifuged for 30 min at 4 °C and 1000 x g. The following steps were performed on ice under a clean 
bench. The supernatant of each vial was collected by using a 5 mL serological pipette and was pooled in 
a 50 mL conical tube. Subsequently, the serum was again centrifuged for 15 min at 4 °C and 2570 x g. 
The supernatant was transferred to a new 50 mL conical tube, distributed in 1.5 mL safe-lock tubes and 
stored at -80 °C.  
 
4.3.2. Serum collection 
 
In order to isolate normal human serum (NHS), whole blood was collected from 10 different 
donors in tubes without anticoagulants. After blood sampling, the tubes were stored for 1 h at 2-8 °C to 
allow blood clotting and centrifuged for 30 min at 4 °C and 1000 x g. Following steps were performed 
on ice under a clean bench. The supernatant of each vial was collected by using a 5 mL serological pipette 
and was pooled in a 50 mL conical tube. Subsequently, the serum was again centrifuged for 15 min at 
4 °C and 2570 x g. The supernatant was transferred to a new 50 mL conical tube, distributed in 1.5 mL 
safe-lock tubes and stored at -80 °C.  
 
4.3.3. CH50 test 
 
The CH50 test determines the activity of the classical complement pathway in plasma or serum. 
For the following in vitro assays, NHS, antibody-depleted serum or EDTA-plasma was used as 
complement source. Their activity was pre-analytically confirmed, because the complement system in 
general is very heat-sensitive as well as vulnerable to degradation at room temperature and requires 
appropriate storage conditions188. The analysis of NHS (in-house preparation), EDTA-plasma (in-house 
preparation) as well as IgM-/IgG-depleted serum (Pel-Freez) was performed by the Institute for 
Immunology (University Hospital Heidelberg) and heat-inactivated (hi) serum or plasma was used as 
control. The test is based on the lysis of antibody-sensitized sheep erythrocytes at 37 °C (Figure 5) and 
the results are calculated by plotting the dilution factor of the sample against the degree of haemolysis 
measured in a spectralphotometer (at 415 nm). CH50 determines the dilution of the sample to obtain 
50% lysis of the erythrocytes.  
 
Figure 5 Overview of the CH50 test. Sheep RBCs coated with anti-sheep RBC antibodies are incubated with the diluted serum 
or plasma samples at 37 °C. The classical pathway is triggered by binding of C1q to the anti-sheep RBC antibodies and the 
generation of the MAC leads to the lysis of the target cells in samples with active complement. After measuring free hemoglobin 
in the supernatant, the dilution of the sample to obtain 50% lysis of the sheep RBCs is calculated. 
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4.4. Complement targeting assays  
 
To investigate whether trimodulin can interact with the complement system, thereby inhibiting 
activated complement factors and reduce complement-mediated cytotoxicity, the following in vitro 
assays were developed.  
 
4.4.1. Opsonin ELISA  
 
To analyze, if trimodulin is able to bind the opsonins C3b and C4b, an ELISA assay was established. 
The ELISA was adjusted to the protocol described by Rieben et al.99. For activation of the complement 
system, aggregated IgG (Intratect) was generated by incubation at 63 °C for 1 h and subsequent 
centrifugation at 3000 x g for 10 min to remove insoluble aggregates. The aggregated IgG was coated 
to the wells of a 96 well plate. Trimodulin and Intratect (used as IVIg control) in different dilutions as 
well as EDTA-plasma were added to the plate. Exclusively the remaining opsonins are detected (Figure 
6). For this purpose, a secondary anti-IgG antibody, conjugated to a peroxidase, was used. The 
peroxidase in turn is able to cleave the added TMB substrate and sulfuric acid stops the reaction, thereby 
generating a color change. After that, the plate is measured at 450/690 nm in a spectralphotometer.  
 
 
Figure 6 Detection of remaining C3b or C4b after trimodulin addition. A 96 well flat (F) bottom plate is coated with aggregated 
IgG and incubated overnight at 2-8 °C. After washing, different dilutions of trimodulin and Intratect (used as IVIg control) are 
mixed with EDTA-plasma, distributed to the wells and the residual opsonins are detected with a goat anti-rabbit antibody, 
conjugated to a HRP. The ELISA was adjusted to the protocol described by Rieben et al. 99. 
Each well of a 96 well F-bottom plate was coated with 100 µL of 0.1 µg/mL aggregated IgG in 
carbonate bicarbonate buffer (pH 9.4) and incubated overnight at 2-8 °C. After that, the plate was 
washed three times with 300 µL/well tris-buffered saline with tween 20 (TBS-T) washing buffer in an 
automated plate washer. The following steps were performed on wet ice. EDTA-plasma was 100-fold 
diluted in Gelatin Veronal Buffer with Mg2+ and Ca2+ containing 0.05% Tween 20 (GVB++) and different 
concentrations of trimodulin and Intratect were prepared in their appropriate formulation buffer (FB) 
using cluster tubes (Table 1).  
Table 1 Dilutions of trimodulin and Intratect used in the Opsonin ELISA. 
Dilution Concentration Dilution Factor 
1 25 mg/mL 2 
2 20 mg/mL 2.5 
3 15 mg/mL 3.33 
4 10 mg/mL 5 
5 5 mg/mL 10 
6 1 mg/mL 50 
7 0.5 mg/mL 100  
8 0.1 mg/mL 500 
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50 µL of the prepared EDTA-plasma was mixed with 50 µL of trimodulin (B588036) or Intratect 
(B791256) dilutions and distributed to the 96 well plate according to the plate layout in Table 2. As 
negative control for C3b and C4b detection, 50 µL trimodulin as well as Intratect were added to column 
1 and 2 and mixed with 50 µL GVB++. As positive control (column 3) served 50 µL EDTA-plasma mixed 
with 50 µL GVB++. 50 µL of the pre-diluted trimodulin batches (B588016, B588026 and B588036) and 
Intratect were distributed to columns 4-11 in duplicates and mixed with 50 µL EDTA-plasma.  
Table 2 Plate layout of the Opsonin ELISA, indicating the distribution of the controls and samples. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Dil. 1 Dil. 1 1 Dil. 1 Dil. 1 Dil. 1 Dil. 1 Dil. 1 Dil. 1 Dil. 1 Dil. 1  
B Dil. 2 Dil. 2 2 Dil. 2 Dil. 2 Dil. 2 Dil. 2 Dil. 2 Dil. 2 Dil. 2 Dil. 2  
C Dil. 3 Dil. 3 3 Dil. 3 Dil. 3 Dil. 3 Dil. 3 Dil. 3 Dil. 3 Dil. 3 Dil. 3  
D Dil. 4 Dil. 4 4 Dil. 4 Dil. 4 Dil. 4 Dil. 4 Dil. 4 Dil. 4 Dil. 4 Dil. 4  
E Dil. 5 Dil. 5 5 Dil. 5 Dil. 5 Dil. 5 Dil. 5 Dil. 5 Dil. 5 Dil. 5 Dil. 5  
F Dil. 6 Dil. 6 6 Dil. 6 Dil. 6 Dil. 6 Dil. 6 Dil. 6 Dil. 6 Dil. 6 Dil. 6  
G Dil. 7 Dil. 7 7 Dil. 7 Dil. 7 Dil. 7 Dil. 7 Dil. 7 Dil. 7 Dil. 7 Dil. 7  
H Dil. 8 Dil. 8 8 Dil. 8 Dil. 8 Dil. 8 Dil. 8 Dil. 8 Dil. 8 Dil. 8 Dil. 8  
 Neg. 
Ctr. 
trim. 
Neg. 
Ctr. 
Intra. 
Pos. 
Ctr. 
trimodulin 
(B588016) + 
EDTA-Plasma 
trimodulin 
(B588026) + 
EDTA-Plasma 
trimodulin 
(B588036) + 
EDTA-Plasma 
Intratect 
(B791256) + 
EDTA-Plasma 
 
 
Ctr. = control; Dil. = dilution; Neg. = negative; Pos. = positive 
 
Subsequently, the plate was covered with a sealing tape and was incubated for 1 h at 37 °C. After 
that, the supernatant was transferred to a U-bottom 96 well plate and was stored at -20 °C for additional 
Western Blot analysis. The F-bottom plate was washed three times with 300 µL/well TBS-T washing 
buffer in an automated plate washer and the primary antibody was prepared. A rabbit anti-human C3c 
or C4c antibody that can also detect C3b/C4b and iC3b/iC4b was used and diluted 3000-fold in GVB++. 
100 µL were added to each well and the plate was incubated for 1 h at room temperature (RT). After 
incubation, the secondary goat anti-rabbit antibody, conjugated to a horseradish peroxidase (HRP), was 
2000-fold diluted and was distributed to the 96 well plate. It was incubated for 1 h at RT, following 
washing with 300 µL/well TBS-T washing buffer. For detection of the remaining C3b or C4b, 3,3',5,5'-
tetramethylbenzidine (TMB) substrate was 20-fold diluted in TMB substrate buffer and 50 µL added to 
each well. After incubation for 20 min at RT, 50 µL of TMB stopping solution, containing sulfuric acid, 
was distributed to the plate and the absorbance subsequently measured in a spectralphotometer at 
450/690 nm.  
 
4.4.2. Fluid phase ELISA 
 
In order to analyze if IgM of trimodulin can bind to the opsonins C3b or C4b, a fluid phase ELISA 
was developed. The ELISA was adjusted to the protocol described by Rieben et al.99. One 96 well F-
bottom plate was coated with 100 µL/well of 0.1 µg/mL aggregated IgG in carbonate bicarbonate buffer 
(pH 9.4) (plate 1) and a second 96 well F-bottom plate was coated with 100 µL/well of 0.1 µg/mL rabbit 
anti-human C3c or C4b antibody (plate 2). Both plates were incubated at 2-8 °C overnight. Subsequently, 
plate 1 was washed three times with 300 µL/well TBS-T washing buffer in an automated plate washer. 
After that, the same plate layout and concentrations as described in the opsonin ELISA were used for the 
control as well as for sample preparation. Plate 1 was incubated at 37 °C for 1 h and plate 2 was washed 
with TBS-T washing buffer. 90 µL of PBS, containing 0,3% BSA and 0,05% Tween20 were distributed to 
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the wells, the supernatant of plate 1 was transferred to plate 2, mixed and incubated for additional 1 h 
at 37 °C. Plate 2 was washed three times with 300 µL/well TBS-T washing buffer in an automated plate 
washer and the primary antibody was prepared. A mouse anti-human IgM antibody was used and diluted 
3000-fold in GVB++. 100 µL were added to each well and the plate was incubated for 1 h at RT. After 
incubation, the secondary rabbit anti-mouse antibody, conjugated to a HRP, was 5000-fold diluted and 
was distributed to the 96 well plate. It was incubated for 1 h at RT, following washing with 300 µL/well 
TBS-T washing buffer. For detection of the IgM, TMB substrate was 20-fold diluted in TMB substrate 
buffer and 50 µL added to each well. After incubation for 20 min at RT, 50 µL of TMB stopping solution 
containing sulfuric acid was distributed to the plate and the absorbance subsequently measured in a 
spectralphotometer at 450/690 nm.  
 
4.4.3. Anaphylatoxin ELISA 
 
To investigate if trimodulin can bind the anaphylatoxins C3a and C5a and therefore reduce the 
complement-mediated cytotoxicity, an anaphylatoxin ELISA was developed. Two setups were 
established, one with zymosan-activated EDTA-plasma and the other with purified C5a.  
 
4.4.3.1. Coating of the 96 well plate with trimodulin 
 
Trimodulin (B588036) was 500-fold pre-diluted in FB, then 10-fold serially diluted in carbonate 
bicarbonate buffer and 100 µL/well were coated to a 96 well F-bottom plate. As negative control for 
anaphylatoxin binding, carbonate bicarbonate buffer instead of trimodulin was added to the wells. After 
incubation overnight at 2-8 °C, the plate was washed three times with 300 µL/well TBS-T washing buffer 
in an automated plate washer and free binding-sites were blocked for 1 h at 37 °C by the addition of 
100 µL PBS containing 5% BSA and 0.1% Tween 20. The plate was again washed with TBS-T washing 
buffer and 50 µL of 350 ng/mL purified C5a diluted in GVB++ was distributed to each well. To control 
unspecific binding of the primary antibody, GVB++ instead of purified C5a was added. The plate was 
incubated at 37 °C for 1 h. After that, the plate was washed with TBS-T washing buffer and a primary 
rabbit anti-human C5a antibody as well as a secondary goat anti-rabbit antibody, conjugated to HRP, 
were used to detect the bound C5a (Figure 7). 100 µL of 5000-fold diluted primary antibody in GVB++ 
was distributed to the wells and the plate incubated for 1 h at RT. Following washing with TBS-T washing 
buffer, the secondary antibody was diluted 2000-fold in GVB++ and was added to the wells. The plate 
was again incubated for 1 h at RT. By the addition of 20-fold diluted TMB substrate, in TMB substrate 
buffer and the stopping of the reaction after 20 min with TMB stopping solution, the absorbance was 
measured in a spectralphotometer at 450/690 nm.  
 
 
Figure 7 Detection of C5a bound to trimodulin. A 96 well F-bottom plate was coated with different dilutions of trimodulin in 
carbonate bicarbonate buffer, blocked with BSA and incubated with 350 ng/mL purified C5a. After washing with TBS-T, bound 
C5a was detected with a primary rabbit anti-human C5a antibody and a secondary goat anti-rabbit antibody, conjugated to 
HRP. 
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4.4.3.2. Coating of the 96 well plate with zymosan 
 
This ELISA was performed by using two in-house coated plates and an anti-human C5a or C3a 
ELISA kit from BD (Figure 8). A 96 well F-bottom plate was coated with 100 µL of 20 µg/mL zymosan 
in carbonate bicarbonate buffer and was incubated overnight at 2-8 °C (plate 1). Zymosan is a 
carbohydrate complex derived from yeast cell walls and can activate the complement system in the 
absence of antibodies via the alternative pathway189,190. Furthermore, a second plate was coated with 
5 µg/mL of a goat anti-human IgG+IgA+IgM antibody mix in carbonate bicarbonate buffer (plate 2) for 
the immobilization of trimodulin as well as Intratect on plate 2 and was incubated overnight at 2-8 °C. 
After that, the plates were washed three times with 300 µL TBS-T washing buffer in an automated plate 
washer. EDTA-plasma was 50-fold diluted in GVB++ and 60 µL of this dilution was added to the wells of 
plate 1. It was incubated at 37 °C for 1 h. Subsequently, 50 µL of this supernatant containing activated 
complement factors was transferred to plate 2. For C3a detection, trimodulin (B588036) as well as 
Intratect were 20-fold pre-diluted, before a 2-fold serial dilution was performed in their appropriate FB. 
For C5a detection, trimodulin (B588036) and Intratect were 1250-fold pre-diluted and then 1.8-fold 
serially diluted in FB. After that, 50 µL of the respective dilutions were distributed to plate 2 As negative 
controls, trimodulin and Intratect without EDTA-plasma as well as EDTA-plasma without the products, 
as positive control for C3a or C5a detection, were added to the plate (see plate layout, Table 3). After 
mixture, the plate was incubated for 1 h at 37 °C. Subsequently, the supernatant of plate 2, containing 
the unbound C3a and C5a molecules, was transferred to the anti-human C3a or C5a coated microplate 
(plate 3) of the ELISA kit and the anaphylatoxins were detected after the manufacturers’ instruction in 
a spectralphotometer at 450/690 nm.  
 
 
 
Figure 8 Schematic overview of the anaphylatoxin ELISA, using a zymosan-coated microplate. A 96 well F-bottom plate was 
coated with 20 µg/mL zymosan in carbonate bicarbonate buffer (plate 1). EDTA-plasma was incubated on plate 1 to activate 
the complement system and generate the anaphylatoxins. The activated supernatant was transferred to a second plate coated 
with an anti-human IgG+IgA+IgM antibody and mixed with different dilutions of trimodulin or Intratect (plate 2). After that, 
an anti-human C3a or C5a coated plate of a C3a or C5a ELISA kit was used to detect the unbound anaphylatoxins with specific 
antibodies (plate 3) in a spectralphotometer. 
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Table 3 Plate layout of the anaphylatoxin ELISA, indicating the distribution of the controls and samples.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A Dil. 1 Dil. 1 Dil. 1 Dil. 1 1 Dil. 1 Dil. 1 Dil. 1 Dil. 1    
B Dil. 2 Dil. 2 Dil. 2 Dil. 2 2 Dil. 2 Dil. 2 Dil. 2 Dil. 2    
C Dil. 3 Dil. 3 Dil. 3 Dil. 3 3 Dil. 3 Dil. 3 Dil. 3 Dil. 3    
D Dil. 4 Dil. 4 Dil. 4 Dil. 4 4 Dil. 4 Dil. 4 Dil. 4 Dil. 4    
E Dil. 5 Dil. 5 Dil. 5 Dil. 5 5 Dil. 5 Dil. 5 Dil. 5 Dil. 5    
F Dil. 6 Dil. 6 Dil. 6 Dil. 6 6 Dil. 6 Dil. 6 Dil. 6 Dil. 6    
G Dil. 7 Dil. 7 Dil. 7 Dil. 7 7 Dil. 7 Dil. 7 Dil. 7 Dil. 7    
H Dil. 8 Dil. 8 Dil. 8 Dil. 8 8 Dil. 8 Dil. 8 Dil. 8 Dil. 8    
 Negative 
Control 
trimodulin 
Negative 
Control 
Intratect 
Pos. 
Ctr.  
trimodulin 
(B588036) + 
EDTA-Plasma 
Intratect 
(B791256) + 
EDTA-Plasma 
   
 
4.4.4. Complement-dependent cytotoxicity (CDC) assay 
 
CDC can be initiated by binding of the complement protein C1q to the Fc domain of an antibody 
opsonizing a target cell. The binding of C1q triggers the activation of the complement cascade and leads 
to the formation of the MAC, which forms pores into the membrane causing the lysis of target cells 
(Figure 9).  
 
 
Figure 9 Schematic overview of a CDC assay. (a) Ramos cells that express CD20 on their surface can be used as target cells in the 
CDC assay. (b) The chimeric monoclonal antibody Rituximab binds CD20 and the subsequent incubation with normal human 
serum (NHS) leads to the activation of the complement cascade by binding of C1q to the Fc domain of Rituximab. This triggers 
the formation of the MAC, which forms pores into the membrane and causes the lysis of the Ramos cells. (c) By the addition of 
trimodulin, activated complement components could be inhibited, leading to a reduced complement deposition and cell lysis.  
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4.4.4.1. Rituximab  
 
Rituximab is a CD20 specific chimeric monoclonal antibody used for the treatment of non-
Hodgkin’s lymphoma. By binding human complement component C1q, it activates the classical 
complement pathway and thereby induces B-cell death through CDC. Additionally, it can mediate ADCC 
with human effector cells as well as apoptosis 191,192. 
In the CDC assay, Rituximab is used to initiate the CDC by binding of the complement protein C1q 
to its Fc domain, opsonizing the Ramos cells.  
 
4.4.4.2. Assay procedure 
 
To investigate whether trimodulin can reduce CDC of Ramos cells through the interaction with 
activated complement factors (the complement cascade was activated by the binding of complement 
protein C1q to Rituximab), a flow cytometer-based assay was implemented. Intratect was used as IVIg 
control (see Figure 9). 
Ramos cells were washed twice and adjusted to 5∙106 cells/mL in CDC assay buffer, composed of 
serum-free RPMI-1640 medium and 10 mM HEPES. 50 µL of the cells/well were seeded to a V-bottom 
96 well plate (plate 1) (Table 4) and stored at 37 °C and 5% CO2. For the preparation of different 
dilutions of trimodulin (B588036), Intratect and Rituximab, a 96 well round (U) bottom plate was used 
(plate 2) (Table 5). Rituximab was pre-diluted to 1600 µg/mL in assay buffer and a 10-fold serial dilution 
was performed. In addition, six wells with 150 µL of 160 µg/mL Rituximab in assay buffer were 
distributed. Trimodulin and Intratect were 2-fold serially diluted in their appropriate FB. In another 96 
well U-bottom plate (plate 3) (Table 6), 30 µL of 80% NHS in assay buffer were distributed. The wells 
of plate 3 with only assay buffer are the 100%-killing control.  
Table 4 Distribution of the Ramos cells on plate 1. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
    50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
B       50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
C 50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
        
D       50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
E 50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
 50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
F 50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
50 µL 
Ramos 
cells 
       
G             
H             
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Table 5 Prepared dilutions of Ig preparations and Rituximab on plate 2. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Assay 
buffer 
Assay 
buffer   
  50 
mg/mL 
trim. 
25 
mg/mL 
trim. 
12.5 
mg/mL 
trim. 
6.25 
mg/mL 
trim. 
3.125 
mg/mL 
trim. 
1.5625 
mg/mL 
trim. 
B 
    
        
C Assay 
buffer 
Assay 
buffer 
Assay 
buffer 
Assay 
buffer 
        
D       50 
mg/mL 
Intra. 
25 
mg/mL 
Intra. 
12.5 
mg/mL 
Intra. 
6.25 
mg/mL 
Intra. 
3.125 
mg/mL 
Intra. 
1.5625 
mg/mL 
Intra. 
E 1600 
µg/mL 
Ritux. 
160 
µg/mL 
Ritux. 
16   
µg/mL 
Ritux. 
1.6  
µg/mL 
Ritux. 
0.16  
µg/mL 
Ritux. 
       
F             
G 160 
µg/mL 
Ritux. 
160 
µg/mL 
Ritux. 
160 
µg/mL 
Ritux. 
160 
µg/mL 
Ritux. 
160 
µg/mL 
Ritux. 
160 
µg/mL 
Ritux. 
      
H             
 
Intra. = Intratect; Ritux. = Rituximab; trim. = trimodulin.  
 
Table 6 Distribution of 80% NHS and assay buffer (as 100% killing control) on plate 3. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Assay 
buffer 
Assay 
buffer   
  80% 
NHS 
80% 
NHS 
80% 
NHS 
80% 
NHS 
80% 
NHS 
80% 
NHS 
B 
    
  80% 
NHS 
80% 
NHS 
80% 
NHS 
80% 
NHS 
80% 
NHS 
80% 
NHS 
C Assay 
buffer 
Assay 
buffer 
Assay 
buffer 
Assay 
buffer 
        
D       80% 
NHS 
80% 
NHS 
80% 
NHS 
80% 
NHS 
80% 
NHS 
80% 
NHS 
E 80% 
NHS 
80% 
NHS 
80% 
NHS 
80% 
NHS 
80% 
NHS 
 80% 
NHS 
80% 
NHS 
80% 
NHS 
80% 
NHS 
80% 
NHS 
80% 
NHS 
F 80% 
NHS 
80% 
NHS 
80% 
NHS 
80% 
NHS 
80% 
NHS 
       
G             
H             
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After preparation, the assay components were mixed and incubated in different sequences on their 
appropriate plates:  
 
(1) Pre-incubation of Ig preparations and NHS: 
 
To investigate the effect of trimodulin on complement factors, 15 µL of the diluted Ig preparations 
(trimodulin or Intratect as IVIg control) of plate 2 was mixed with 30 µL of 80% NHS on plate 3. The 
plate was incubated for 1 h at 37 °C and 5% CO2. Afterwards, 15 µL of 160 µg/mL Rituximab (plate 2) 
was mixed with the pre-incubated Ig preparations and NHS. In addition, 15 µL of serially diluted 
Rituximab was mixed with the appropriate wells on plate 3 and 15 µL assay buffer was added. 50 µL/well 
of these dilutions was then transferred to the prepared Ramos cells on plate 1 and incubated for 65 min 
at 37°C and 5% CO2. As 100%-killing control, 10 µL of 8% Triton-X 100 was added to the wells 
containing Ramos cells only and was incubated for additional 15 min at 37 °C and 5% CO2. 
 
(2) Pre-incubation of Ig preparations and NHS and simultaneous pre-incubation of Rituximab and 
Ramos cells: 
 
An additional pre-incubation step was added, in order to evaluate potential effects on CDC of the 
Ramos cells through Rituximab binding to CD20 before the addition of trimodulin. 30 µL of the diluted 
Ig preparations was mixed with the same amount of assay buffer and 60 µL of these dilutions was 
transferred to plate 3. Additionally, 16.5 µL of 160 µg/mL Rituximab was mixed with the Ramos cells 
on plate 1. Both plates were incubated for 1 h at 37 °C and 5% CO2. Subsequently, 66.5 µL of plate 3 
was mixed with the appropriate wells on plate 1 and was incubated for 65 min at 37°C and 5% CO2. As 
100%-killing control, 10 µL of 8% Triton-X 100 was added to the wells containing Ramos cells only and 
was incubated for additional 15 min at 37 °C and 5% CO2. 
  
(3) Incubation of Ig preparations, Rituximab, NHS and Ramos cells at the same time: 
 
To investigate whether the order of the incubation of each component influences the effect of 
trimodulin on CDC, 60 µL of 160 µg/mL Rituximab was mixed with the serially diluted Ig preparations 
on plate 2. In addition, 60 µL of serially diluted Rituximab was mixed with the same amount of assay 
buffer. After that, 30 µL of these dilutions was transferred to plate 3 and was added to the appropriate 
wells. 50 µL/well of these dilutions was added to the prepared Ramos cells on plate 1 and incubated for 
65 min at 37 °C and 5% CO2. As control, 10 µL of 8% Triton-X 100 was added to the wells containing 
Ramos cells only and was incubated for additional 15 min at 37 °C and 5% CO2. 
 
(4) Pre-incubation of Rituximab and Ig preparations: 
 
To analyze, if trimodulin has an impact on the binding of Rituximab to CD20 on the Ramos cells, 
the two components were pre-incubated. Therefore, 60 µL of the wells with 160 µg/mL Rituximab was 
mixed with the serially diluted Ig preparations on plate 2 before the plate was pre-incubated for 1 h at 
37 °C and 5% CO2. The following steps were the same as described in (3).  
 
(5) Incubation of Ig preparations, NHS and Ramos cells, without Rituximab: 
 
To analyze, if trimodulin is able to interact with CD20 on the Ramos cells and thereby inhibits the 
binding of Rituximab to this surface antigen, the same steps as described in (3) were performed. 
Different to the mentioned procedure in (3) was the addition of assay buffer to the Ig preparations, 
instead of Rituximab.  
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(6) Incubation of Ig preparations, Rituximab, Ramos cells and hi NHS: 
 
To examine the effect of Rituximab in the absence of active complement factors, NHS was heat-
inactivated for 30 min in a 56 °C water bath. 30 µL was distributed to the appropriate wells on plate 3. 
After that, the procedure followed the steps described in (3).  
 
After the incubation as described in detail in 1,2,3,4,5 or 6, the plates were analyzed in a flow 
cytometer. To monitor the CD20 expression, the cells were stained with an anti-CD20 antibody, 
conjugated with APC. The antibody was 6-fold pre-diluted in PBS, 10 µL was distributed to the wells and 
the plate was incubated for 30 min at 2-8 °C. To exclude live from dead cells, the plates were centrifuged 
at 1000 x g for 5 min and resuspended in 100 µL propidiumiodid (PI), diluted 500-fold in assay buffer. 
This dye is able to detect dead cells in a population by specific binding the DNA and is not permeant to 
live cells. After incubation for 15 min at RT, the plate was measured in the flow cytometer and CDC was 
indicated as percentage [%-parent] of dead cells within all applied cells per well. The FB of each product 
was used as base level for CDC triggered by Rituximab and given in cell viability [%]. Based on this, the 
change in cell viability caused by trimodulin or Intratect was determined.  
 
4.5. Opsonophagocytosis assay 
 
Opsonophagocytosis is initiated by the opsonization of target cells by antibodies or opsonins, which 
bind to specific receptors on the phagocyte and lead to the killing as well as clearance of the pathogen. 
This opsonophagocytic killing assay was used to determine the antimicrobial ability of trimodulin to 
phagocyte bacteria, like S. aureus and E. coli. Moreover, the influence of the strong ability of IgM in 
trimodulin to activate the complement system compared to Intratect was examined regarding 
opsonization and phagocytosis. Differentiated HL-60 cells were used as effector cells and IgG-/IgM-
depleted serum (NHS minus) as complement source.  
 
4.5.1. Differentiation of HL-60 cells 
 
In order to differentiate HL-60 cells to mature neutrophil-like granulocytes, the cells were counted 
in a Neubauer chamber, centrifuged at 350 x g for 5 min in a 50 mL conical tube and the supernatant 
discarded. After that, they were gently resuspended to 6∙105 cells/mL in IMDM medium containing 20% 
FBS, 1% penicillin-streptomycin and 1.3% DMSO or 0.8% dimethylformamide (DMF). The suspension 
was transferred to a T-175 cell culture flask and was incubated at 37 °C and 5% CO2 for 3-4 days. After 
that, the differentiated HL-60 cells were tested for their phenotype in a FACS Canto II. 
 
4.5.2. Assay procedure (E. coli)  
 
The OPA was performed in 96 well U-bottom plates and was adjusted to the OPA protocol 
described by Burton and Nahm193. Initially, the opsonization buffer (OB) was prepared by mixing 40 mL 
of distilled H2O (dH2O) with 5 mL of 10x Hanks’ Balanced Salt Solution (HBSS) containing Mg2+ and 
Ca2+ and 5 mL of 1% gelatin. 20 µL of the OB was transferred to the wells H1-H9, G4-G9, C1-C9 and B4-
B9 (plate layout, see Table 7). After that, trimodulin and Intratect as IVIg control were 10-fold serially 
diluted in cluster-tubes and 3 µL of the pre-diluted products added to the wells H4-H9, G4-G9, C4-C9 
and B4-B9. Subsequently, the differentiated as well as undifferentiated HL-60 cells (as control) were 
counted in a Neubauer chamber with 0.2% trypan blue solution, centrifuged at 350 x g for 5 min and 
washed with 10 mL OB. A requirement for using the HL-60 cells in the OPA was a cell viability of at least 
90%. For the preparation of the cells, they were again centrifuged at 350 x g for 5 min and resuspended 
to 1∙107 cells/mL in OB. After that, a vial from the frozen assay stock of the E. colis was rapidly thawed 
in a 37 °C water bath and centrifuged at 12000 x g for 2 min. The supernatant was carefully removed 
and discarded. For washing, 1 mL OB was added, mixed and the vial was centrifuged again at 12000 x g 
for 2 min. The bacterial pellet was resuspended in the original volume (0.5 mL) and was 4000-fold 
diluted in 10 mL OB to a concentration of approximately 10000 colony-forming units per mL (CFU/mL). 
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10 µl of this dilution was distributed to the samples and controls, indicated in Table 7 as well Table 8 
and the plate was incubated at RT on a mini orbital shaker (700 rpm) for 30 min. Moreover, NHS minus 
was removed from the freezer and was thawed at RT. To prepare hi NHS minus as control, one vial was 
incubated for 30 min at 56 °C. Afterwards, hi and active NHS minus were diluted to 0.8% in the prepared 
HL-60 cells and 50 µL added to the appropriate wells. The plate was incubated for 45 min at 37 °C and 
5% CO2 on a mini orbital shaker (700 rpm). A required amount of LB agar-plates was dried by removing 
the lid under a clean bench for 30-60 min. After incubation, the 96 well plate was put on ice for 20 min 
to stop the phagocytic process and 5 µL of each well applied in triplets on the LB agar plates as 5 µL 
spots. The plate was immediately tilted until the spots were shaped into small fluid strips of about 2-3 cm 
and left for 10 min at RT to let the excess fluid seek into the agar. Subsequently, the plates were 
incubated upside-down at 37 °C and 5% CO2 for 16-18 h. On the next day, the plates were removed from 
the incubator and the colonies manually counted. The data were analyzed with GraphPad Prism, after 
determination of CFU/mL by the following formula: 
 
CFU/mL = 
Colonies counted ∙ Dilution factor of the bacteria
Amount plated [mL]
 
 
Table 7 Overview of the 96 well plate, indicating the controls and samples used in the OPA (E. coli). 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
            
B    Intra. 
1 
Intra. 
2 
Intra. 
3 
Intra. 
4 
Intra. 
5 
Intra. 
6 
 
  
C Ctr. A Ctr. B Ctr. C Ctr. 
D1 
Ctr. 
D2 
Ctr. 
D3 
Ctr. 
D4 
Ctr. 
D5 
Ctr. 
D6 
   
D       
      
E 
     
 
      
F 
            
G    trim. 
1 
trim. 
2 
trim. 
3 
trim. 
4 
trim. 
5 
trim. 
6 
   
H Ctr. A Ctr. B Ctr. C Ctr. 
D1 
Ctr. 
D2 
Ctr. 
D3 
Ctr. 
D4 
Ctr. 
D5 
Ctr. 
D6 
   
 
Ctr. = control; Intra. = Intratect; trim. = trimodulin.  
Table 8 Composition of the controls and samples used in the OPA (E. coli). 
Sample Composition 
Ctr. A Bacteria + hi NHS minus + undifferentiated HL-60 cells + FB 
Ctr. B Bacteria + hi NHS minus + differentiated HL-60 cells + FB 
Ctr. C Bacteria + NHS minus + differentiated HL-60 cells + FB 
Ctr. D Bacteria + hi NHS minus + differentiated HL-60 cells + Ig preparation  
Sample Bacteria + NHS minus + differentiated HL-60 cells + Ig preparation 
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4.5.3. Assay procedure (S. aureus)  
 
The OPA, described in 4.5.2 was performed with living E. coli (K12) bacteria that were non-
pathogenic. Here, an additional OPA was performed with Alexa Fluor 488 labeled S. aureus bioparticles. 
The particles are devitalized and could therefore be used in a biosafety level 1 laboratory. The test was 
adjusted to a FACS-based method (based on the protocol of Fabian Bohländer; PhD thesis), to determine 
the fluorescence of differentiated HL-60 cells after the phagocytosis of the labeled bacteria. The 
composition of the controls and samples was the same as described in Table 8. Initially, one vial 
containing the lyophilized S. aureus pellet was resuspended with 500 µL Dulbecco’s PBS (D-PBS) to 
obtain approximately 5∙107 particles/mL and sonicated for 1 min. After that, the differentiated and 
undifferentiated HL-60 cells were centrifuged at 350 x g for 5 min, the supernatant removed and 
resuspended to 1.25∙106 cells/mL. 1 mL of the cells was distributed per well to 24 well F-bottom plates. 
Subsequently, 10 µL of the S. aureus bioparticles and 20 µL of NHS minus as well as hi NHS minus were 
added to the cells and mixed. Different dilutions of trimodulin and Intratect were prepared by 
distributing the appropriate volume of the products to the wells and filling up with FB to obtain the same 
end-volume (1700 µL) in every well (Table 9). Moreover, Intratect was 1.8-fold pre-diluted in FB to the 
same IgG amount like trimodulin (⋲ 56% IgG) and was afterwards added to the plate. The plates were 
incubated for 45 min at 37 °C. After incubation, the content of the 24 well plate was transferred to a 96 
well deep well plate and centrifuged for 5 min at 350 x g. The supernatant was removed and the pellet 
was resuspended with 250 µL D-PBS. After an additionally centrifugation step at 350 x g for 5 min and 
resuspension with 250 µL D-PBS, 125 µL per well were transferred to a 96 well V bottom plate in doublets 
(Table 10). To ensure the measurement of just phagocytosed bioparticles by the differentiated HL-60 
cells and to reduce the background fluorescence produced by bacteria that bound unspecifically to the 
surface of the cells, 30 µL of trypan blue solution was added for quenching. The plate was incubated for 
5-10 min at 2-8 °C and centrifuged at 350 x g for 5 min. Subsequently, the pellet was resuspended with 
100 µL D-PBS and the plate measured in the flow cytometer. To monitor the opsonophagocytosis of the 
Alexa Fluor 488 labeled S. aureus bioparticles initiated by trimodulin, the phagocytic index of the HL-60 
cells was analyzed by using Excel and GraphPad Prism. It depicts the uptake of the labeled bacteria by 
the effector cells and was calculated by multiplying the median fluorescence intensity of the bacteria per 
positive cell with the percentage of the HL-60 cells containing at least one bacterium.  
Table 9 Dilutions of trimodulin and Intratect used in the OPA (S. aureus) 
Dilution Concentration Dilution Factor 
1 20 mg/mL 2.5 
2 15 mg/mL 3.33 
3 10 mg/mL 5 
4 5 mg/mL 10 
5 1 mg/mL 50 
6 0.5 mg/mL 100 
7 0.1 mg/mL 500 
8 0.05 mg/mL 1000  
9 0.01 mg/mL 5000 
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Table 10 Overview of the 96 well plate, indicating the controls and samples used in the OPA (S. aureus) 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
   
Intra. 
1 
Intra. 
2 
Intra. 
3 
Intra. 
4 
Intra. 
5 
Intra. 
6 
Intra. 
7 
Intra. 
8 
Intra. 
9 
B    Intra. 
1 
Intra. 
2 
Intra. 
3 
Intra. 
4 
Intra. 
5 
Intra. 
6 
Intra. 
7 
Intra. 
8 
Intra. 
9 
C Ctr. A Ctr. B Ctr. C Ctr. 
D1 
Ctr. 
D2 
Ctr. 
D3 
Ctr. 
D4 
Ctr. 
D5 
Ctr. 
D6 
Ctr. 
D7 
Ctr. 
D8 
Ctr. 
D9 
D Ctr. A Ctr. B Ctr. C Ctr. 
D1 
Ctr. 
D2 
Ctr. 
D3 
Ctr. 
D4 
Ctr. 
D5 
Ctr. 
D6 
Ctr. 
D7 
Ctr. 
D8 
Ctr. 
D9 
E 
   
trim. 
1 
trim. 
2 
trim. 
3 
trim. 
4 
trim. 
5 
trim. 
6 
trim. 
7 
trim. 
8 
trim. 
9 
F 
   
trim. 
1 
trim. 
2 
trim. 
3 
trim. 
4 
trim. 
5 
trim. 
6 
trim. 
7 
trim. 
8 
trim. 
9 
G Ctr. A Ctr. B Ctr. C Ctr. 
D1 
Ctr. 
D2 
Ctr. 
D3 
Ctr. 
D4 
Ctr. 
D5 
Ctr. 
D6 
Ctr. 
D7 
Ctr. 
D8 
Ctr. 
D9 
H Ctr. A Ctr. B Ctr. C Ctr. 
D1 
Ctr. 
D2 
Ctr. 
D3 
Ctr. 
D4 
Ctr. 
D5 
Ctr. 
D6 
Ctr. 
D7 
Ctr. 
D8 
Ctr. 
D9 
 
Ctr. = control; Intra. = Intratect; trim. = trimodulin.  
 
4.5.4. Flow cytometric analysis  
 
In order to determine the phagocytosis of S. aureus bioparticles by HL-60 cells, a flow cytometer 
was used. This instrument allows the analysis of separated cells and particles one by one. The 
fluorescence-labeled samples are diluted inside the instrument to single-cells and therefore pass 
uniformly through the center of laser beams. This leads to the excitation of the fluorophores, thereby 
emitting fluorescence that is guided through optical filters as well as mirrors to specific detectors. The 
detectors are wavelength-sensors in terms of photomultiplier tubes (PMTs), which amplify electric 
signals and convert them to a voltage pulse. It is displayed in the software as event and shows detailed 
information as well as characteristics of a cell population. Moreover, two detectors of a flow cytometer 
measure the light scattering. The forward scatter (FSC) defines the size and the sideward scatter (SSC) 
the granularity of a cell. 
The used FACS Canto II is a flow cytometer that offers a blue (488 nm), a red (633 nm) and a 
violet (405 nm) laser. The 8 fluorescence channels can define up to 8 cellular parameters.  
In the OPA (S. aureus) the HL-60 cells were initially tested for their phenotype and their 
differentiation status, before the phagocytosis of the bioparticles could be determined. Therefore, the 
antibodies were added to 100 µL of 1∙106 cells/mL: 
Table 11 Antibodies and volumes required for HL-60 cell stain. 
Excitation Laser Fluorescence channel Antibody Required Volume  
488 nm 
PE Anti-human CD32 20 µL 
FITC Anti-human CD35 20 µL 
633 nm 
APC Anti-human CD71 20 µL 
Alexa Fluor 700 Anti-human CD64 5 µL 
405 nm 
V500 Anti-human CD16 5 µL 
Pacific Blue Anti-human CD11b 20 µL 
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The anti-human CD16, CD32 and CD64 antibodies bind to the IgG Fc receptors FcγRIII, FcγRII and 
FcγRI, respectively. They are among others expressed on neutrophil granulocytes and play a role in 
mediating phagocytosis. CD35 is known as complement receptor 1 (CR1) or C3b/C4b receptor and 
enhances the clearance of complement opsonized immune complexes through phagocytosis by 
neutrophils. Undifferentiated HL-60 cells show a decreased expression of CD35, whereas the expression 
increases with the differentiation status of the cells. In comparison to CD35, transferrin receptor 1 
(CD71) expression is downregulated in differentiated HL-60 cells. The anti-human CD11b antibody 
binds to one subunit of the complement receptor 3 (CR3), which consists of CD11b as well as CD18 and 
can be found on neutrophil granulocytes, where it is a specific receptor for iC3b and additionally 
mediates phagocytosis.  
To monitor the expression of these receptors on differentiated HL-60 cells, they were centrifuged 
at 350 xg for 5 min, the supernatant discarded and resuspended to 1∙106 cells/mL in D-PBS. 100 µL/well 
was distributed on a V-bottom 96 well plate and the required volume of each antibody was added (Table 
11). When performing multicolor fluorescence, spectral overlap between the fluorophores is possible. 
Therefore it is important to apply a mathematically correction, called compensation. For this purpose, 
single stained cells were distributed to the plate. Moreover, background fluorescence through unspecific 
binding of the antibodies was measured by the addition of the appropriate isotype controls. 
Subsequently, the plate was incubated for 30 min at 2-8 °C. After that, it was centrifuged at 350 x g for 
5 min and resuspended in 100 µL D-PBS. The cell suspension was analyzed using the FACS Canto II and 
the software BD FACSDiva. A template for each stain was designed and the appropriate PMT voltages, 
strategies and the automatic compensation applied. After that, the data were analyzed by using the 
software FlowJo X.  
 
4.6. Protein analyses  
 
In order to determine, if trimodulin is able to inhibit complement activation by scavenging the 
activated factors C3b and C4b in the fluid phase or if this is due to a covering of the deposited opsonins, 
the supernatant of the ELISA described in 4.4.1 was analyzed in a sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) and a subsequent Western Blot.  
 
4.6.1. SDS-PAGE 
 
SDS-PAGE is a method to separate proteins in an electric field depending on their size. It is 
performed by using a discontinuous polyacrylamide gel and a reducing agent that destroys the disulfide 
bonds of the proteins. Moreover, SDS is used to cover the intrinsic charge of the proteins to obtain 
continuous negatively charged, denatured samples. After the prepared samples are applied to the gel, 
an electric field is generated upon voltage application. The negatively charged proteins migrate towards 
the anode and are separated depending on their size, which is proportional to their molecular mass. The 
specific protein bands that develop through the separation emerge by the migration of smaller and larger 
proteins. The smaller ones move faster and the larger proteins are stronger retained in the gel. These 
bands can be visualized by using a Coomassie solution or by blotting it to a membrane and labeling the 
proteins with specific antibodies.  
The SDS-PAGEs were performed by using a NuPage system and 8% bis-tris gels. Initially, the 
samples were diluted 2-fold in loading buffer, consisting of 1x LDS-sample buffer, 1x TCEP solution 
(reducing agent) and distilled water. In order to denature the samples, they were incubated for 10 min 
at 70 °C in a heating block. After that, the bis-tris gels were installed to the XCell SureLock Mini-Cell 
electrophoresis chamber and filled with 1x MOPS SDS running buffer. Additionally, 500 µL Antioxidant 
was added to the inner chamber. 10 µL of the prepared samples was distributed to the slots of the gel 
and 10 µL of the ready-to-use All Blue Prestained Protein Standard was added to the outer two slots. 
The electrophoresis chamber was connected to a power supply and run at 200 V for approximately 45 
min. Subsequently, the gel was removed from the plastic cover and was transferred to a membrane for 
Western Blotting.  
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4.6.2. Western Blot 
 
During a Western Blot, proteins that were separated by SDS-Page (4.6.1) are transferred to a 
nitrocellulose membrane and detected via specific antibodies. The transfer is achieved by an electric 
field, in which the negatively charged proteins move towards the anode. The proteins migrate from the 
gel to the membrane, thereby remain in place and bind. After that, the membrane is blocked to prevent 
unspecific binding of the detection antibody. The antibodies are added, incubated and bind to the specific 
proteins of interest. Moreover, the secondary antibody that is labeled with a fluorophore, binds to the 
primary antibody and the proteins are detected by an imager.  
The Western Blots were performed by using an X Cell II Blot Module. Initially, a nitrocellulose 
membrane was equilibrated in 1x Western Blot Buffer for 10 min, containing Transfer Buffer (Thermo 
Scientific), 10% methanol, 0.1% Antioxidant and distilled water. Meanwhile, sponge pads and filter 
papers were also soaked in 1x Western Blot Buffer and transferred to the Blot Module. Three sponge 
pads were placed at the bottom of the module, followed by a filter paper, the gel, the membrane, a 
second filter paper and again three sponge pads. The Blot Module was transferred to the X Cell Sure 
Lock electrophoresis chamber and filled up with 1x Western Blot Buffer, whereas distilled water was 
added to the outer chamber. After that, the chamber was connected to the power supply and run at 
100 V as well as 60 mA for 85-95 min. Subsequently, the membrane was transferred to Blocking Buffer 
and was incubated for 1 h on an orbital shaking platform at RT. The buffer was discarded and the 
primary antibody mix, diluted in Blocking Buffer containing 0.005% Tween 20 was added to the 
membrane (see Table 12). It was incubated for 1 h on an orbital shaking platform at RT. Afterwards, the 
membrane was washed in PBS containing 1x Tween 20 and incubated for 5 min on an orbital shaking 
platform. The washing solution was decanted and the washing procedure was repeated 4-5 times. The 
secondary antibody mix, diluted in Blocking Buffer containing 0.005% Tween 20 was added to the 
membrane and was incubated overnight on the orbital shaker at RT (see Table 12). On the next day, the 
antibody solution was discarded and washed in PBS containing 1x Tween 20 for 4-5 times as before. 
After that, two additional washing steps with 1x D-PBS were applied for 5 min each and finally the 
membrane was rinsed in distilled water, dried between filter paper and was scanned with the Typhoon 
Imager.  
Table 12 Primary and secondary antibodies used in the Western Blot. 
Primary antibody mix Dilution 
In 25 mL 
Blocking 
Buffer 
Secondary antibody mix Dilution 
Mouse anti-human IgM 1000-fold Donkey anti-mouse 26666-fold 
Rabbit anti-human IgG 20000-fold Donkey anti-rabbit 26666-fold 
Goat anti-human C3c 1000-fold Donkey anti-goat 26666-fold 
Tween 20 20000-fold Tween 20 20000-fold 
 
 
4.7. Statistical analyses  
 
All statistical analyses were performed with the software GraphPad Prism. The data were depicted 
as mean with SD or standard error of the mean (SEM). To verify normal distribution of the data, a 
Kolmogorov-Smirnov or a Shapiro-Wilk test was used. Moreover, the significance for normally 
distributed data was calculated using a one-way ANOVA and a Bonferroni correction to compare more 
than two different groups. In order to compare more than two groups that are not normally distributed, 
the Kruskal-Wallis test was used. In addition, the Mann-Whitney test or Wilcoxon test was used for 
non-parametric calculations of two groups or pairs. The significance was shown as p-values and 
quantified with asterisks: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
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5. Results 
 
Trimodulin exhibits various antimicrobial as well as immunomodulatory functions, which were 
shown in the past in many in vitro assays (see chapter 1.9.2)165,166. Nevertheless, the complex interactions 
caused by the mixture of IgG, IgM and IgA in trimodulin are not fully understood and have to be further 
evaluated in pre-clinical as well as clinical studies. The aim of this thesis was to further characterize the 
effects of trimodulin on the human complement system. Therefore, different in vitro assays were 
developed, to analyze if trimodulin is able to activate, but also to inhibit the complement cascades 
concentration-dependently. An opsonin, a fluid phase as well as an anaphylatoxin ELISA were used to 
monitor the binding and inhibition of various complement factors by trimodulin. Moreover, a CDC assay 
was established to evaluate the functional effect of trimodulin regarding complement inhibition. Finally, 
different OPA assays were used to detect complement activation and the associated opsonophagocytosis 
of bacteria.  
 
5.1. Analysis of the hemolytic activity of different complement sources for the use in this 
thesis  
 
In order to use different complement sources in the following assays, their hemolytic activity was 
previously determined by using the CH50 test. EDTA-plasma was used as complement source in the 
complement targeting assays, whereas NHS and hi NHS (used as control) were suitable complement 
sources for the CDC assay. Moreover, NHS IgG/IgM depleted as well as hi NHS IgG/IgM depleted (used 
as control) were applied in the OPA. For this purpose, active as well as hi plasma and serum were 
incubated with antibody-sensitized sheep erythrocytes. The more hemolysis was induced, the higher was 
the activity of the tested complement sources. Sera that were heat-inactivated and served as negative 
controls for complement activity did not show hemolytic activity in the CH50 test and were considered 
as suitable for the use in the assays as controls. NHS and EDTA-plasma were also appropriate 
complement sources for the different assays, because the values were within the reference range, with 
activities of 97% and 90%. IgG/IgM depleted NHS exhibited an activity of 51% in the CH50 test. 
Although, this was beneath the lower limit of the reference range, it was still used, because the absence 
IgM and IgG was an important requirement for the use in the OPA. Other depleted serum sources, tested 
in the CH50 showed even no activity due to their treatment by which the Igs were removed (data not 
shown).  
Table 13 Activity of different complement sources in the CH50 test. 
Complement Source CH50 Activity  Reference Range 
EDTA-plasma 90% 
74-151% 
NHS 97% 
Hi NHS No activity 
NHS IgG/IgM depleted 51% 
Hi NHS IgG/IgM depleted No activity 
 
5.2. Immunomodulatory effects of trimodulin on the complement system 
 
The activation of the complement cascade is an important function of the body’s immune system 
to react against invading pathogens and to fight infections. Nevertheless, complement activation is not 
always beneficial and can also lead to inflammatory reactions due to an over-stimulated immune system. 
Hence, the ability of trimodulin to interact with activated complement factors and to reduce 
complement-mediated cytotoxicity was determined.  
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5.2.1. Trimodulin reduces the detection of the complement factors C3b and C4b 
concentration-dependently in the ELISA setting 
 
In order to analyze, if trimodulin is able to interact with the opsonins C3b and C4b, an ELISA was 
performed. Initially, C3b was detected, after the addition of different concentrations of trimodulin. 
Moreover, three batches (B588016, B588026 and B588036) were compared in their ability to reduce 
the C3b detection (Figure 10). Intratect was used as IVIg control, because the differences between IgM 
and IgA in binding complement factors compared to pure IgG should be evaluated. Figure 10 shows the 
detection of C3b deposition on aggregated IgG. Trimodulin induced a concentration-dependent decrease 
in C3b detection. In addition, all three batches were highly comparable (Figure 10a). The optical density 
(OD) of the 100% C3b control (without trimodulin) was approximately 3.3 and was continually reduced 
to approximately 0.9 after addition of 12.5 mg/mL, which was the highest used trimodulin 
concentration. Compared to this, Intratect initially induced a slight increase in C3b detection in the 
lowest used concentration (0.05 mg/mL) and only after the addition of 0.5 mg/mL a slight decrease was 
seen. To compare the abilities of trimodulin and Intratect to reduce the C3b detection concentration-
dependently, a statistical analysis was performed (Figure 10b). A significant decrease was seen after the 
addition of 12.5 mg/mL trimodulin compared to the addition of only trimodulin FB. Moreover, the 
difference between the highest used trimodulin and Intratect concentration (12.5 mg/mL) to compare 
the ability of both products was statistically significant. The difference between 12.5 mg/mL Intratect 
and the addition of only Intratect FB (w/o Intratect), was not significant. These data suggests that 
trimodulin inhibits the detection of C3b stronger than Intratect.  
  
 
Figure 10 Trimodulin inhibits the detection of C3b concentration-dependently. (a) A 96 well F bottom plate was coated with 
0.1 µg/mL aggregated IgG (Intratect). After washing with TBS-T washing buffer, different dilutions of three batches trimodulin 
(blue) and Intratect (green; used as IVIg control) were distributed to the plate and mixed with 100-fold pre-diluted EDTA-plasma. 
After incubation for 1 h at 37 °C, an anti-human C3c antibody that is able to detect C3b and iC3b as well as a secondary goat 
anti-rabbit antibody (conjugated to HRP) were added. Finally, the plate was measured in an ELISA reader. Error bars indicate 
the standard error of the mean (SEM). Data represent results from six independent experiments performed in duplicates. (b) 
The highest used trimodulin and Intratect concentrations were compared with each other as well as with FB only (without (w/o) 
the products). Error bars indicate the SEM. Data represent results from six independent experiments performed in duplicates. 
The statistical analyses were performed using a Kruskal-Wallis test. Significance is shown as p-value: * p ≤ 0.05 and **** p ≤ 
0.0001.  
In order to analyze, if trimodulin is also able to reduce the C4b detection, an additional ELISA was 
performed. Figure 11 shows the detection of C4b on aggregated IgG after different concentrations of 
trimodulin and Intratect were added. Three batches of trimodulin (B588016, B588026 and B588036) 
were again compared in their ability to reduce the C4b detection. The detection of C4b was 
concentration-dependently decreased after the addition of trimodulin and all three used batches were 
highly comparable. The OD was reduced from 1.8 (w/o trimodulin) to approximately 0.4. In comparison 
to this, Intratect induced a strong increase in C4b detection in the lowest used concentration 
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(0.05 mg/mL) and the decrease started after the addition of 5 mg/mL Intratect. In order to compare the 
abilities of 12.5 mg/mL trimodulin to 12.5 mg/mL Intratect and to the appropriate FBs, a statistical 
analysis was performed (Figure 11). The difference between 12.5 mg/mL and trimodulin FB (w/o 
trimodulin) to reduce the C4b detection, was statistically significant. Moreover, the comparison of 
12.5 mg/mL trimodulin and 12.5 mg/mL Intratect showed that the products were significantly different 
in their ability to decrease the C4b detection. Trimodulin can inhibit the detection of C4b stronger 
compared to Intratect. 
 
 
Figure 11 Trimodulin inhibits the detection of C4b concentration-dependently. (a) A 96 well F bottom plate was coated with 
0.1 µg/mL aggregated IgG (Intratect). After washing with TBS-T washing buffer, different dilutions of three batches trimodulin 
(blue) and Intratect (green; used as IVIg control) were distributed to the plate and were mixed with 100-fold pre-diluted EDTA-
plasma. After incubation for 1 h at 37 °C, an anti-human C4c antibody that is able to detect C4b and iC4b as well as a secondary 
goat anti-rabbit antibody (conjugated to HRP) were added. Finally, the plate was measured in an ELISA reader. Error bars 
indicate the standard error of the mean (SEM). Data represent results from six independent experiments performed in 
duplicates. (b) The highest used trimodulin and Intratect concentrations were compared with each other as well as with FB only 
(without (w/o) the products). Error bars indicate the SEM. Data represent results from six independent experiments performed 
in duplicates. The statistical analyses were performed using a Kruskal-Wallis test. Significance is shown as p-value: **** p ≤ 
0.0001.  
 
5.2.2. Analysis of the influence of IgM on C3b deposition 
 
In order to determine, if the IgM fraction of trimodulin was responsible for the reduced C3b 
detection in the opsonin ELISA (see section 5.2.1), a fluid phase ELISA was performed. For this purpose, 
the supernatant of the opsonin ELISA was transferred to a second plate, coated with an anti-human C3c 
antibody (that is also able to bind C3b as well as iC3b) and the binding of IgM to C3b was detected with 
a mouse anti-human IgM antibody (Figure 12). The data revealed, the more trimodulin was added to 
the opsonin ELISA plate, the more IgM was able to bind to the C3b fragments in the supernatant, which 
was transferred to the fluid phase ELISA plate. Nevertheless, trimodulin incubated with GVB++ instead 
of EDTA-plasma showed the same concentration-dependent increase in IgM detection as incubated with 
EDTA-plasma. It was suggested that the effect, seen after addition of the control (without EDTA-plasma), 
was due to an unspecific binding of trimodulin to the C3c coating in the absence of plasma. For this 
reason, it could not be assumed that the IgM fraction of trimodulin was mainly responsible for the 
binding of C3b in the fluid phase on the opsonin ELISA plate, which resulted in the reduced detection of 
C3b (see Figure 10). 
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Figure 12 Analysis of the IgM-C3b interaction using a fluid phase ELISA. The supernatant of the opsonin ELISA (see chapter 
4.4.1) was transferred to a second plate coated with an anti-human C3c antibody and the binding of IgM to C3b was detected 
with a primary mouse anti-human IgM antibody and a secondary rabbit anti-mouse IgG antibody conjugated to HRP. In order 
to exclude unspecific binding of trimodulin (B588036) to the anti-C3c coating, trimodulin was incubated with GVB++ instead of 
EDTA-plasma. After incubation of the plate for 1 h at 37 °C and the addition of the specific antibodies, the plate was measured 
in an ELISA reader. Error bars indicate the SEM. Data represents results from three independent experiments performed in 
duplicates. 
 
5.2.3. Trimodulin covers activated complement factors in the ELISA setting 
 
The opsonin ELISA revealed a concentration-dependent decrease in C3b and C4b detection after 
trimodulin addition. In order to analyze, if this was due to scavenging of the opsonins or to an overlay 
of trimodulin on the deposited complement factors, a SDS-PAGE and a subsequent Western blot analysis 
of the ELISA supernatants were performed (Figure 13). C3b (blue) as well as IgM (green) and IgG (red) 
were detected in the Western Blot analysis. The All Blue Prestained Protein Standard served as molecular 
weight marker (MW Marker) and was distributed to lane 1 and 12. It was used as standard for the 
determination of the sample size. In general, the IgG heavy chain was detected at ⋲ 50 kDa and the light 
chain at ⋲ 25 kDa. The bands in between were analyzed using mass spectrometry (PhD Thesis Fabian 
Bohländer) and show fragments of IgG. Bands at ⋲ 80 kDa represent IgG heavy and light chains that 
were non-separated. Moreover, bands at ⋲ 125 kDa show IgG molecules that were not reduced in the 
SDS-PAGE. The heavy chain of IgM was clearly detected at ⋲ 75 kDa, whereas the bands at ⋲ 60 kDa 
depict IgM fragments. Moreover, the alpha-chain of C3b is visible at ⋲ 105 kDa, the iC3b alpha-chain at 
⋲ 65 kDa and in addition the C3b as well as iC3b beta-chain slightly at ⋲ 75 kDa. Lane 2 was used as 
negative control for C3b detection consisting of 12.5 mg/mL trimodulin and GVB++ without serum. The 
positive control for C3b detection (lane 3), containing serum and GVB++, was used as 100% control for 
C3b detection and exhibits a band for the iC3b alpha-chain at ⋲ 65 kDa. Lane 4 and 5 were also used as 
controls for pure C3b. The bands in lane 6-8 represent the EDTA-plasma samples from the opsonin ELISA 
(see 5.2.1), treated with 12.5 mg/mL (lane 6), 5 mg/mL (lane 7) and 0.05 mg/mL (lane 8) trimodulin. 
In the highest and the medium used trimodulin concentrations, the iC3b alpha-chain was not detectable. 
Just after addition of the lowest used trimodulin concentration a band became visible. This was also the 
case for lane 9-11, where Intratect-treated EDTA-plasma samples are displayed. No bands for the iC3b 
alpha-chain could be detected after the addition of 12.5 mg/mL (lane 9) as well as 5 mg/mL Intratect 
(lane 10). Just after the treatment with 0.05 mg/mL Intratect (lane 11), a band for iC3b was revealed.  
These data were used to analyse, if a scavenging or the covering of C3b by trimodulin leads to its 
reduced detection in the ELISA assay. It is suggested that trimodulin rather covers and binds C3b 
deposited on aggregated IgG, because the supernatant contained no C3b in the highest as well as 
medium used trimodulin concentration (lane 6 and 7). For confirmation of the scavenging theory, which 
means the binding and removal of C3b in the fluid phase, the tested supernatant should have contained 
a high amount of C3b, when treated with a high amount of trimodulin. In the lowest used trimodulin 
concentration (0.05 mg/mL), a band for iC3b alpha-chain became visible. This leads to the assumption 
that the less trimodulin is available, the less C3b is pushed down to the aggregates and therefore a high 
amount of C3b is still in the supernatant, which is subsequently detected in the Western Blot analysis.  
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Figure 13 SDS-PAGE and Western blot of the opsonin ELISA supernatant. An opsonin ELISA was performed as described in 4.4.1 
and the supernatant was used for a subsequent SDS-PAGE and Western Blot analysis. As molecular weight (MW) marker the All 
Blue Prestained Protein Standard was added to lane 1 and 12. Lane 2 contained the negative control for C3b detection 
(12.5 mg/mL trimodulin + GVB++). The positive controls for C3b detection (EDTA-plasma + GVB++ as well as purified C3b) were 
distributed to lane 3-5. Lane 6-8 contained the plasma samples from the opsonin ELISA (described in 5.2.1) with low, medium 
and high trimodulin (B588036) concentrations and lane 9-11 the serum samples with low, medium and high Intratect 
concentrations (used as IVIg control). The Western Blot was scanned in a Typhoon imager and was analyzed with the software 
Image Quant TL. The green band at ⋲ 75 kDa represents the heavy chain of IgM, whereas the green band at ⋲ 60 kDa is an IgM 
fragment. The blue bands show the C3b alpha-chain at ⋲ 105 kDa and the iC3b alpha-chain at ⋲ 65 kDa. The C3b and iC3b beta-
chains are weakly visible at ⋲ 75 kDa. IgG is depicted in red with the heavy chain at ⋲ 50 kDa and the light chain at ⋲ 25 kDa. 
Between 50 kDa and 25 kDa fragments of IgG are detected. Moreover, non-reduced IgG is depicted at ⋲ 125 kDa and non-
separated heavy and light chains of IgG at ⋲ 80 kDa. Data represent results from three independent experiments. 
 
5.2.4. Interaction of trimodulin and anaphylatoxins 
 
Besides the generation of opsonins after activation of the complement cascade, it is also important 
to control the amount of generated anaphylatoxins, to prevent complement-mediated cytotoxicity and 
inflammation. The opsonin ELISA showed a significant decrease of C3b and C4b detection after the 
addition of trimodulin (see 5.2.1). In order to determine, if trimodulin is also able to interact with C3a 
and C5a, an anaphylatoxin ELISA was established.  
 
5.2.4.1. Detection of C5a using a trimodulin-coated plate 
 
After trimodulin was coated to the plate in different dilutions, purified C5a was added, incubated 
and the plate was measured in an ELISA reader (Figure 14). In general, the detection of C5a was rather 
low, nevertheless a concentration-dependent decrease after the addition of trimodulin was observed. 
However, the incubation of trimodulin with only GVB++ revealed the same detection and concentration-
dependent decrease as with purified C5a. These results suggest that the used primary or secondary 
detection antibody bound unspecifically to trimodulin, which was coated to the plate. For this reason, it 
could not be distinguished, if the detected decrease of C5a was caused by the binding of trimodulin to 
this anaphylatoxin or if just the trimodulin coating was detected.  
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Figure 14 Results of the anaphylatoxin ELISA using a trimodulin-coated plate. A 96 well F bottom plate was coated with 100 µL 
serially diluted trimodulin (B588036) and was incubated overnight at 2-8 °C. Carbonate bicarbonate buffer served as control for 
the specific binding of C5a to trimodulin. After washing, the plate was blocked with PBS containing 5% BSA as well as 0.1% 
Tween 20 and 50 µL of 350 ng/mL purified C5a was added to the wells. Additionally, GVB++ instead of C5a was used as control 
for the unspecific binding of the primary anti-C5a antibody to trimodulin. The plate was incubated for 1 h at 37 °C, washed and 
after addition of the primary as well as secondary goat antibodies measured in an ELISA reader. Error bars indicate the SD. Data 
represent results from two independent experiments performed in duplicates.  
 
5.2.4.2. Detection of C5a and C3a after trimodulin addition using a zymosan-
coated plate 
 
Since the trimodulin-coated ELISA plate was unsuitable for the analysis of the trimodulin-
anaphylatoxin interaction due to unspecific binding of the detection antibody to the coating, another 
setup was chosen. A zymosan-coated plate was used for the activation of the complement cascade and 
the generation of C3a as well as C5a in human EDTA-plasma. After transferring the supernatant 
containing the activated anaphylatoxins to a second plate coated with an anti-IgG, -IgA and -IgM 
antibody mix, trimodulin was added in different dilutions. Only the unbound C3a or C5a molecules were 
transferred to a third plate coated with specific anti-human C3a or C5a antibodies and detected in an 
ELISA reader (Figure 15). If trimodulin is able to bind and immobilize activated C3a or C5a on plate 2, 
then the anaphylatoxin detection on plate 3 would be reduced, compared to the control with trimodulin 
FB only. Figure 15a shows a high amount of generated C3a during the ELISA without the addition of 
trimodulin. The controls revealed that the detection antibody (anti-human C3a) did not bind to the anti-
C3a coating unspecifically. Nevertheless, the addition of different dilutions of trimodulin as well as 
Intratect (used as IVIg control) did not induce a reduction of the C3a detection, which stayed high at 
⋲ OD 3.3.  
Figure 15b shows the detection of C5a after the treatment with trimodulin and Intratect (used as 
IVIg control). In comparison to C3a, the generation of C5a was lower, but still well detectable without 
trimodulin (⋲ OD 2.2). As described in Figure 15a for C3a, the C5a detection antibody did not bind to 
the anti-C5a coating unspecifically. After the addition of 0.65 µg/mL trimodulin, a slight decrease of C5a 
was visible. This decrease proceeded until a concentration of 22.22 µg/mL trimodulin. The difference 
between the OD of the 100% C5a control without trimodulin and the OD at 22.22 µg/mL trimodulin 
treatment was 0.85. Statistical analyses were performed using a Kruskal-Wallis test, because the data 
were not normally distributed, but revealed no significance. Moreover, in comparison to trimodulin, 
Intratect had no decreasing effects on the C5a detection. 
1
0
0
 µ
g
/m
L
 t
r i
m
o
d
u
li
n
 +
 C
5
a
1
0
0
 µ
g
/m
L
 t
r i
m
o
d
u
li
n
 +
 G
V
B
+
+
1
0
 µ
g
/m
L
 t
r i
m
o
d
u
li
n
 +
 C
5
a
1
0
 µ
g
/m
L
 t
r i
m
o
d
u
li
n
 +
 G
V
B
+
+
1
 µ
g
/m
L
 t
r i
m
o
d
u
li
n
 +
 C
5
a
1
 µ
g
/m
L
 t
r i
m
o
d
u
li
n
 +
 G
V
B
+
+
0
.1
 µ
g
/m
L
 t
r i
m
o
d
u
li
n
 +
 C
5
a
0
.1
 µ
g
/m
L
 t
r i
m
o
d
u
li
n
 +
 G
V
B
+
+
C
a
rb
o
n
a
te
 b
ic
a
rb
o
n
a
te
 b
u
ff
e
r  
+
 C
5
a
0 .0 0
0 .0 5
0 .1 0
0 .1 5
C
5
a
 d
e
te
c
ti
o
n
 [
O
D
4
5
0
/6
9
0
 n
m
]
   
Results   47 
These results suggests that trimodulin is able to slightly reduce activated C5a and can therefore 
influence the complement-mediated cytotoxicity triggered by this anaphylatoxin. The inhibition of C3a 
could not be detected in the described ELISA, which leads to the assumption that trimodulin can not 
bind to this anaphylatoxin and influences its activation.  
 
Figure 15 Results of the anaphylatoxin ELISA using a zymosan-coated plate. One 96 well F bottom plate was coated with 
zymosan and another 96 well F bottom plate with an anti-human IgG/IgA/IgM antibody mix in carbonate bicarbonate buffer 
and incubated overnight at 2-8 °C. After washing, EDTA-plasma was added to the zymosan-coated plate for activation of the 
complement cascade and was incubated at 37 °C for 1 h. The supernatant was transferred to the anti-IgG/IgA/IgM-coated plate 
and was mixed with different dilutions of trimodulin (B588036). For immobilization and binding of C3a or C5a to trimodulin, 
the plate was again incubated for 1 h at 37 °C. Finally, the supernatant was transferred to a third plate, either coated with a 
specific anti-human C3a (a) or a specific anti-human C5a antibody (b) and measured in an ELISA reader at 450/690 nm. Error 
bars indicate the SEM. Data represent results from three independent experiments performed in duplicates.  
 
5.2.5. Functional interaction of trimodulin with activated complement components  
 
5.2.5.1. Trimodulin reduces the CDC of Ramos cells concentration-
dependently  
 
In order to confirm the previous results of the C3b/C4b ELISA in a biologically functional context 
and to investigate whether trimodulin can reduce CDC of Ramos cells through interaction with activated 
complement factors, a flow-cytometer-based CDC assay was used.  
Initially, control experiments were performed, to determine the CD20 expression and the viability 
of the Ramos cells with and without the addition of Rituximab. Figure 16a shows the CD20 expression 
on Ramos cells (red line) in comparison to the unstained (filled grey area) and the isotype control 
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(dotted black line). After treatment with serial dilutions of Rituximab (Figure 16b) and 80% NHS, the 
CD20 expression obviously decreased from 98% to 19% and the viability from 92% to 22%. The previous 
results confirmed the suitability of the Ramos cells for the CDC assay.  
 
 
Figure 16 CD20 expression on human Ramos cells. (a) Ramos cells (5∙106 cells/mL) were seeded to a V-bottom 96 well plate, 
diluted in assay buffer and stained with an anti-CD20 antibody and the appropriate isotype control. The expression of CD20 
was measured in a flow cytometer. The filled grey area indicates the unstained Ramos cells, the dotted black line the isotype 
control and the red line the CD20 expression of the untreated cells. The data are representative for three independent 
experiments performed in duplicates. (b) Rituximab was serially diluted and incubated with 80% NHS and 50 µL Ramos cells 
(5∙106 cells/mL). After incubation, the cells were stained with PI as well as anti-CD20 antibody and measured in a flow cytometer. 
Error bars indicate the SD. Data represent results from three independent experiments performed in duplicates. 
In order to examine the influence of trimodulin on complement activation and CDC of the Ramos 
cells, NHS and trimodulin were pre-incubated. Figure 17a shows the impact of trimodulin on CDC of the 
Ramos cells after pre-incubation with 80% NHS and subsequent addition of 160 µg/mL Rituximab. By 
addition of the FB control (without trimodulin), just 30% of the cells survived. In comparison to this, 
trimodulin reduced the CDC of the cells significantly in high concentrations. The survival of the cells 
increased concentration-dependent and was approximately 36% enhanced after the addition of 
3.125 mg/mL trimodulin. In Figure 17b, the influence of Intratect as IVIg control was analyzed. 
Compared to the FB control, just the highest used concentration (6.25 mg/mL) induced a slight viability 
increase of the Ramos cells of about 7.8%. In total, the survival of the cells was up to 28% enhanced 
after the addition of trimodulin compared to Intratect.  
 
 
Figure 17 Trimodulin reduces CDC of the Ramos cells after pre-incubation with NHS. (a) Trimodulin or (b) Intratect was pre-
incubated with NHS and mixed with 20 µg/mL Rituximab as well as 50 µL Ramos cells (5∙106 cells/mL) on a 96 well plate. As 
control, the FB of the products was used to determine the base level of CDC. After incubation, the survival of the cells was 
measured by PI staining in a flow cytometer. Error bars indicate the SD. Data represent results from six independent experiments 
performed in duplicates. Statistical analyses were performed using a one-way ANOVA and a Bonferroni test. Significance is 
shown as p-value: ** p ≤ 0.01. See Table 16 and Table 17 (appendix) for a detailed overview of the statistical analysis.  
To analyze, if an additional pre-incubation step reduces or even inhibits the increasing effect of 
trimodulin regarding the cell viability of Ramos cells, Rituximab and the cells were pre-incubated 
simultaneously to the pre-incubation of trimodulin and NHS (see chapter 4.4.4.2, paragraph (2)). After 
that, both plates were pooled and the viability of the cells was monitored (Figure 18). As control, FB 
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without trimodulin was added and induced a survival of the cells of about 38% (Figure 18a). Compared 
to this, a concentration-dependent viability increase was induced by trimodulin addition. The highest 
used concentration (6.25 mg/mL) obviously enhanced the survival of the Ramos cells of about 22.7%. 
Figure 18b shows a small increasing effect on the cell viability of about 5.5% with the highest used 
Intratect concentration (6.25 mg/mL). In total, the survival was up to 17.2% enhanced after the addition 
of trimodulin compared to Intratect. In comparison to the results described in Figure 17, the increase in 
the cell viability was about 11% lower after the pre-incubation of Rituximab and the cells and the 
independent pre-incubation of trimodulin and NHS. 
 
 
Figure 18 Trimodulin still reduces the CDC of Ramos cells after an additional pre-incubation step. A pre-incubation step of 
trimodulin (a) or Intratect (b) with NHS and simultaneously of 20 µg/mL Rituximab and 50 µL Ramos cells/well (5∙106 cells/mL) 
was performed. After incubation, both plates were pooled, incubated and the survival of the cells was measured by PI staining 
in a flow cytometer. The FB of the products were used as control, to determine the base level of CDC. Error bars indicate the 
SD. Data represent results from five independent experiments performed in duplicates. Statistical analyses were performed 
using a one-way ANOVA and a Bonferroni test. Significance is shown as p-value: * p ≤ 0.05. See Table 18 and Table 19 (appendix) 
for a detailed overview of the statistical analysis. 
To analyze, weather the order of the incubation has an influence on the effect of trimodulin 
regarding CDC, all assay components were incubated simultaneously. Figure 19a shows a survival of 
25% of the Ramos cells after treatment with the FB control. The viability increased concentration-
dependently by the addition of serially diluted trimodulin until 40% in the highest used concentration 
(6.25 mg/mL). This was a significant change of about 15% in the CDC of the Ramos cells. The addition 
of Intratect FB induced 24.5% survival, whereas 6.25 mg/mL Intratect enhanced the viability of the 
Ramos cells about 13.3% (Figure 19b). The difference between the effect of trimodulin and Intratect in 
the highest used concentrations was 2.2%. Compared to the results described in Figure 17, trimodulin 
was not as effective in the inhibition of CDC after simultaneous incubation of the assay components. The 
highest viability increase in Figure 19a was 21% lower than the highest increase in Figure 17a.  
 
 
Figure 19 The simultaneous incubation of all assay components reduces the influence of trimodulin on CDC of the Ramos cells. 
Trimodulin (a) or Intratect (b) was mixed with 20 µg/mL Rituximab, 80% NHS as well as 50 µL Ramos cells (5∙106 cells/mL) and 
incubated on a 96 well plate. The FB of the products were used to determine the base level of CDC. After incubation, the survival 
of the cells was measured by PI staining in a flow cytometer. Data represent results from six independent experiments performed 
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in duplicates. Statistical analyses were performed using a one-way ANOVA and a Bonferroni test. Significance is shown as p-
value: ** p ≤ 0.01 and * p ≤ 0.05. See Table 20 and Table 21 (appendix) for a detailed overview of the statistical analysis. 
In order to investigate, if trimodulin can interact with Rituximab and thereby inhibit the binding 
to CD20 which could lead to enhanced cell viability, both products were pre-incubated. There was no 
increasing effect regarding the Ramos cell viability compared to the other tested settings. The highest 
used trimodulin concentration (6.25 mg/mL) enhanced the survival of the cells significantly about 15% 
compared to the FB control (Figure 20a). The addition of 6.25 mg/mL Intratect (Figure 20b) increased 
the cell viability from 40.5% (FB control) to 50.3%. These results showed a 21% lower effect of 
6.25 mg/mL trimodulin on CDC of the Ramos cells, compared to Figure 17a. 
 
 
Figure 20 Trimodulin does not influence the binding of Rituximab to CD20. Trimodulin (a) or Intratect (b) was pre-incubated 
with 20 µg/mL Rituximab on a 96 well plate. Subsequently, they were mixed with 80% NHS as well as 50 µL Ramos cells 
(5∙106cells/mL). The FB of the products were used as control, to determine the base level of CDC. After incubation, the survival 
of the cells was measured by PI staining in a flow cytometer. Error bars indicate the SD. Data represent results from three 
independent experiments performed in duplicates. Statistical analyses were performed using a one-way ANOVA and a 
Bonferroni test. Significance is shown as p-value: ** p ≤ 0.01. See Table 22 and Table 23 (appendix) for a detailed overview of 
the statistical analysis. 
To determine if the inhibition of CDC by trimodulin is due to a functional interaction with activated 
complement factors or due to a blocking of the complement cascade through an unspecific CD20 overlay 
by IgM, IgA or IgG, control experiments were performed. Figure 21 shows the viability and the CD20 
expression of the Ramos cells after trimodulin (Figure 21a) and Intratect (Figure 21b) addition. The 
CD20 expression as well as the survival of the cells stayed high, about 98% and 94% for both products, 
and did not change concentration-dependently. Furthermore, the subsequent addition of Rituximab 
induced nearly the same CDC as shown in Figure 19, where all components were incubated 
simultaneously and did not lead to an increased cell viability of the Ramos cells (see appendix Figure 
28). These results confirmed that trimodulin did not interact with CD20 and inhibited the binding of 
Rituximab to this surface antigen.  
 
 
Figure 21 Trimodulin does not interact with CD20 on Ramos cells. Trimodulin (a) or Intratect (b) was mixed with assay buffer, 
80% NHS as well as 50 µL Ramos cells (5∙106 cells/mL) and incubated on a 96 well plate. The FB of the products were used as a 
control, to determine the base level of CDC. After incubation, the survival of the cells was measured by PI staining in a flow 
cytometer. Data represent results from three independent experiments performed in duplicates.  
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5.3. Concentration-dependent activation of the opsonophagocytosis of pathogens by 
trimodulin 
 
The analyses described in 5.2 showed a concentration-dependent effect of trimodulin on the 
complement cascade that resulted in reduced CDC. It was suggested that this was caused by the binding 
as well as by the inhibition of complement factors in high trimodulin doses. In general, the control of 
the complement system is an important function to prevent the excessive activation of the immune 
system in an inflammatory environment, which can lead to tissue damage and multiple organ failure. 
Nevertheless, it is also necessary to protect the body against invading pathogens like bacteria, viruses 
and fungi, by mechanisms, like CDC or phagocytosis that require the activation of the complement 
cascade. In the following OPAs it was analyzed, if trimodulin is able to activate the complement system 
that opsonizes bacterial cells and to induce the subsequent phagocytosis of the pathogens. Initially, the 
phenotype of the differentiated HL-60 cells was characterized and the titration of IgG/IgM depleted NHS 
was performed prior to the use in the different OPAs.  
 
5.3.1. Characterization of the HL-60 cell phenotype after differentiation for use in the OPA 
 
Differentiated neutrophil-like HL-60 cells were used as effector cells in the OPA. Their 
differentiation status after three days as well as their Fcγ receptor expression for a successful induction 
of the opsonophagocytosis by Igs was monitored prior to use. Therefore, the expression of Fcγ as well as 
of the complement receptors was examined by screening the surface antigens in the FACS. For this 
purpose, differentiated HL-60 cells were incubated with antibodies that bind to the low (CD16), the 
medium (CD32) and the high (CD64) affinity receptors for IgG. Moreover, an anti-CD11b antibody was 
used to detect the CR3 on the differentiated cells. To control the differentiation status, an anti-CD35 
antibody that binds to CR1, which is highly expressed on differentiated neutrophils, as well as an anti-
CD71 antibody that is specific for neutrophilic progenitor cells, was incubated with the HL-60 cells 
(Figure 22). For using the HL-60 cells in the OPA, they should exhibit a high CD35 and a low CD71 
expression. Unstained cells served as control and the specific isotype controls were added. 
The detection of the Fcγ receptors showed an expression of 34.9% CD16 and 99.8% CD32, whereas 
CD64 expression was only slightly detected (7.9%). In addition, the complement receptors CD11b (CR3) 
as well as CD35 (CR1) were strongly expressed by differentiated HL-60 cells, whereas CD71 was not 
detected.  
These data suggests that the differentiated HL-60 cells express Fcγ as well as the complement 
receptors, which are necessary to induce the phagocytosis of pathogenic cells after binding of IgG or 
opsonins. Furthermore, the high expression of CD35 as well as the absence of CD71 shows a successful 
differentiation. For that reason, the Ramos cells were assessed to be suitable for the OPA assay. 
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Figure 22 Phenotype characterization of differentiated HL-60 cells. After differentiation, HL-60 cells were incubated with anti-
CD16, anti-CD32, anti-CD64, anti-CD11b, anti-CD35 and anti-CD71 antibodies. As control, undifferentiated cells were used and 
the specific isotype controls were added to the wells. The expression of the surface receptors was measured in a flow cytometer. 
The filled grey area indicates the unstained HL-60 cells, the dotted black line the particular isotype control and the colored lines 
the individual receptor expressions of the differentiated cells. Dark green = CD16 expression, orange = CD32 expression, pink = 
CD64 expression, dark blue = CD11b expression, light green = CD35 expression and turquoise = CD71 expression. The data are 
representative for two experiments performed in duplicates. 
 
5.3.2. Serum titration for use in the E. coli (K12) OPA 
 
In order to analyze the effect of trimodulin in activating complement and induce the 
opsonophagocytosis of E. coli (K12), an OPA was developed. As complement source for the OPA, IgG/IgM 
depleted NHS (NHS minus) was used and analyzed in the CH50 test (see 5.1). Initially, the serum was 
titrated prior to use (Figure 23), to determine the appropriate concentration. Different concentrations 
of NHS minus were tested for their ability to induce the killing of E. coli. It was important to find a 
balance between a concentration of NHS minus that did not entirely kill the bacteria by itself (non-
specific killing) and a concentration that was not as low as the Igs were not able to activate the 
complement system anymore. It was primarily in the focus, to examine if the addition of trimodulin 
could amplify the activation of the complement system and therefore the complement-mediated 
phagocytosis of E. coli, compared to Intratect (used as IVIg control). Figure 23 shows the bacterial 
survival [%] of E. coli after the addition of undifferentiated or differentiated HL-60 cells, active or 
inactive NHS minus and trimodulin FB. The data were normalized to control A comprised of bacteria, 
undifferentiated HL-60 cells, hi NHS minus as well as FB, which served as 100% control for bacterial 
survival. Approximately 25% less bacterial survival was seen compared to control A, after the addition 
of differentiated instead of undifferentiated cells. The addition of active serum in different 
concentrations induced 100% killing in the highest used concentrations (2%-10%), whereas 7% of the 
E. coli bacteria survived after 1% NHS minus addition. The lower the concentration of NHS minus was 
chosen, the higher was the survival of the bacterial cells. Moreover, it must paid attention that control 
C did not induce the same bacterial survival as control B without active complement, because otherwise 
the concentration of NHS was too low to be activated. 0.8% and 0.7% NHS minus were therefore tested 
CD32CD16 CD64
CD11b CD35 CD71
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by addition of trimodulin or Intratect as IVIg control for their complement activity (see appendix Figure 
29). After that, 0.8% NHS minus was found to be the optimal concentration for the OPA. Trimodulin did 
not further activate the complement system by addition of 0.7% NHS minus, whereas the killing of the 
bacteria was stronger compared to control C with 0.8% NHS minus when incubated together with low 
concentrations of trimodulin.  
 
 
Figure 23 Titration of IgG/IgM depleted serum for use in the OPA. Initially, OB was prepared and 20 µL transferred to the 
appropriate wells of a 96 well U-bottom plate. 3 µL of trimodulin FB was added to the wells. Differentiated as well as 
undifferentiated HL-60 cells were counted and resuspended to 1∙107 cells/mL. One vial of the cryopreserved E. coli assay stock 
was rapidly thawed in a water bath, centrifuged at 12000 x g for 2 min and washed with 1 mL OB. After additional 
centrifugation, the supernatant was removed and the pellet resuspended in 0.5 mL OB. The bacteria were 4000-fold diluted in 
10 mL OB, 10 µL was added to the wells of the 96 well plate and the plate was incubated for 30 min at RT under shaking. In the 
meantime, the HL-60 cells were mixed with IgG/IgM depleted NHS (NHS minus) or hi IgG/IgM depleted NHS and OB for serum 
titration. After incubation, 50 µL of the HL-60 cell and NHS minus mix was distributed to the 96 well plate and was again 
incubated at 37 °C for 45 min. To stop the phagocytic process, the plate was placed on ice for 20 min, before 5 µL per well was 
distributed in triplets on a LB agar plate. The plates were incubated overnight in a 37 °C incubator and the CFU counted manually 
on the next day. The data were analyzed with GraphPad Prism, after determination of CFU/mL with Excel and the bacterial 
survival [%] was determined by normalization of the data. Control A served as 100% control for bacterial survival. Data represent 
results from two independent experiments performed in duplicates. 
 
5.3.3. The E. coli (K12) OPA is suitable for investigating phagocytosis, but not for analyzing 
the opsonophagocytic activity induced by trimodulin  
 
After the appropriate serum concentration for the E. coli OPA was determined in pre-experiments 
(see 5.3.2), the opsonophagocytosis of the bacteria induced by trimodulin (B588039) was analyzed. 
Therefore, the OPA was performed with all controls as well as the samples (trimodulin or Intratect) 
described in 4.5.2.. Initially, E. coli was pre-incubated with trimodulin (B588039) to enable the binding 
of the Igs before NHS minus as well as the HL-60 cells were added. After activation of the complement 
cascade, the covering of the bacterial surface by opsonins (opsonization) in general causes the 
enticement of effector cells and the subsequent opsonophagocytosis. As control, trimodulin was 
incubated with the components in the absence of NHS minus, to determine the ADCC, which is induced 
by antibodies and effector cells only. In addition, bacteria that were treated with hi NHS minus, as well 
as with undifferentiated HL-60 cells and trimodulin FB, were used as 100% control for the E.coli survival. 
The control, consisting of bacteria, hi NHS minus, differentiated HL-60 cells and trimodulin FB only, 
determined the direct killing of the E. colis by binding to TLRs on the neutrophils. Moreover, another 
control was used (bacteria, differentiated HL-60 cells, IgG/IgM depleted NHS and trimodulin FB) to 
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define the complement activity without Ig addition by the alternative pathway, which also leads to the 
opsonophagocytosis of pathogens and induces CDC. 
Figure 24 shows the phagocytosis of E. coli bacteria by trimodulin. The growth of the bacteria is 
representatively seen in Figure 24a, where control D1-D6 (composed of the bacteria, hi NHS minus, 
differentiated HL-60 cells and the different used concentrations of trimodulin) was distributed to an LB 
agar plate. By counting the CFUs, a concentration-dependent increase in the bacterial survival was seen 
after trimodulin addition. The highest used trimodulin concentration (control D1 with 1810 µg/mL 
trimodulin) induced the slightest growth (11 CFUs), whereas 24 CFUs were counted after addition of 
0.181 µg/mL trimodulin (control D5). In Figure 24b, the bacterial survival [CFU/mL] of the E. colis was 
calculated and analyzed after addition of all controls and the samples. Control A, which was used as 
100% control, showed the highest viability of the bacteria with approximately 2.6∙108 CFU/mL. 
Compared to this, the survival of the cells was slightly lower in control B (composed of the bacteria, hi 
NHS minus, differentiated HL-60 cells and FB), whereas control C (composed of the bacteria, NHS 
minus, differentiated HL-60 cells and FB) induced a survival of only 9∙107 CFU/mL. A concentration-
dependent increase of the viability was triggered after addition of trimodulin and incubation with hi 
NHS minus (light blue; control D1-D6) that was also seen in Figure 24a. Trimodulin was able to induce 
the phagocytosis without complement, triggered by the direct binding of Igs to the HL-60 cells. Moreover, 
the lowest viability was detected after 1810 µg/mL and the highest after 0.0181 µg/mL trimodulin 
addition. Trimodulin induced a different progression of the viability, when incubated together with 
active NHS depleted of IgG/IgM (dark blue). In the highest used concentration (1810 µg/mL) a high 
bacterial survival was detected, which correlates with low complement activity. The lower the 
concentration of trimodulin, the lower was the viability of the E. coli bacteria. In the lowest used 
concentration (0.0181 µg/mL), a slight increase in the survival was detected. Nevertheless, there was 
no significant difference between control C (w/o trimodulin) that showed high non-specific killing and 
the addition of 1.81 µg/mL trimodulin (dark blue), which induced the lowest bacterial survival. These 
data suggest that trimodulin is able to induce the phagocytosis of E. coli, but the opsonophagocytic 
capacity of trimodulin could not be detected. Moreover, it was shown that trimodulin inhibits the 
complement activation in high concentrations. However, the SD of the samples was too high to 
distinguish between assay variations and real effects induced by trimodulin.  
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Figure 24 Trimodulin induces the phagocytosis of E. coli (K12) bacteria and is able to inhibit complement activation 
concentration-dependently. Trimodulin (B588039) and E. coli bacteria were pre-incubated on a 96 well U-bottom plate for 
30 min at RT. After that, NHS depleted of IgG/IgM as well as HL-60 cells were added, mixed and were incubated for additional 
45 min at 37 °C. (a) The plate was put on ice for 20 min and 5 µL of every well were distributed in triplets to LB agar plates for 
overnight incubation at 37 °C. The distribution of control D1-D6 (composed of the bacteria, hi NHS minus, differentiated HL-60 
cells and the different used concentrations of the Ig preparations) is representative for the whole assay procedure and shows 
the growth of the bacterial cells. The CFUs were counted and the data was analyzed using GraphPad Prism. (b) Control A served 
as 100% control for bacterial survival [CFU/mL], control B determined the direct killing of the cells via binding of E. coli to the 
TLRs, control C was used to examine the activation of complement without Ig addition and control D showed the ADCC induced 
by trimodulin and HL-60 cells only. Trimodulin was 10-fold serially diluted (1810 µg/mL to 0.0181 µg/mL) to monitor 
concentration-dependent effects. Error bars indicate the SD. Data represent results from three independent experiments 
performed in triplicates. Statistical analyses were performed by using a Kruskal-Wallis test and are given in Table 26 and Table 
27 (appendix). 
To compare the effect of an IVIg and an IgM-/IgA-enriched preparation, Intratect was also tested 
in the OPA. The controls and the used concentrations of the samples were the same as described in 4.5.2. 
Figure 25 shows the opsonophagocytosis of E. coli induced by Intratect. The bacterial survival [CFU/mL] 
was calculated with Excel and was analyzed by the use of GraphPad Prism. Control A (the 100% survival 
control for E. coli) showed the highest viability with approximately 3.5∙108 CFU/mL. Control B 
(composed of the bacteria, hi NHS minus, differentiated HL-60 cells and FB), which was used to monitor 
the direct killing of the bacteria by differentiated HL-60 cells without the addition of serum or the Ig 
preparations, a slight decrease of the bacterial survival was seen. Compared to this, control C (w/o 
trimodulin), which was used to determine the non-specific killing of the E. colis by NHS minus, induced 
a viability of only 8.6∙107 CFU/mL. Moreover, Control D (Figure 25; light green; composed of the 
bacteria, hi NHS minus, differentiated HL-60 cells and the different used concentrations of Intratect) 
was compared to control D with different trimodulin concentrations (Figure 24). This comparison 
exhibited a higher total increase of approximately 2.5∙107 CFU/mL in the survival of the cells by the 
addition of control D with Intratect (Figure 25), contrary to control D where trimodulin was added 
(approximately 1∙107 CFU/mL; see Figure 24). The addition of active NHS minus (dark green) induced 
the same concentration-dependent progression of the bacterial viability as with hi NHS depleted of 
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Control B Bacteria, differentiated HL-60 cells, hi NHS minus, FB
Control C Bacteria, differentiated HL-60 cells, NHS minus, FB
Control D Bacteria, differentiated HL-60 cells, hi NHS minus, immunoglobulin preparation
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IgG/IgM (light green). Nevertheless, the decrease of the survival was stronger with active, compared to 
inactive NHS minus. The highest used concentration of Intratect (1810 µg/mL) induced the lowest cell 
viability, which was due to high complement activity. Compared to control C that caused high non-
specific killing, the difference was not significant. These data suggest that Intratect can also induce the 
phagocytosis as well as opsonophagocytosis of E. coli bacteria, but does not lead to a reduced 
complement activity in high concentrations. In addition, the SD of the samples treated with active NHS 
minus was again too high to distinguish between assay variations and real effects induced by Intratect. 
 
Figure 25 Intratect (used as IVIg control) induces the opsonophagocytosis of E. coli (K12), but does not inhibit complement 
activation concentration-dependently. Intratect and E. coli bacteria were pre-incubated on a 96 well U-bottom plate for 30 min 
at RT. After that, NHS depleted of IgG/IgM as well as HL-60 cells were added, mixed and were incubated for additional 45 min 
at 37 °C. The plate was put on ice for 20 min and 5 µL of every well were distributed in triplets to LB agar plates for overnight 
incubation at 37 °C. The CFUs were counted and the data was analyzed using GraphPad Prism. Control A served as 100% control 
for bacterial survival [CFU/mL], control B determined the direct killing of the cells via binding of E. coli to the TLRs, control C was 
used to examine the activation of complement without Ig addition and control D showed the ADCC induced by Intratect and 
HL-60 cells only. Intratect was 10-fold serially diluted (1810 µg/mL to 0.0181 µg/mL) to monitor concentration-dependent 
effects. Error bars indicate the SD. Data represent results from two independent experiments performed in triplicates. Statistical 
analyses were performed by using a Kruskal-Wallis test and are given in Table 28 and Table 29 (appendix). 
 
5.3.4. Serum titration for use in the S. aureus bioparticles OPA 
 
In the E. coli OPA, trimodulin induced an inhibition of the complement system, but the 
opsonophagocytic capacity regarding the bacteria could not be detected. This was caused by the high 
non-specific killing of the serum (control C) while trimodulin was not able to further activate the 
complement system. Moreover, the SD of the samples treated with active NHS was too high to distinguish 
between real effects and assay variations. Therefore, a FACS-based method was applied to reduce the 
high assay variations caused by the manually counting of the E. colis as well as to determine the non-
specific killing of the serum in another setting. This additional OPA was could be evaluated in a flow 
cytometer, using S. aureus bioparticles conjugated to Alexa Fluor 488 instead of living E. coli bacteria. 
For this purpose, IgG/IgM depleted NHS was titrated prior to use in the assay, to find the appropriate 
concentrations. The HL-60 cell number and the concentration of the bioparticles were initially tested by 
Sample Composition
Control A Bacteria, undifferentiated HL-60 cells, hi NHS minus, FB
Control B Bacteria, differentiated HL-60 cells, hi NHS minus, FB
Control C Bacteria, differentiated HL-60 cells, NHS minus, FB
Control D Bacteria, differentiated HL-60 cells, hi NHS minus, immunoglobulin preparation
Sample Bacteria, differentiated HL-60 cells, NHS minus, immunoglobulin preparation
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Fabian Bohländer (PhD thesis; data not shown) and were adopted in this OPA. Different serum 
concentrations were analyzed in preliminary experiments (0.6%, 1.2%, 1.5%) and 1.2% was regarded 
as best concentration (see appendix Figure 30). Trimodulin was able to activate the complement system 
by using 0.6% NHS minus. Nevertheless, a stronger activation was seen by using 1.2% NHS minus. 1.5% 
serum triggered a high complement-mediated phagocytosis of the bacteria, whereby only a slight 
increase in the opsonophagocytosis of E. coli was detected after trimodulin addition.  
 
5.3.5. The S. aureus bioparticles OPA is suitable for analyzing the opsonophagocytosis 
induced by trimodulin  
 
In order to analyze the ability of trimodulin to initiate the opsonophagocytosis of S. aureus 
bioparticles, an additional OPA was performed. Differentiated HL-60 cells were mixed with the 
bioparticles, NHS minus as well as trimodulin or Intratect (as IVIg control) was added and incubated for 
45 min at 37 °C. The controls were the same as described in 5.3.3. In addition, untreated HL-60 cells 
were used to determine the background fluorescence without bacteria. After incubation, the cells were 
quenched with 0.2% trypan blue solution to delete the fluorescence of bacteria that were not 
phagocytosed and did unspecifically bind to the surface of the effector cells. Finally, the plate was 
measured in a flow cytometer and the phagocytic index was determined. Figure 26 shows the 
opsonophagocytosis of S. aureus bioparticles induced by trimodulin. The background fluorescence of the 
untreated HL-60 cells as well as of control A was negligible, because there was almost no fluorescence 
detectable. Control B (composed of the bioparticles, hi NHS minus, differentiated HL-60 cells and FB) 
showed a slight phagocytic index, which was due to the direct phagocytosis of the bacteria by the 
differentiated HL-60 cells. After the addition of the highest used trimodulin concentration (20 mg/mL) 
to hi NHS minus (control D composed of the bioparticles, hi NHS minus, differentiated HL-60 cells and 
20 mg/mL trimodulin; light blue), which was used to determine the IgG-mediated phagocytosis of 20 
mg/mL trimodulin, the phagocytic index was approximately 1.2∙107. Compared to this, the values 
increased by the addition of lower trimodulin concentrations and reached the maximum at 1 mg/mL 
trimodulin. Furthermore, a strong decrease of the phagocytic index was detected by addition of lower 
trimodulin concentrations, with a minimum at 0.01 mg/mL. It was suggested that the values, detected 
in the high trimodulin concentrations (20-1 mg/mL), were caused by an inhibition of the phagocytosis. 
Moreover, control C (w/o trimodulin), which was used for the detection of the S.aureus phagocytosis 
induced by NHS minus only, showed a phagocytic index of approximately 1.5∙107. After the addition of 
trimodulin and incubation with active NHS minus (dark blue), a strong increase of the phagocytic index 
was induced, with a maximum (2.3∙107) at 1 mg/mL trimodulin. The values of the phagocytic index 
decreased by addition of lower concentrations (0.5-0.01 mg/mL trimodulin). Finally, the statistical 
analysis revealed that the highest effect, caused by 1 mg/mL trimodulin, induced a significantly different 
phagocytic index, compared to control C (composed of the bioparticles, NHS minus, differentiated HL-
60 cells and FB). In addition, the phagocytic index, induced by trimodulin without active NHS minus 
(control D 1mg/mL), was significantly lower in comparison to 1 mg/mL trimodulin with active NHS 
minus. It was assumed that the phagocytic indices that were detected in the range of 20-1 mg/mL, were 
caused by inhibitory effects of trimodulin regarding the opsonophagocytosis of S. aureus bioparticles. 
Table 14 as well as Table 15 give an overview of the differences between the trimodulin samples and 
controls in detail. The phagocytic indices of control D (w/o trimodulin) were subtracted from the 
phagocytic indices of the trimodulin samples and the significance shown as p-value (**** p ≤ 0.0001) 
(Table 14). In Table 15, the differences of the phagocytic indices of the trimodulin samples and control 
C are depicted and the significances shown as p-value (* p ≤ 0.05; *** p ≤ 0.001; **** p ≤ 0.0001). These 
data indicate that trimodulin is able to induce the phagocytosis and significantly increases the 
opsonophagocytosis of the bioparticles in the presence of active serum. Moreover, trimodulin can also 
inhibit the uptake of the bacteria in high concentrations. 
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Figure 26 Trimodulin induces the concentration-dependent opsonophagocytosis of S. aureus bioparticles. Differentiated HL-60 
cells, S. aureus bioparticles, NHS depleted of IgG/IgM as well as trimodulin (B588039) and the appropriate FB were mixed and 
incubated at 37 °C for 45 min. After that, the cells were quenched with 0.2% trypan blue solution and were subsequently 
analyzed by using a flow cytometer. The phagocytic index was calculated and the data depicted in a bar diagram using excel 
and GraphPad Prism. Control A served as 100% control for the bacteria, control B determined the direct phagocytosis of the 
cells via binding of E. coli to the TLRs, control C was used to examine the activation of complement without Ig addition and 
control D showed the ADCC induced by trimodulin and HL-60 cells only. Different dilutions of trimodulin were used to monitor 
concentration-dependent effects. Error bars indicate the SD. Data represent results from six independent experiments 
performed in duplicates. Statistical analyses were performed using a one-way ANOVA and a Bonferroni test. Significance is 
shown as p-value: **** p ≤ 0.0001. 
Table 14 Comparison of the phagocytic index of trimodulin samples without active NHS minus (control D) with trimodulin 
samples after the addition of active NHS minus. Statistical analyses were performed using a one-way ANOVA and a Bonferroni 
test. Significance is shown as p-value: **** p ≤ 0.0001. 
Trimodulin 
concentration 
Phagocytic 
index control D 
Phagocytic index 
trimodulin samples 
Difference (trimodulin 
sample – control D)  
Significance 
(p-value)  
20 mg/mL 1.2∙107 1.8∙107 6∙106 **** 
15 mg/mL 1.2∙107 1.9∙107 7∙106 **** 
10 mg/mL 1.3∙107 2. 0∙107 7∙106 **** 
5 mg/mL 1.4∙107 2.1∙107 7∙106 **** 
1 mg/mL 1.6∙107 2.3∙107 7∙106 **** 
0.5 mg/mL 1.5∙107 2.3∙107 8∙106 **** 
0.1 mg/mL 1.1∙107 2.2∙107 1.1∙107 **** 
0.05 mg/mL 9.0∙106 2.0∙107 1.1∙107 **** 
0.01 mg/mL 3.0∙106 1.6∙107 1.3∙107 **** 
Sample Composition
Control A Bacteria, undifferentiated HL-60 cells, hi NHS minus, FB
Control B Bacteria, differentiated HL-60 cells, hi NHS minus, FB
Control C Bacteria, differentiated HL-60 cells, NHS minus, FB
Control D Bacteria, differentiated HL-60 cells, hi NHS minus, immunoglobulin preparation
Sample Bacteria, differentiated HL-60 cells, NHS minus, immunoglobulin preparation
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Table 15 Comparison of the phagocytic index of control C (without trimodulin) with the samples after trimodulin addition. 
Statistical analyses were performed using a one-way ANOVA and a Bonferroni test. Significance is shown as p-value: * p ≤ 0.05, 
*** p ≤ 0.001 and **** p ≤ 0.0001. 
Phagocytic index 
control C 
Trimodulin 
concentration 
Phagocytic index 
trimodulin samples 
Difference (trimodulin 
sample – control C)  
Significance 
(p-value)  
1.5∙107 20 mg/mL 1.8∙107 3∙106 * 
15 mg/mL 1.9∙107 4∙106 *** 
10 mg/mL 2. 0∙107 5∙106 **** 
5 mg/mL 2.1∙107 6∙106 **** 
1 mg/mL 2.3∙107 8∙106 **** 
0.5 mg/mL 2.3∙107 8∙106 **** 
0.1 mg/mL 2.2∙107 7∙106 **** 
0.05 mg/mL 2.0∙107 5∙106 **** 
0.01 mg/mL 1.6∙107 1∙106 ns 
 
In order to compare the ability of an IgM-/IgA-enriched preparation to induce the 
opsonophagocytosis of S. aureus bioparticles with an IVIg, Intratect was used in the assay. The IgG 
preparation was initially pre-diluted in FB to the same IgG concentration as trimodulin (⋲ 56%). After 
that, controls and samples were similarly diluted as described in 4.5.3. Figure 27 shows the 
opsonophagocytosis of the S. aureus bioparticles caused by Intratect. Compared to Figure 26, the 
background fluorescence was also negligible, as the untreated HL-60 cells as well as control A showed 
almost no fluorescence. In addition, control B (composed of the bioparticles, hi NHS minus, 
differentiated HL-60 cells and FB), which indicates the phagocytosis of the bacteria by the direct binding 
to TLRs of the HL-60 cells, was comparable to Figure 26. Control D (light green; composed of the 
bioparticles, hi NHS minus, differentiated HL-60 cells and Intratect) that was used to determine the 
effect of Intratect without active NHS minus, increased the phagocytic index to a maximum of 1.1∙107 
(0.056 mg/mL Intratect), whereas lower concentrations decreased the values concentration-
dependently. Moreover, control C (composed of the bioparticles, NHS minus, differentiated HL-60 cells 
and FB)exhibited a phagocytic index of approximately 1.5∙107, which was also comparable to Figure 26. 
The addition of Intratect (dark green) induced no increase in high concentrations (11.2-2.8 mg/mL), 
whereas a maximum phagocytic index (2.3∙107) was detected at 0.028 mg/mL Intratect that was again 
comparable to the effect of trimodulin (seen in Figure 26). By addition of the lowest used Intratect 
concentration (0.0056 mg/mL), the value of the phagocytic index decreased. Finally, the statistical 
analysis revealed that the highest effect, caused by 0.028 mg/mL Intratect induced a significantly 
different phagocytic index, compared to control C that was used to determine the phagocytosis triggered 
by NHS minus only. In addition, the phagocytic index, induced by Intratect without active NHS minus 
(control D 0.056 mg/mL), was significantly lower in comparison to 0.028 mg/mL trimodulin with active 
NHS minus. It was assumed that the phagocytic indices that were detected in the range of 11.2-
0.56 mg/mL, were caused by an inhibition of the S. aureus opsonophagocytosis. The opsonophagocytic 
capacity of Intratect was comparable to the effects caused by trimodulin.  
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Figure 27 Intratect induces the concentration-dependent opsonophagocytosis of S. aureus bioparticles. Differentiated HL-60 
cells, S. aureus bioparticles, NHS depleted of IgG/IgM as well as Intratect (as IVIg control) and the appropriate FB were mixed 
and were incubated at 37 °C for 45 min. After that, the cells were quenched with 0.2% trypan blue solution and were 
subsequently analyzed by using a flow cytometer. The phagocytic index was calculated and the data depicted in a bar diagram 
using excel and GraphPad Prism. Control A served as 100% control for the bacteria, control B determined the direct phagocytosis 
of the cells via binding of E. coli to the TLRs, control C was used to examine the activation of complement without Ig addition 
and control D showed the ADCC induced by Intratect and HL-60 cells only. Different dilutions of Intratect were used to monitor 
concentration-dependent effects. Error bars indicate the SD. Data represent results from five independent experiments 
performed in duplicates. Statistical analyses were performed using a one-way ANOVA and a Bonferroni test. Significance is 
shown as p-value: **** p ≤ 0.0001. See Table 30 and Table 31 (appendix) for a detailed overview of the statistical analysis. 
 
  
Sample Composition
Control A Bacteria, undifferentiated HL-60 cells, hi NHS minus, FB
Control B Bacteria, differentiated HL-60 cells, hi NHS minus, FB
Control C Bacteria, differentiated HL-60 cells, NHS minus, FB
Control D Bacteria, differentiated HL-60 cells, hi NHS minus, immunoglobulin preparation
Sample Bacteria, differentiated HL-60 cells, NHS minus, immunoglobulin preparation
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6. Discussion 
 
In the 19th century, von Behring and Kitasato discovered for the first time antibody molecules in 
the serum of immunized rabbits that destroyed or neutralized virulent tetanus bacteria in mice, which 
obtained this immune serum194. These findings signed the beginning of the modern therapeutic Ig 
treatment195. Today it is known that antibodies exhibit a broad spectrum of functions, supporting the 
immune system to fight infections44,74. IVIg preparations, comprised of high amounts of polyvalent IgG 
molecules pooled from thousands of healthy donors, are primarily used as replacement therapy for 
patients with immunodeficiencies, but also for the treatment of autoimmune and inflammatory 
disorders150–152,196. Both, antimicrobial as well as immunomodulatory effects are of high relevance, to 
find a balance between activation and inhibition of the immune system. Especially the complement 
system has a dual role in health and disease. On the one hand, it is responsible for the protection of the 
host against pathogens by activating complement factors leading to the destruction of microorganisms, 
but on the other hand it triggers many inflammatory effects that can be harmful to the host by an 
uncontrolled activation9,197. Inflammation is mainly caused by anaphylatoxins, but also opsonins, like 
the fragments C3b, C4b and iC3b, can induce damage due to excessive and continuous activation of the 
complement system. Therefore, this system has to be tightly regulated. Basta et al. already reported that 
Igs have the ability to activate but also to inhibit the complement system concentration-dependently11.  
 
In this PhD thesis, the ambivalent effects of the IgM- and IgA-enriched Ig preparation trimodulin 
regarding complement activation and inhibition were evaluated. Initially, the ability of trimodulin to 
bind and inhibit the deposition of the activated opsonins C3b as well as C4b on aggregated IgG was 
characterized. For this purpose, an ELISA was established, which was based on the studies of Rieben et 
al.99,166. It was shown that trimodulin was responsible for the concentration-dependent decrease in the 
detection of the complement factors C3b and C4b. The highest used concentrations of trimodulin had 
the strongest effect in reducing the detection of the opsonins (see Figure 10). In comparison, the addition 
of Intratect, used as IVIg control, was not as effective as trimodulin in inhibiting the detection of 
deposited C3b and C4b. Only a slight decrease in the C3b detection occurred, whereas the amount of 
detected C4b even increased in low concentrations before a decrease was detectable in high 
concentrations. The interaction of the complement system with high-dose IVIg preparations was already 
seen in various studies of Basta et al. They reported the binding of C3b as well as C4b to IgG molecules 
and the prevention of opsonin deposition on target cells94,95,198. In addition, Rieben et al. determined the 
capacity of different Ig preparations (IVIg, IgM-enriched, IgA-enriched as well as IgM- and IgA-enriched 
preparations) regarding complement inhibition by using an ELISA and measuring the deposition of the 
complement factors C3, C4 and C1q on aggregated IgG. They also detected a reduced deposition of the 
factors after the addition of IVIg, IgM-enriched as well as IgM- and IgA-enriched preparations and 
reported that IgM-enriched Ig preparations were more efficient in the inhibition of complement than 
IVIgs, whereas IgA had no inhibitory capacity99,166. Moreover, Roos et al. demonstrated that IgM-enriched 
Ig preparations have an up to 10 times stronger complement inhibitory capacity than IVIg preparations, 
seen in experiments were the hyperacute rejection of pig xenografts in primates was prevented by 
complement inhibition through Ig preparations98. Trimodulin, which consists of approximately 56% IgG, 
21% IgA and 23% IgM, was also more potent in the reduction of complement deposition in the opsonin 
ELISA than Intratect as IVIg control (see Figure 10 and Figure 11). The IgM molecules of trimodulin, are 
able to bind to activated complement components and therefore contribute to the strong inhibitory 
capacity seen after trimodulin addition11. Moreover, the main component of trimodulin is IgG that is also 
able to bind and inhibit activated complement factors. This composition makes trimodulin a more potent 
inhibitor compared to IVIgs like Intratect. Moreover, the pentameric structure of serum IgM in trimodulin 
is able to bind complement factors in a higher amount at the same time, compared to the monomeric 
IgG molecules60. It is suggested that the higher avidity of IgM also contributes to the stronger efficacy of 
trimodulin to complement factors compared to Intratect. It was seen that the decrease in the C3b level 
(⋲ OD 2.4) was higher as compared to the decrease in the C4b level (⋲ OD 1.4) after the addition of 
trimodulin. This might be due to the generally lower amount of factor C4 in serum (approximately 100-
400 mg/mL), which is cleaved to C4b as well as C4a. C3, which is processed to C3b and C3a, has an 
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approximate serum concentration of about 900-1800 mg/mL199. The increase of C4b (⋲ OD 2) in the low 
Intratect concentrations (compared to the serum control) could be due to an activation of the 
complement system by the Ig preparation. Compared to Intratect, no increase in C4b was detectable 
after the addition of trimodulin in low concentrations. Complement needs two or more IgG molecules 
in a specific distance to each other for the binding of C1q and activation of the classical pathway45. 
Compared to this, IgM molecules must change their confirmation for C1q binding from the planar 
secreted (= “star”) to the “staple” form. This mechanism takes place when IgM binds to antigens on the 
surface of target cells200. It is suggested that in the opsonin ELISA IgM did not change its confirmation 
in the presence of only aggregated IgG molecules compared to the presence of target cells, therefore was 
not able to activate the complement system and only its inhibitory capacity was detected in the ELISA 
setting. Moreover, after the addition of Intratect to the EDTA-plasma on the 96 well plate, a high 
generation of C4b compared to C3b was detected. C4b is only produced during classical and lectin 
pathway activation, whereas C3b is also generated in the alternative pathway12. In general, it is known 
that aggregated IgG, IgA or IgM molecules activate the complement system via the alternative 
pathway201. In the ELISA setting, the alternative pathway is already activated when C3 binds to the 
aggregated IgG coating. Therefore, the generation of C3b was assumed to be completed before Intratect 
was added and no increase of C3b compared to C4b could be detected.  
Rieben et al. demonstrated that the inhibition of the complement system by using Ig preparations 
is not caused by excessive complement activation and associated consumption of the complement 
factors99. It is rather discussed if the mechanism of complement inhibition is due to the scavenging (= 
binding and removal) of the activated complement factors from the site of inflammation94,95,99,102,198,202. 
To investigate, which Ig subclass was mainly responsible for the reduced C3b as well as C4b detection 
and to determine if this inhibition was due to a scavenging of the factors, a fluid phase ELISA was 
established. The analysis revealed the more trimodulin was added, the more IgM bound to C3b in the 
fluid phase and was detected on a second ELISA plate coated with an anti-human C3c antibody (that is 
also able to detect C3b as well as iC3b). However, the negative control (w/o EDTA-plasma) detected a 
non-specific binding of IgM to the coating or to the plate and therefore the assay was unsuitable for the 
determination of the mechanism as well as of the Ig subclass responsible for the inhibition of complement 
factors (see Figure 12). In general, problems with the specificity of an ELISA are well known 
challenges203. Non-specific binding of Igs causes false positive results, induced for example by Ig 
preparations that directly bind to the polystyrene surface of the plate due to non or inadequate blocking 
or to the blocking agent itself204–206. For this reason, a Western Blot analysis of the opsonin ELISA 
supernatant was performed, where IgG, IgM and C3b (as well as iC3b and C3c) were detected in order 
to determine whether scavenging of the opsonins by Ig preparations caused the reduced complement 
detection. It was clearly seen that just the treatment with 0.05 mg/mL trimodulin or Intratect revealed 
a band for the iC3b alpha chain, compared to higher (12.5 mg/mL as well as 5 mg/mL) trimodulin or 
Intratect concentrations (see Figure 13). The assumption for the scavenging theory, which means the 
binding and removal of the activated complement factors by Igs, was a detection of high C3b (iC3b/C3c) 
amounts and at the same time high amounts of the Ig preparation in the Western Blot analysis. The more 
trimodulin or Intratect was added, the more C3b (iC3b/C3c) should be detected. Since this was not the 
case (no C3b was detected in high Ig concentrations), it is suggested that the inhibitory effect, which 
was seen in the opsonin ELISA measured by reduced C3b concentrations, was not due to a scavenging 
of this opsonin. It is rather supposed to be caused by a binding and covering as well as an associated 
retention of the complement factors on the opsonin ELISA plate by the Ig preparations. In the opsonin 
ELISA setting, the molecular weight of the Ig molecules seems to play a role for the decreased detection 
of C3b as well as C4b. After the cleavage of the complement factors upon their activation, they may be 
directly bound by the Ig preparations and pushed down to the coating. Because IgM in its pentameric 
form has a molecular weight of 990 kDa compared to the IgG monomers with a molecular weight of 
150 kDa, trimodulin was able to bind and cover the opsonins more efficiently than Intratect. Therefore, 
high amounts of the Ig preparations imply a more efficient covering as lower amounts of trimodulin or 
Intratect, where more C3b can be detected in the supernatant. Additionally, Basta et al. reported that 
IgG is able to covalently bind to C3b molecules11.It is suggested that also in the ELISA setting the 
complement factors covalently bind to the coating (aggregated IgG) as well as to the Ig molecules and 
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are consequently retained on the opsonin ELISA plate. Therefore, they were not detectable after the 
addition of high trimodulin or Intratect concentrations in the supernatant, which was analyzed in the 
Western Blot. 
The results of the opsonin ELISA and the subsequent Western Blot analysis did not show a 
scavenging of the activated complement components that was described in various studies24,99,166. 
Nevertheless, these data were the first evidences that trimodulin is able to interact with activated 
opsonins in high concentrations and may inhibit further activation of the complement system that is 
associated with inflammatory reactions.  
 
Anaphylatoxins are small polypeptides that are released in the circulation after the cleavage of its 
precursors and mediate inflammation caused by various effector functions. They contribute to the 
pathogenesis of many autoimmune, neurodegenerative as well as infectious diseases207. It is important 
to regulate and control their activation to prevent harmful effects for the host triggered by an over-
stimulation of the immune system. To analyze the capacity of trimodulin to bind the anaphylatoxins C5a 
and C3a an ELISA was developed. The test was performed by using a trimodulin-coated plate and 
purified C5a or C3a was added. After washing, it was analyzed if the complement factors were bound 
by trimodulin and could therefore be detected by specific antibodies. A concentration-dependent 
decrease of C5a was seen, but the negative control (w/o EDTA-plasma) revealed the non-specific binding 
of the detection antibodies to the coating (see Figure 14). The problem of such non-specific bindings is 
also described by Tate & Ward, where the interference of detection antibodies with specific ELISA 
systems is reported208. Since the problem of non-specific binding was also revealed in the anaphylatoxin 
ELISA, it was impossible to distinguish if the binding of trimodulin to C5a or just the non-specific 
interference of the detection antibodies with the trimodulin coating was detected. Therefore, a second 
ELISA was performed by using a zymosan-coated plate. It was suggested that this setting reduced the 
non-specific binding, which was seen in the ELISA using a trimodulin-coated plate. In this setting, the 
complement factors that were not bound after the incubation with trimodulin on a second plate, were 
detected by transferring the supernatant to an anti-C3a or anti-C5a coated third plate. The results 
showed no influence of trimodulin or Intratect (used as IVIg control) on C3a detection. Compared to 
this, the detection of C5a revealed a slight decrease of this complement factor after trimodulin addition, 
whereas Intratect did not reduce the detection of C5a concentration-dependently (see Figure 15). The 
first evidences that Igs are able to bind to activated C3a as well as C5a molecules is described by Nezlin 
et al. They reported that the binding sites for both anaphylatoxins are mainly found in the Fab region of 
the IgG molecule209. Basta et al. supported this theory with in vitro and in vivo assays, demonstrating 
that Fab containing IVIg fragments were able to reduce anaphylatoxin mediated effector functions and 
prevented lethal cardio respiratory distress induced by C5a in a porcine model. Moreover, they 
demonstrated a shift in the molecular weight of the anaphylatoxins after the incubation with Fab 
fragments in a Western Blot analysis, indicating the binding of the fragments to C3a as well as C5a11. In 
general, the studies support the results of the anaphylatoxin ELISA, where a slight decrease in the C5a 
amount due to trimodulin addition was detected and it was suggested that this decrease was caused by 
trimodulin binding to the anaphylatoxin. Nevertheless, trimodulin did not inhibit the detection of C3a. 
This effect could be beneficial in inflammatory conditions, because the C3a molecule exhibit also anti-
inflammatory properties. Besides triggering inflammatory reactions, it is also able to operate as an 
antagonist for C5a and balances between pro- and anti-inflammatory mechanisms. Especially in an acute 
setting of inflammation, it prevents the mobilization as well as accumulation of neutrophils and is 
therefore important for the limitation of inflammatory reactions30,38. Moreover, Intratect did not exhibit 
any inhibitory capacity regarding C3a or C5a, which can be due to different binding affinities caused by 
another manufacturing process or due to the absence of IgM molecules compared to trimodulin.  
In future studies, it is important to further evaluating the interaction of trimodulin and C5a, 
because only a trend of C5a inhibition by trimodulin was detectable and should be supported by 
additional analyses. 
 
One important effector function, triggered by the activation of the complement system is the CDC 
of target cells. It is a substantial mechanism for the destruction of pathogens or infected cells, but if 
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dysregulated it contributes to a number of inflammatory pathologies or autoimmune diseases48,83. The 
control and inhibition of the complement system to prevent excessive CDC is therefore of high relevance. 
In the opsonin and anaphylatoxin ELISA it was observed that trimodulin is able to interact with the 
activated complement system by binding to the target molecules C3b, C4b and C5a. To determine, if the 
binding of these factors by the Igs of trimodulin has also functional impacts on complement-mediated 
effector functions, a CDC assay was developed. In general, CDC assays are used to test the ability of 
therapeutic monoclonal antibodies (e.g. Rituximab, anti CD20 mAb) to induce the CDC of target 
cells83,210,211. In this study, the assay was established to determine whether trimodulin is able to bind as 
well as functionally neutralize complement factors and therefore to inhibit CDC. Initially, the human B 
lymphocytic Ramos cell line, which was used as target for CDC, was characterized. The Ramos cells 
exhibited a high CD20 expression on their surface that confirmed the suitability of the cells for the use 
in the CDC assay. Moreover, they reacted highly sensitive to Rituximab addition and showed a 
concentration-dependent decrease in their cell viability. In addition, the CD20 detection decreased 
concentration-dependently after the addition of Rituximab (see Figure 16). Dorvignit et al. compared 
different B lymphocytic cell lines (Daudi, Raji and Ramos cells) in their CD20 expression as well as in 
their sensitivity to Rituximab and reported that Ramos cells showed the highest CD20 expression as well 
as the highest sensitivity to CDC activity172. A CD20-negative phenotypic change of Ramos cells after 
Rituximab treatment was also described in various studies212–215. It is reported that this is to some extent 
due to a masking of CD20, but mainly caused by the down-modulation of this transmembrane protein212. 
The complete mechanism of down-modulation is not fully understood, but it is suggested that an 
internalization of CD20 takes place after Rituximab binding. Additionally, mechanisms like protein 
folding, exportation, glycosylation or microRNA binding are discussed213,216. After characterization of the 
CD20 positive Ramos cells, the assay was performed by the pre-incubation of trimodulin with serum and 
subsequently addition to the cells in parallel with Rituximab. It was seen that trimodulin (compared to 
only FB) obviously increased the viability of the Ramos cells in all used concentrations, which suggests 
that it is able to inhibit activated complement factors concentration-dependently and therefore to prevent 
the CDC of Ramos cells (see Figure 17). It also confirmed the previous ELISA results, where the binding 
of C3b, C4b as well as C5a was confirmed. These results demonstrated for the first time that trimodulin 
can functionally inhibit CDC, which leads to a reduced inflammatory response. It is assumed that this is 
due to binding and inhibition of the activated complement factors by trimodulin. In comparison, Intratect 
showed only a slight increasing effect of the cell viability in the highest used concentration. This supports 
the assumption that IgM is more efficient in inhibiting complement activation than IgG and underlines 
the advantages of using trimodulin to reduce inflammation compared to IVIG preparations. The results 
were supported by the study of Rieben et al. that described the functional reduction of C3, C5b-9 as well 
as C6 deposition in an in vivo rat model by an IgM- and IgA-enriched preparation, whereas the effect of 
an IVIg was not as effective. In addition, Walpen et al. exposed the advantages of IgM in preventing 
hyperacute xenograft rejection by demonstrating a strong complement inhibitory effect in an in vitro 
xenotransplantation model with PK15 cells compared to IgG, where no inhibition was seen.  
Nevertheless, control experiments were performed, to determine if the decrease in complement 
deposition was due to the binding of complement and not due to unspecific overlay (e.g. to CD20) by 
trimodulin. A pre-incubation of the Ramos cells and Rituximab simultaneously to the pre-incubation of 
trimodulin and serum was performed to ensure that Rituximab already bound to CD20 before trimodulin 
was added and that trimodulin was not able to inhibit the binding of Rituximab to its target. An obvious 
concentration-dependent increase in the viability of the Ramos cells was detected after trimodulin 
addition, which confirms the assumption that trimodulin inhibits activated complement factors and does 
not influence the binding of Rituximab to CD20 (see Figure 18). Anyhow, the increase was slightly less 
effective compared to the viability that was seen after the pre-incubation of only trimodulin and serum. 
This could be due to an interaction of trimodulin with Rituximab when added at the same time, which 
can prevent the binding of Rituximab to CD20. However, it could also be caused by a faster and more 
efficient complement activation when Rituximab already bound to CD20, compared to the situation in 
which Rituximab initially bind CD20 before it can interact with C1q. It is known that C1q binds 
monomeric IgG with very low affinity, but clustering of IgG allows multivalent C1q binding and promotes 
efficient complement activation217–220. Recently, it was also shown that the C1 molecule is strongly 
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activated by ordered IgG hexamers, formed on the surface of a target cell221. Rituximab, not pre-
incubated with the Ramos cells and added together with pre-incubated trimodulin and serum (see Figure 
17) could sterically be inhibited from forming hexamers through the immune complexes or C3b 
molecules, which are generated by the alternative complement pathway and bind subsequently to the 
cell surface. This is one possible mechanism to explain the higher cell viability after the pre-incubation 
of serum and trimodulin compared to the incubation order where also Rituximab was pre-incubated 
together with the Ramos cells. Moreover, to exclude that trimodulin covered CD20 and Rituximab was 
not able to bind to CD20 anymore, a pre-incubation of trimodulin with the Ramos cells and without 
addition of Rituximab was performed. The subsequent detection of CD20 revealed that the expression 
of the surface antigen was as high as without trimodulin. This implies that no steric hindrance of 
Rituximab through trimodulin was induced and furthermore that CD20 was not covered by trimodulin, 
which further supports the direct inhibition of the activated complement factors by trimodulin (see 
Figure 21). Moreover, the subsequent addition of Rituximab clearly triggered the lysis of the target cells 
and was not as much inhibited as seen after the pre-incubation with trimodulin and serum (see appendix 
Figure 28). These results finally supported the hypothesis that trimodulin is able to prevent CDC by 
binding to activated complement factors and that this inhibition was not due to a functionally covering 
of CD20 by trimodulin.  
In addition, all assay components were also incubated at the same time to further characterize the 
mechanism by which trimodulin inhibited complement activity. A lower Ramos cell viability after 
trimodulin addition was detected (see Figure 19) as compared to the cell viability, which was seen after 
the pre-incubation of trimodulin and serum (see Figure 17). This result leads to the hypothesis that 
activated complement factors, like C3b or C4b are torn between the binding to the Ramos cells and to 
IgG as well as IgM molecules of trimodulin. For example, the binding of C1q to two IgG molecules of 
Rituximab (classical pathway) or the spontaneous induction of the alternative pathway, generate 
activated C3b as well as C4b molecules. These factors are on the one hand able to bind to the cell surface 
and further activate the complement cascade or on the other hand, to IgM and IgG molecules that inhibits 
the activation11,222,223. Therefore, it is suggested that a balance between activation and inhibition of the 
complement system takes place when all components were incubated at the same time and the cell 
viability is not as high as seen after pre-incubation of trimodulin and serum.  
Finally, the pre-incubation of Rituximab and trimodulin was performed, to exclude that Ig 
molecules of trimodulin can interact with the murine variable regions of the chimeric Rituximab 
antibody, which could neutralize Rituximab and lead similarly to an increase in the cell viability. It is 
known that patients that received monoclonal anti-mouse antibodies developed human anti-murine 
antibodies (HAMA), which caused immunogenicity224. With the development of chimeric murine/human 
antibodies, the problem of HAMA should have been solved. Hosono et al. reported that chimeric 
murine/human antibodies show little to no reactivity to HAMA225. Nevertheless, it is reported that indeed 
the immunogenicity was reduced, human anti-chimeric antibodies (HACA) could still develop, because 
of the murine parts226. However, it was observed, that the increase in the viability of the Ramos cells was 
lower, as compared to the viability, which was detected after the pre-incubation of trimodulin and serum 
(see Figure 20). Therefore, it is suggested that trimodulin did not interact with Rituximab and did not 
prevent the binding to CD20, but rather supported a direct effect of trimodulin against the deposition of 
complement components on the surface of Ramos cells.  
The CDC assay showed that trimodulin was able to directly interact with activated complement 
factors and thereby inhibiting the CDC of Ramos cells. In future studies it should evaluated which 
complement factors are inhibited by trimodulin. It is suggested that the first component of the classical 
pathway, C1q, is not bound and inhibited by trimodulin in the fluid phase. C1q needs the staple 
confirmation of the IgM pentamer to enable binding, which is only present when the Ig is bound to an 
antigen200. Moreover, there are no indications in the literature of C1q binding to circulating IgG or IgA 
molecules. It is assumed that the C3b and C4b molecules, generated by the classical and the alternative 
pathway in this setting, are bound by trimodulin in the fluid phase and therefore prevented from further 
activation. The strongest inhibition of CDC was detected after the pre-incubation of trimodulin and 
serum. In general, complement can also be activated upon binding to polymer surfaces, like polystyrene 
plates, triggered by the alternative pathway227,228. Therefore, trimodulin pre-incubated with serum on a 
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polystyrene plate was able to directly interact with the activated opsonins as well as to prevent them 
from binding to the surface of the Ramos cells in the next incubation step and inhibit further activation 
of the complement system.  
 
The anti-inflammatory mechanisms of trimodulin are of high relevance in severe inflammatory 
diseases like sCAP. It is known that inflammation in sCAP is triggered by an over-stimulated immune 
response. Especially the complement system contributes to disease severity after uncontrolled 
activation116,229. This is caused e.g. by high bacterial load or metabolic products of the bacterial lysis, 
together with antibiotic resistant bacteria that cannot be cleared completely by the immune system and 
lead to the release of pro-inflammatory mediators, like cytokines. Therefore, it is important to 
additionally treat the overstimulated host response, besides administering antimicrobial therapeutics.  
Trimodulin was shown to reduce CDC, which contributes to inflammation, by binding and 
inhibiting activated complement factors. This mechanism can also be helpful to reduce the hyper-
activation of the complement cascade, triggered among others by pneumolysin and teichnoic acid of S. 
pneumoniae119. It is assumed that trimodulin can therefore reduce the systemic spread of inflammation 
and prevent pneumonia-induced sepsis, pulmonary damage as well as multi-organ failure in sCAP. The 
studies of Müller-Redetzky et al. support the theory by demonstrating that targeting activated 
complement components can improve the patient’s outcome. They reported that the inhibition of C5a, 
which is considerably elevated in sCAP, could protect against lung and liver injury in mice, infected with 
pneumonia120,123. Trimodulin was also able to bind C5a seen in the anaphylatoxin ELISA (Figure 15). 
The early treatment of sCAP patients with trimodulin can therefore be a promising adjunctive therapy, 
next to the standard antimicrobial application, to prevent nonspecific complement activation and to 
improve the progress of disease. Moreover, the reduced mortality of sCAP patients with an elevated level 
of the inflammatory marker CRP in the CIGMA study, promotes the anti-inflammatory functions of 
trimodulin163. Nevertheless, the time by which a therapeutic is administered to the patients plays also a 
role for the outcome of disease severity. Calbo et al. report that patients with a prolonged time between 
the first symptoms of pneumonia and hospital admission exhibited higher levels of pro-inflammatory 
cytokines as well as a higher expression of acute phase proteins. They also underline that time is crucial 
for an optimal modulation of the inflammatory response, because the release of pneumococcal antigens, 
which cause inflammation, takes place over time. This indicates that it is important for future studies to 
determine the optimal time point at which trimodulin is administered to obtain the best outcome for the 
patients230.  
 
An over-stimulation of the immune system is also observed in severe COVID-19 patients. It is 
reported that this can lead to hyper-inflammation and implies acute organ failure as well as cardiac 
arrest, although an adequate oxygenation of the patients was performed231–233. There is evidence that 
the complement system contributes to the development of hyper-inflammatory conditions. Studies 
described the activation of the complement system in response to SARS-CoV infection and reported that 
mice were protected from pulmonary inflammation as well as respiratory failure with a deficiency of 
complement factor C3138. Severe COVID-19 patients show also an activation of the complement system 
in lung, skin as well as sera and positively respond to a treatment with complement inhibitors141,234,235. 
Exhibiting immunomodulatory properties as one relevant MoA it is assumed that trimodulin might be 
regarded as beneficial for the treatment of hyper-inflammatory conditions in severe COVID-19 patients. 
The results of the CDC assay (see section 5.2.5.1) supported this hypothesis and showed that trimodulin 
is able to interact and inhibit activated complement factors. Especially complement factor C5a seems to 
play a role in the development of inflammation, because its concentrations are elevated in severe COVID-
19 cases above 10 nM in serum or plasma139. In the anaphylatoxin ELISA, a trend in inhibiting 
complement factor C5a by trimodulin was also detected. Multiple therapeutic agents are available that 
also target complement and being studied for COVID-19. They are mostly monoclonal antibodies (e.g. 
eculizumab, ravulizumab, IFX-1 and AMY-101) that inhibit specific complement components or the 
activation of the complement system per se and promote the recovery of the patients 139,147,236,237. In 
comparison to monoclonal antibodies, trimodulin is not exclusively able to inhibit complement, but can 
modulate various effector functions. It was seen that trimodulin can for example reduce the release of 
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proinflammatory cytokines as well as influence the TLR expression on monocytes that contributes to a 
reduced stimulation of the immune system165. Therefore, the ability of trimodulin to modulate various 
effector functions at the same time could be an advantage for severe COVID-19 patients, which suffer 
from an over-stimulated immune system. Moreover, the application of IVIg therapy in severe and 
critically ill COVID-19 patients is recommended by the national diagnosis and treatment protocol for 
COVID-19 (Trial Version 7) in China and by the Peking Union Medical College Hospital238,239. It is 
reported that the early treatment with high-dose IVIgs can lead to a reduced need of mechanical 
ventilation, to a shortened duration of hospital stay and to an improved 28-day survival239. However, in 
future studies the potential of Ig preparations, as add-on therapy to the standard treatment of COVID-
19 patients, should be evaluated to obtain a beneficial outcome.  
 
As discussed in the previous paragraphs, it is an important function of Ig preparations to control 
and prevent excessive activation of the complement system and to protect the host against tissue damage 
as well as multiple organ failure. Nevertheless, the activation of the complement system is also a 
necessary and substantial effect of IgG and IgM molecules to eliminate intruding pathogens by effector 
functions like CDC or phagocytosis45.  
To determine the antimicrobial activity of trimodulin and to compare it with the complement 
inhibitory capacity, two OPAs were developed using E. coli bacteria (K12) and S. aureus bioparticles. 
Initially, the phenotype of the differentiated HL-60 cells was analyzed, to determine the differentiation 
status and to test if they are suitable for the use in the OPA. The analysis of the complement receptors 1 
and 3 (CD35 and CD11b) and the FcγRs (CD16, CD32 and CD64) revealed that both complement receptors 
as well as CD32 were highly expressed, whereas a medium CD16 expression was shown and CD64 was only 
slightly detectable. Moreover, no expression of CD71 was visible on the differentiated HL-60 cells (see 
Figure 22). The results for the FcγR expression on differentiated HL-60 cells are in accordance with 
various studies. Worley et al. reported an upregulation of CD16 and CD32 after differentiation of the 
HL-60 cells with DMSO, whereas CD64 was only slightly detectable240. Moreover, Trayner et al. also 
showed a slight expression of CD64 after DMSO addition and Verbrugge et al. detected that CD64 
expression was lost during differentiation241,242. The upregulation of the complement receptors CD11b 
and CD35 is also described and serves as marker for the successful differentiation of the HL-60 cells243–
245. Additionally, it is reported that HL-60 cells exhibit a loss of CD71 upon differentiation with 
DMSO241,246. In comparison to HL-60 cells, freshly isolated neutrophils show also a high CD16 as well as 
CD32 expression, whereas CD64 is not detectable240,247. Furthermore, CD11b as well as CD35 are also 
upregulated on neutrophils during an infection248. Due to the results of the phenotypic characterization, 
the HL-60 cells were assessed as suitable for the application in the OPA assays. In general, the use of a 
cell line compared to primarily isolated neutrophils allows faster as well as high throughput analyses, 
because isolated neutrophils exhibit short half-lives and must be prepared freshly prior to an assay as 
cryopreservation can affect their functionality249. Nevertheless, differences between HL-60 cells and 
primarily isolated neutrophils, like a lower level of antimicrobial activity of the HL-60 cells or varieties 
in their surface receptor expression, have to be considered when analyzing their effector functions240,250. 
After the phenotypic characterization of the HL-60 cells, the IgM/IgG depleted NHS was titrated 
to determine the optimal concentration for the use in the E. coli OPA and 0.8% NHS minus was assessed 
as best concentration. Higher amounts of NHS minus caused high non-specific killing and lower amounts 
prevented further activation of the complement system by trimodulin. Non-specific killing of serum in 
the absence of antibodies and in the presence of pathogens is a known difficulty in opsonophagocytic 
assays251. A pre-adsorption step with the bacteria of interest prior to the assays should be effective to 
reduce non-specific killing in OPAs. Afterwards, the sera must be tested for their activity in a CH50 
test193. Abbanat et al. described a reduction of more than 40% non-specific killing after addition of a pre-
adsorption step with E. coli bacteria252. Moreover, Burton & Nahm reported a dramatically decrease of 
non-specific killing after the pre-adsorption of baby rabbit serum with an unencapsulated pneumococcal 
strain253. In this thesis, the pre-adsorption of E. coli bacteria with NHS minus was also evaluated, but did 
not significantly decrease the non-specific killing of the serum (data not shown). Therefore, the NHS 
minus was adjusted to use the concentration at which the lowest non-specific killing was detected, but 
trimodulin still was able to activate the complement system.  
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To analyze, if trimodulin is able to induce the opsonophagocytosis of E. coli, the OPA was 
performed with the appropriate NHS minus concentration. Different controls were used to determine 
the 100% survival of the bacteria (control A), the direct effect of the differentiated HL-60 cells on the E. 
coli growth (control B), the mechanisms induced by complement activation without antibody addition 
(control C) and the effector functions triggered by the Ig molecules of trimodulin without NHS minus 
addition (control D). It was detected that control B in comparison to control A showed a slight decrease 
in the survival of the E. colis (see Figure 24). Control B consisted of the bacteria, hi NHS minus, 
differentiated HL-60 cells as well as trimodulin FB. In general, differentiated HL-60 cells express TLRs 
on their surface that can recognize specific conserved patterns of microbial components (PAMPs)254,255. 
Moreover, TLRs can trigger antimicrobial host responses by phagocytosis, degranulation as well as 
NETosis256,257. E. coli K12 compromises lipopolysaccharide (LPS) in its outer membrane that in turn is 
able stimulate TLR4, which is present on differentiated HL-60 cells and this leads to the killing of the 
pathogens258,259. The analysis of control C composed of bacteria, NHS minus, differentiated HL-60 cells 
as well as trimodulin FB, showed a strong decrease in the survival of the E. coli bacteria. Complement 
can be activated via the classical, lectin and the alternative pathway7,12. The classical pathway is in this 
setting negligible, because no IgG and IgM molecules were available in NHS minus for C1q activation. 
It is also reported that the lectin pathway is only involved in opsonization and phagocytosis of yeast 
species trough binding of MBL to mannose residues on the pathogen, whereas the uptake of bacteria is 
mostly MBL independent260. Therefore, it was suggested that complement was activated by the 
spontaneous hydrolysis of C3 in the alternative pathway, upon the presence of microbial inflammatory 
mediators of E. coli. Activated complement factors can trigger various effector functions. They are able 
to lyse pathogens through CDC, by assembly of the terminal MAC into the membrane, can initiate 
complement-mediated phagocytosis by binding to CR1 and CR3 on the phagocyte and lead to NETosis 
as well as degranulation of neutrophils. Control C comprised differentiated HL-60 cells, which express 
CR1 and CR3 on their surface, leading to the assumption that the activated complement factors bound 
to the phagocytes and induced the killing of the pathogens. Moreover, it was detected that trimodulin 
concentration-dependently decreased the cell viability of the bacteria without the addition of NHS minus 
and in presence of differentiated HL-60 cells (control D). High trimodulin concentrations showed an 
obvious decreasing effect in the survival of the E. coli (see Figure 24). There are several effector 
functions, which might be responsible for the reduced viability of the bacteria. The binding of trimodulin 
opsonized the surface of the E. coli cells and attracted the phagocytes (differentiated HL-60 cells), which 
bound to the Ig molecules of trimodulin via their FcRs. After binding to antibody-opsonized bacteria, the 
effector cells are able to destroy the pathogens via ADCP, ADCC (degranulation) or NETosis in the 
absence of serum48,70,261. HL-60 cells only exhibit FcγRs (IgG) as well as the FcαR (IgA), whereas the 
FcµR (IgM) is not expressed63,262. For this reason, the destruction of the bacteria that was seen in control 
D was mostly IgG and to some extent IgA triggered. Nevertheless, it is reported that IgA-mediated 
opsonization as well as phagocytosis induce NETosis and ROS production, which results in the 
subsequent cell death of the phagocyte263. Because the viability of the HL-60 cells was still high after 
assay incubation (data not shown), it is suggested that mainly IgG was responsible for the killing of the 
E. coli bacteria by phagocytosis or degranulation in control D. After incubation of the bacteria with NHS 
minus, differentiated HL-60 cells and trimodulin (sample), a dual effect regarding the bacterial survival 
was detected. In high concentrations, trimodulin exhibited an increasing effect on the E. coli viability 
compared to control C (without trimodulin) and compared to the same concentration of trimodulin in 
control D (without NHS minus). However, the viability decreased in lower concentrations, whereas a 
slight increase in the lowest trimodulin concentration was detected (see Figure 24). These data showed 
for the first time that trimodulin exhibits an ambivalent effect towards the complement system. On the 
one hand, high trimodulin doses triggered the inhibition of the opsonophagocytosis and on the other 
hand, an uptake of the bacteria was induced in low concentrations. It was suggested that the reduction 
in the opsonophagocytic capacity of the HL-60 cells was caused by an inhibition of complement 
activation after trimodulin addition. These findings are in accordance and support the results of the CDC 
assay, where an obvious inhibition of the complement system was also detected in high trimodulin doses 
(see Figure 17). Nevertheless, trimodulin did not stronger activate complement via the classical pathway 
in this setting and thereby did not amplify the opsonophagocytosis of E. coli compared to control C, 
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where complement activation was induced by the alternative pathway. It was already shown that high-
dose Ig preparations can scavenge activated complement factors, whereas low doses are able to activate 
the complement system17,95,198,264,265. However, in the E. coli OPA only the phagocytosis of the bacteria 
could be detected, but the assay was not able to depict the opsonophagocytic effect of trimodulin. The 
use of Intratect (as IVIg control) showed that control A (100% control for the E. coli growth), control B 
(used to determine the direct effect of differentiated HL-60 cells on the viability of E. coli) as well as 
control C (used for evaluating the effects of NHS minus on E. coli growth without addition of the Ig 
preparation) were comparable to trimodulin. However, a stronger decrease of the cell viability was 
induced with high Intratect doses in control D. This was caused by the higher amount of IgG molecules 
in Intratect (≈ 96%) compared to trimodulin (≈ 56%), which were responsible for the induction of 
phagocytosis without the addition of NHS minus. Moreover, Intratect did not inhibit complement 
activation in high doses, but triggered the opsonophagocytosis of E. coli compared to control C. Roos et 
al. as well as Rieben et al. already described that IgM is a more potent complement inhibitor than IgG 
molecules98,223. It is suggested that trimodulin inhibits complement components stronger, because of the 
high avidity of IgM together with the ability of IgG to bind activated complement components as 
compared to Intratect, which exclusively contains IgG molecules. These data are additionally supported 
by the results generated in the opsonin ELISA, which showed a slight reduction in the detection of the 
C3b as well as C4b molecules, whereas a strong decrease of the complement factors was seen after 
trimodulin addition (see Figure 10 and Figure 11). Nevertheless, a high SD was detected in the E. coli 
OPA, which made it difficult to distinguish between assay variations and real effects induced by 
trimodulin. It was assumed that the high SD was caused by the evaluation method used in the OPA, 
because the bacteria were manually counted on LB agar pates, which was susceptible for variations. 
Therefore, another OPA was developed by using a FACS-based method to evaluate the 
opsonophagocytosis of Alexa Fluor 488 conjugated S. aureus bioparticles induced by trimodulin.  
The S. aureus bioparticles OPA was performed by using the same controls and samples as in the E. 
coli OPA. Data were evaluated by calculating the phagocytic index, which depicts the median 
fluorescence intensity of living HL-60 cells that ingested the bioparticles after trimodulin addition. 
Hence, a discrimination between cells that ingested high amounts of bioparticles as well as cells with a 
lower phagocytic capacity was possible. Untreated HL-60 cells were used as additional control to 
determine the background fluorescence of the cells without the addition of Alexa Fluor 488 conjugated 
bioparticles. It was detected that untreated HL-60 cells as well as control A (bacteria, undifferentiated 
HL-60 cells, hi NHS minus and FB) showed nearly no phagocytic index, which implies a low background 
fluorescence of the bioparticles without differentiated HL-60 cells (see Figure 26). Control B that 
comprised bacteria, differentiated HL-60 cells, hi NHS minus and FB, induced a slight increase in the 
phagocytic index compared to control A. In general, S. aureus bioparticles are heat- or chemically 
inactivated pathogens, even though they are suitable for the use in phagocytic assays266. As gram-positive 
bacteria, they exhibit the counterpart to LPS, lipoteichoic acid (LTA) as well as peptidoglycan in their 
cell wall267. These PAMPs are able to stimulate the release of proinflammatory cytokines and activate 
leukocytes in vitro268. TLR2, which is present on differentiated HL-60 cells, is able to detect PAMPs like 
LTA or peptidoglycan and activates the phagocyte254,269. Therefore, an increase of the phagocytic index 
was seen in control B, because the HL-60 cells were activated by the interaction of S. aureus PAMPs with 
TLR2. Control C, which was used to determine the effect of NHS minus regarding opsonophagocytosis 
of the pathogens without the addition of trimodulin, showed a high phagocytic index, as compared to 
the other controls. This was already seen in the E. coli OPA and was suggested to be caused by the 
activation of complement via the alternative pathway by binding to CR1 as well as CR3 on the HL-60 
cells and leading to CDC, degranulation, NETosis as well as opsonophagocytosis. The analysis of control 
D (bacteria, differentiated HL-60 cells, hi NHS minus and trimodulin) revealed a concentration-
dependent increase in the phagocytic index from high to medium concentrations of trimodulin and a 
strong decrease after addition of low concentrations. It was assumed that in this setting high-dose 
trimodulin was able to inhibit the phagocytosis of S. aureus bioparticles by its anti-inflammatory 
functions. Besides their complement inhibitory capacity, high concentrations of Ig preparations are 
additionally able to block FcγRs and therefore to inhibit the binding of immune-complexes to these 
receptors. Moreover, it is described that high-dose Ig preparations can also upregulate the inhibitory 
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receptor FcγRIIb91,157,270–274. These mechanisms are important functions of Ig preparations and used for 
the therapy of autoimmune or inflammatory disorders. For this reason, it was suggested that trimodulin 
is able to activate the phagocytosis of S. aureus bacteria in lower doses by binding of IgG molecules to 
their specific FcƴRs on the HL-60 cells, whereas high doses blocked this interaction. After incubation of 
trimodulin with bacteria, differentiated HL-60 cells as well as NHS minus (sample) a concentration-
dependent increase of the phagocytic index from high to medium trimodulin concentrations and a 
decrease in lowest concentrations was seen. The increase in the opsonophagocytosis of S. aureus was 
significantly stronger compared to control D as well as to control C. This demonstrated for the first time 
that trimodulin is able to activate the complement system and to increase the opsonophagocytosis of the 
bacteria. Additionally, the ambivalent effect of trimodulin in activating and inhibiting the immune 
system was detected. On the one hand, it was suggested that high trimodulin doses could inhibit the 
complement system as well as lead to a blocking of FcγRs and to an upregulation of the inhibitory 
FcγRIIb. On the other hand, trimodulin was able to activate the complement system via the classical 
pathway and to induce the ingestion of the S. aureus bioparticles in the presence of NHS minus. Walpen 
et al. as well as Wagner et al. reported that high-dose Ig preparations are able to inhibit complement 
activation induced by the classical pathway, but not the anti-bacterial activity triggered by the alternative 
pathway275,276. This dual role of Ig preparations ensures the killing of intruding pathogens by mechanisms 
like opsonophagocytosis or CDC, but also prevents excessive complement activation. The alternative 
pathway, induced by NHS minus in the absence of trimodulin (control C), was also active after 
trimodulin treatment (samples), because the phagocytic index of the sample did not exhibit lower values 
than control C. Compared to this, the additional activation of complement via the classical pathway was 
prevented in high trimodulin doses.  
These results show that trimodulin is able to activate the classical complement pathway in low 
concentrations and amplifies the clearance of S. aureus bioparticles. Additionally, the killing of the 
pathogens is ensured, despite the inhibition of the complement system in high trimodulin doses, because 
the alternative pathway was not inhibited by trimodulin. 
For comparison, Intratect (as IVIg control) was diluted to the same IgG amount as trimodulin 
(⋲ 56%) and was used in the S. aureus OPA. It was detected that Intratect without the addition of NHS 
minus (control D) also induced the concentration-dependent phagocytosis of S. aureus bioparticles (see 
Figure 27). High concentrations triggered the strongest phagocytosis of the bacteria, whereas the effect 
decreased in low Intratect concentrations. Nevertheless, the phagocytic index was lower as observed for 
trimodulin. It is suggested that the higher values generated after trimodulin treatment, were caused by 
the presence of IgA molecules in trimodulin compared to Intratect, which only consists of IgG molecules. 
IgA is able to initiate phagocytosis via the binding to its FcαR, which is also present on differentiated 
HL-60 cells262. Moreover, a blocking of the phagocytosis in high Intratect doses could not be detected. 
Compared to this, trimodulin induced the blocking of the phagocytosis (seen in control D), which was 
assumed to be caused by a higher amount of IgG-aggregates in trimodulin as compared to Intratect 
(master thesis Fabian Bohländer). In general, FcγRs exhibit low affinity for binding monomeric 
circulating IgG and are rather activated by immune complexes92. Therefore, the blocking of the FcγRs is 
also more likely due to an interaction with IgG-aggregates than to the binding of monomeric IgG 
molecules. However, in the Intratect sample an ambivalent effect of the IVIg preparation was detected 
regarding complement activation. High Intratect doses revealed an inhibition of the S. aureus 
opsonophagocytosis and low concentrations triggered the ingestion of the particles. This dual effect was 
already seen in the trimodulin sample with almost the same phagocytic indices. It is reported that 
generally IgM molecules are more potent complement inhibitors /activators than IgG12,98,223. One IgM 
molecule is able to bind and activate C1q, the first component of the classical pathway, whereas two or 
more IgG molecules in a specific distance to each other are needed for the same purpose. Moreover, IgM 
has a higher avidity as IgG to bind activated complement components due to its pentameric structure60. 
Therefore, it was assumed that trimodulin was able to induce a stronger opsonophagocytosis compared 
to Intratect. Nevertheless, the results of the S. aureus OPA showed that trimodulin and Intratect induced 
the same activation of the classical complement pathway as well as the same opsonophagocytosis. 
However, the OPA was performed by using S. aureus bioparticles instead of living bacteria. These 
particles are fragments of S. aureus and are not present in their native conformation as well as size. 
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Moreover, living S. aureus bacteria express a polysaccharide capsule, which masks their surface, impedes 
phagocytosis and therefore contributes to the pathogenesis of S. aureus277,278. It is assumed that the 
bioparticles did not exhibit an intact capsule, because of their treatment for inactivation, hence being 
less pathogenic. For this reason, it is suggested that less complement and Igs are necessary to induce the 
opsonophagocytosis of the bioparticles, compared to living bacteria. This in turn leads to the assumption 
that the IgG molecules of Intratect already induced the complete opsonophagocytosis of the bacteria 
cells in low concentrations and no further activation of the complement system through IgM was 
necessary. Therefore, no difference in the phagocytic capacity of trimodulin and Intratect was visible.  
For an improved comparison of trimodulin and Intratect as well as for the evaluation of the 
differences between IgM and IgG molecules in inducing the opsonophagocytosis of pathogens, the OPA 
should be performed by using living S. aureus bacteria in future studies. Moreover, gram-positive S. 
aureus bacteria are, contrary to E. coli bacteria, one of the relevant pathogens in sCAP and cause excess 
mortality 279,280. For this reason, it is important to analyze the opsonophagocytic capacity of trimodulin 
regarding living S. aureus bacteria, as sCAP relevant pathogens. Nevertheless, the results of the OPA 
provided the first evidence that trimodulin is able to induce the opsonophagocytosis of gram-positive 
bacteria and that it could therefore improve the outcome of patients with sCAP. 
 
In general, trimodulin was developed for the treatment of patients with severe infections and is 
currently tested for the indications sCAP as well as COVID-19. It is known that patients with severe 
infections often suffer from antibody depletion. In the study of de la Torre et al., they reported that sCAP 
patients, which require ICU treatment, showed a decreased level of IgG and IgA molecules in serum as 
compared to patients with milder progression of sCAP. Moreover, it was observed that the low Ig levels 
contribute to disease severity as well as mortality281. In addition, Bermejo-Martín et al. showed that the 
combined decrease of IgG1, IgM as well as IgA is responsible for a higher mortality rate in patients with 
severe sepsis or septic shock282. Therefore, it could improve the patient’s outcome when treated with an 
IgM- or IgA-enriched Ig preparation like trimodulin. The CIGMA study already demonstrated that sCAP 
patients, which exhibited a reduced IgM level, an elevated CRP level or both, showed a reduced 28-day 
mortality when treated with trimodulin as add-on therapy163. In the S. aureus OPA it was clearly 
demonstrated that trimodulin has an antimicrobial effect against sCAP relevant pathogens. Especially in 
patients with reduced Ig levels, the supplementation of exogenous Igs with trimodulin, next to the 
standard antibiotic therapy, is therefore an important tool to provide the patients with sufficient amounts 
of Igs to reduce disease severity as well as mortality.  
The severity of infections, like sCAP or COVID-19, can also be increased by the simultaneous 
infection of the host with multiple pathogens. For example, bacterial co-infections are common in viral 
respiratory infections and contribute to disease severity216,283. It was already demonstrated that SARS- 
and MERS-CoV patients develop major complications due to bacterial co-infections284,285. Relating to 
COVID-19, various studies report bacterial co-infections in SARS-CoV-2 positive patients as well. 
Nevertheless, Landsbury et al. revealed that only 7% of hospitalized COVID-19 patients and 14% of ICU 
patients exhibit bacterial co-infections. This can be due to an unavailability of data, because most of the 
studies that are available until now, did not screen for co-infecting pathogens and could therefore be an 
underestimated problem. In general, the most commonly co-infecting bacteria identified in SARS-CoV-2 
positive patients, are M. pneumoniae, P. aeruginosa, H. influenzae and K. pneumoniae286. Additionally, 
C. pneumoniae, L. pneumoniae, S. aureus and S. pneumoniae were also detected in COVID-19 patients287–
289. It is also reported that bacterial co-infections contribute to ICU admission as well as mechanical 
ventilation of COVID-19 patients287. Furthermore, the alveoli in severe SARS-CoV-2 infections are often 
injured290. This in turn can lead to a facilitated influx of bacteria and viruses, which at worst can induce 
sepsis and septic shock291. Indeed, trimodulin does not exhibit antibodies directed against SARS-CoV-2, 
nevertheless it contains a broad spectrum of other anti-viral as well as anti-bacterial antibodies. 
Therefore, it is suggested that trimodulin is able to neutralize various pathogens, like co-infecting 
bacteria, by its antimicrobial mechanisms like CDC, ADCP, ADCC as well as opsonophagocytosis. In the 
S. aureus OPA it was detected that trimodulin is able to activate complement and leads to the 
opsonophagocytosis of the pathogens. Moreover, trimodulin comprises IgA and IgM molecules, which 
are the first line of defense at the lung epithelium54,292. All these characteristics support the assumption 
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that trimodulin can also help to neutralize co-infectious bacteria in severe viral infections like COVID-19, 
besides modulating the immune system and that this reduces disease severity as well as mortality. 
 
The aim of this PhD thesis was the functional characterization of trimodulin to obtain new insights 
in the MoA of this IgM- and IgA-enriched Ig preparation. In summary, it was demonstrated that 
trimodulin exhibits an ambivalent effect regarding complement activity by activating but also by 
inhibiting the complement system concentration-dependently. Initially, the opsonin and anaphylatoxin 
ELISAs showed the interaction of trimodulin with the activated complement factors C3b, C4b as well as 
C5a. The detection was obviously reduced by the binding and an overlay of these factors on the 96 well 
plate. Moreover, trimodulin showed a stronger ability to decrease the detection of C3b as well as C4b 
compared to the IVIg control (Intratect). In order to functionally prove the complement inhibitory 
mechanisms of trimodulin, a CDC assay was developed. This assay showed for the first time that 
trimodulin was able to reduce the CDC of Ramos cells and therefore obviously inhibited activated 
complement factors, which was supported by various control experiments. Additionally, it was shown 
that Intratect did not exhibit complement inhibitory capacity. This clearly demonstrated the benefit of 
using trimodulin compared to a standard IVIg preparation for preventing the over-stimulation of the 
complement system. Therefore, it is assumed that trimodulin may help patients with a hyper-activation 
of the immune system that causes inflammation, seen in autoimmune or inflammatory disorders.  
Moreover, an OPA was developed to additionally examine the antimicrobial mechanisms of 
trimodulin. The assay demonstrated that trimodulin activated the complement system in relatively low 
doses and therefore induced the opsonophagocytosis of S. aureus bioparticles. Simultaneously, it was 
detected that trimodulin still inhibited complement activation via the classical pathway in high doses. 
These results revealed that the OPA was able to depict the dual MoA of trimodulin regarding complement 
activity. Indeed, the complement system was inhibited in high trimodulin concentrations; however, the 
neutralization of the bacteria was still ensured by the addition of low trimodulin doses. These 
antimicrobial functions of trimodulin are relevant for the destruction of invading pathogens, which 
trigger severe infections, like sCAP. Nevertheless, the complement system can also be harmful to the 
host, when over-activated and induce tissue damage as well as multiple organ failure. Therefore, it is 
important that the complement system is balanced between activation and inhibition.  
 
In this PhD thesis, trimodulin was functionally characterized regarding its ability to activate and 
to inhibit the complement system. The results gave new insights and improved the understanding of the 
complex MoA of this IgM- and IgA-enriched preparation. Moreover, the data support the hypothesis that 
trimodulin can be used for the treatment of inflammatory or autoimmune diseases, besides for the 
therapy of severe infections. Especially for COVID-19 patients, it would be beneficial to prevent the 
hyper-activation of the complement system, which makes trimodulin a promising agent for the treatment 
of this infection. Nevertheless, to further decipher the MoA of trimodulin regarding complement 
activation and inhibition, various functions should be addressed in future studies. It is important to 
evaluate the detailed mechanisms of the individual Ig subclasses in trimodulin and to analyze which 
subclass is mainly responsible for activation and for inhibition of the complement system. Moreover, it 
should be examined which complement factors and pathways are inhibited by trimodulin. Finally, it is 
also important to analyze the modulation of signaling pathways in effector cells after the inhibition of 
the complement system.  
The findings of this PhD thesis gave substantial insights into the MoA of trimodulin, displaying the 
complex network and various interactions of the human immune system and can be regarded as valuable 
results for the future research on IgM- and IgA-enriched preparations. 
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7. Appendix 
 
7.1. Additional Results 
 
7.1.1. Complement-dependent cytotoxicity assay 
 
 
Figure 28 Trimodulin does not inhibit CDC after pre-incubation with Ramos cells. Trimodulin (a) or Intratect (b) was mixed with 
assay buffer, 80% NHS as well as 50 µL Ramos cells (5∙106 cells/mL) and pre-incubated on a 96 well plate for 30 min at 37 °C. 
After that, 15 µL of 160 µg/mL Rituximab was added to the wells and the plate was incubated for additional 80 min at 37 °C. 
After incubation, the survival of the cells was measured by PI staining in a flow cytometer. Data represent results from two 
independent experiments performed in duplicates. See Table 24 and Table 25 for a detailed overview of the statistical analysis. 
 
Table 16 Statistical analysis of the pre-incubation of trimodulin with NHS (see Figure 17) by using a one-way ANOVA and a 
Bonferroni test. Significance is shown as p-value: * p ≤ 0.05 and ** p ≤ 0.01. 
Comparison  Significance (p-value)  
Rituximab vs. trimodulin 0.390625 mg/mL ns 
Rituximab vs. trimodulin 0.78125 mg/mL ns 
Rituximab vs. trimodulin 1.5625 mg/mL * 
Rituximab vs. trimodulin 3.125 mg/mL ** 
Rituximab vs. trimodulin 6.25 mg/mL ** 
 
Table 17 Statistical analysis of the pre-incubation of Intratect (see Figure 17) with NHS by using a one-way ANOVA and a 
Bonferroni test. 
Comparison  Significance (p-value)  
Rituximab vs. Intratect 0.390625 mg/mL ns 
Rituximab vs. Intratect 0.78125 mg/mL ns 
Rituximab vs. Intratect 1.5625 mg/mL ns 
Rituximab vs. Intratect 3.125 mg/mL ns 
Rituximab vs. Intratect 6.25 mg/mL ns 
 
  
Rituximab + trimodulin FB +
Rituximab + trimodulin 0.390625 mg/ml +
Rituximab + trimodulin 0.78125 mg/ml +
Rituximab + trimodulin 1.5625 mg/ml +
Rituximab + trimodulin 3.125 mg/ml +
Rituximab + trimodulin 6.25 mg/ml +
Rituximab + Intratect FB +
Rituximab + Intratect 0.390625 mg/ml +
Rituximab + Intratect 0.78125 mg/ml +
Rituximab + Intratect 1.5625 mg/ml +
Rituximab + Intratect 3.125 mg/ml +
Rituximab + Intratect 6.25 mg/ml +
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Table 18 Statistical analysis of the pre-incubation of trimodulin with NHS and simultaneous of Rituximab and Ramos cells (see 
Figure 18) by using a one-way ANOVA and a Bonferroni test. Significance is shown as p-value: * p ≤ 0.05. 
Comparison  Significance (p-value)  
Rituximab vs. trimodulin 0.390625 mg/mL ns 
Rituximab vs. trimodulin 0.78125 mg/mL ns 
Rituximab vs. trimodulin 1.5625 mg/mL ns 
Rituximab vs. trimodulin 3.125 mg/mL * 
Rituximab vs. trimodulin 6.25 mg/mL * 
 
Table 19 Statistical analysis of the pre-incubation of Intratect with NHS and simultaneous of Rituximab and Ramos cells (see 
Figure 18) by using a one-way ANOVA and a Bonferroni test. 
Comparison  Significance (p-value)  
Rituximab vs. Intratect 0.390625 mg/mL ns 
Rituximab vs. Intratect 0.78125 mg/mL ns 
Rituximab vs. Intratect 1.5625 mg/mL ns 
Rituximab vs. Intratect 3.125 mg/mL ns 
Rituximab vs. Intratect 6.25 mg/mL ns 
 
Table 20 Statistical analysis of the simultaneous incubation of all assay components with trimodulin (see Figure 19) by using a 
one-way ANOVA and a Bonferroni test. Significance is shown as p-value: ** p ≤ 0.01. 
Comparison  Significance (p-value)  
Rituximab vs. trimodulin 0.390625 mg/mL ns 
Rituximab vs. trimodulin 0.78125 mg/mL ns 
Rituximab vs. trimodulin 1.5625 mg/mL ns 
Rituximab vs. trimodulin 3.125 mg/mL ns 
Rituximab vs. trimodulin 6.25 mg/mL ** 
 
Table 21 Statistical analysis of the simultaneous incubation of all assay components with Intratect (see Figure 19) by using a one-
way ANOVA and a Bonferroni test. Significance is shown as p-value: * p ≤ 0.05. 
Comparison  Significance (p-value)  
Rituximab vs. Intratect 0.390625 mg/mL ns 
Rituximab vs. Intratect 0.78125 mg/mL ns 
Rituximab vs. Intratect 1.5625 mg/mL ns 
Rituximab vs. Intratect 3.125 mg/mL ns 
Rituximab vs. Intratect 6.25 mg/mL * 
 
Table 22 Statistical analysis of the pre-incubation of trimodulin with Rituximab (see Figure 20) by using a one-way ANOVA and 
a Bonferroni test. Significance is shown as p-value: ** p ≤ 0.01. 
Comparison  Significance (p-value)  
Rituximab vs. trimodulin 0.390625 mg/mL ns 
Rituximab vs. trimodulin 0.78125 mg/mL ns 
Rituximab vs. trimodulin 1.5625 mg/mL ns 
Rituximab vs. trimodulin 3.125 mg/mL ns 
Rituximab vs. trimodulin 6.25 mg/mL ** 
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Table 23 Statistical analysis of the pre-incubation of Intratect with Rituximab (see Figure 20) by using a one-way ANOVA and a 
Bonferroni test.  
Comparison  Significance (p-value)  
Rituximab vs. Intratect 0.390625 mg/mL ns 
Rituximab vs. Intratect 0.78125 mg/mL ns 
Rituximab vs. Intratect 1.5625 mg/mL ns 
Rituximab vs. Intratect 3.125 mg/mL ns 
Rituximab vs. Intratect 6.25 mg/mL ns 
 
Table 24 Statistical analysis of the pre-incubation of trimodulin with Ramos cells (see Figure 21) by using a one-way ANOVA and 
a Bonferroni test. 
Comparison  Significance (p-value)  
Rituximab vs. trimodulin 0.390625 mg/mL ns 
Rituximab vs. trimodulin 0.78125 mg/mL ns 
Rituximab vs. trimodulin 1.5625 mg/mL ns 
Rituximab vs. trimodulin 3.125 mg/mL ns 
Rituximab vs. trimodulin 6.25 mg/mL ns 
 
Table 25 Statistical analysis of the pre-incubation of Intratect with Ramos cells (see Figure 21) by using a one-way ANOVA and 
a Bonferroni test. 
Comparison  Significance (p-value)  
Rituximab vs. Intratect 0.390625 mg/mL ns 
Rituximab vs. Intratect 0.78125 mg/mL ns 
Rituximab vs. Intratect 1.5625 mg/mL ns 
Rituximab vs. Intratect 3.125 mg/mL ns 
Rituximab vs. Intratect 6.25 mg/mL ns 
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7.1.2. E. coli opsonophagocytosis assay 
 
 
Figure 29 Comparison of 0.7% and 0.8% NHS minus for use in the E. coli OPA. Trimodulin (B588039) and E. coli bacteria were 
pre-incubated on a 96 well U-bottom plate for 30 min at RT. After that, (a) 0.7% NHS minus or (b) 0.8% NHS minus as well as 
HL-60 cells were added, mixed and were incubated for additional 45 min at 37 °C. The plate was put on ice for 20 min and 5 µL 
of every well was distributed in triplets to LB agar plates for overnight incubation at 37 °C. The CFUs were counted and the data 
was analyzed using GraphPad Prism. Control A served as 100% control for bacterial survival [CFU/mL], control B determined the 
direct killing of the cells via binding of E. coli to the TLRs and control C was used to examine the activation of complement 
without Ig addition. Trimodulin was 100-fold serially diluted (1810 µg/mL to 0.181 µg/mL) to monitor concentration-dependent 
effects. Data represent results from two independent experiments performed in triplicates. 
 
Table 26 Statistical analysis of the E. coli OPA by comparing control C (bacteria, differentiated HL-60 cells, NHS minus and FB) 
with the trimodulin samples (see Figure 24). Statistical analyses were performed using a Kruskal-Wallis test.  
Comparison  Significance (p-value)  
Control C vs. trimodulin 1810 µg/mL ns 
Control C vs. trimodulin 181 µg/mL ns 
Control C vs. trimodulin 18.1 µg/mL ns 
Control C vs. trimodulin 1.81 µg/mL ns 
Control C vs. trimodulin 0.181 µg/mL ns 
Control C vs. trimodulin 0.0181 µg/mL ns 
Table 27 Statistical analysis of the E. coli OPA by comparing control D (bacteria, differentiated HL-60 cells, hi NHS minus and 
different trimodulin concentrations) with the trimodulin samples (see Figure 24). Statistical analyses were performed using a 
Kruskal-Wallis test.  
Comparison  Significance (p-value)  
Control D 1810 µg/mL vs. trimodulin 1810 µg/mL ns 
Control D 181 µg/mL vs. trimodulin 181 µg/mL ns 
Control D 18.1 µg/mL vs. trimodulin 18.1 µg/mL ns 
Control D 1.81 µg/mL vs. trimodulin 1.81 µg/mL ns 
Control D 0.181 µg/mL vs. trimodulin 0.181 µg/mL ns 
Control D 0.0181 µg/mL vs. trimodulin 0.0181 µg/mL ns 
Sample Composition
Control A Bacteria, undifferentiated HL-60 cells, hi NHS minus, FB
Control B Bacteria, differentiated HL-60 cells, hi NHS minus, FB
Control C Bacteria, differentiated HL-60 cells, NHS minus, FB
Sample Bacteria, differentiated HL-60 cells, NHS minus, immunoglobulin preparation
0.7% NHS minus 0.8% NHS minus
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Table 28 Statistical analysis of the E. coli OPA by comparing control C (bacteria, differentiated HL-60 cells, NHS minus and FB) 
with the Intratect samples (see Figure 25). Statistical analyses were performed using a Kruskal-Wallis test. 
Comparison  Significance (p-value)  
Control C vs. Intratect 1810 µg/mL ns 
Control C vs. Intratect 181 µg/mL ns 
Control C vs. Intratect 18.1 µg/mL ns 
Control C vs. Intratect 1.81 µg/mL ns 
Control C vs. Intratect 0.181 µg/mL ns 
Control C vs. Intratect 0.0181 µg/mL ns 
 
Table 29 Statistical analysis of the E. coli OPA by comparing control D (bacteria, differentiated HL-60 cells, hi NHS minus and 
different Intratect concentrations) with the Intratect samples (see Figure 25). Statistical analyses were performed using a 
Kruskal-Wallis test. 
Comparison  Significance (p-value)  
Control D 1810 µg/mL vs. Intratect 1810 µg/mL ns 
Control D 181 µg/mL vs. Intratect 181 µg/mL ns 
Control D 18.1 µg/mL vs. Intratect 18.1 µg/mL ns 
Control D 1.81 µg/mL vs. Intratect 1.81 µg/mL ns 
Control D 0.181 µg/mL vs. Intratect 0.181 µg/mL ns 
Control D 0.0181 µg/mL vs. Intratect 0.0181 µg/mL ns 
 
 
7.1.3. S. aureus opsonophagocytosis assay 
 
 
Figure 30 Comparison of 0.6%, 1.2% and 1.5% NHS minus for the use in the S. aureus OPA. Differentiated HL-60 cells, S. aureus 
bioparticles, (a) 0.6% NHS minus or (b) 1.2% NHS minus or (c) 1.5% NHS minus as well as trimodulin (B588039) and the 
appropriate FB were mixed and incubated at 37 °C for 45 min. After that, the cells were quenched with 0.2% trypan blue 
solution and were subsequently analyzed by using a flow cytometer. The phagocytic index was calculated and the data depicted 
in a bar diagram using excel and GraphPad Prism. Control A served as 100% control for the bacteria, control B determined the 
direct phagocytosis of the cells via binding of E. coli to the TLRs and control C was used to examine the activation of complement 
without Ig addition. Different dilutions of trimodulin were used to monitor concentration-dependent effects. Error bars indicate 
the SD. Data represent results from two independent experiments performed in duplicates.  
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Control B Bacteria, differentiated HL-60 cells, hi NHS minus, FB
Control C Bacteria, differentiated HL-60 cells, NHS minus, FB
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Table 30 Comparison of the phagocytic index of Intratect samples without active NHS minus (control D) with Intratect samples 
after the addition of active NHS minus (see Figure 27). Statistical analyses were performed using a one-way ANOVA and a 
Bonferroni test. Significance is shown as p-value: *** p ≤ 0.001 and **** p ≤ 0.0001. 
Intratect 
concentration 
Phagocytic 
index control D 
Phagocytic index 
Intratect samples 
Difference (Intratect 
sample – control D)  
Significance 
(p-value)  
11.2 mg/mL 1.0∙107 1.4∙107 4∙106 *** 
8.4 mg/mL 9.9∙106 1.4∙107 4.1∙106 **** 
5.6 mg/mL 9.9∙106 1. 5∙107 5.1∙106 **** 
2.8 mg/mL 9.2∙106 1.4∙107 4.8∙106 **** 
0.56 mg/mL 1.0∙107 1.6∙107 6∙106 **** 
0.28 mg/mL 1.0∙107 1.9∙107 9∙106 **** 
0.056 mg/mL 1.1∙107 2.3∙107 1.2∙107 **** 
0.028 mg/mL 1.0∙107 2.3∙107 1.3∙107 **** 
0.0056 mg/mL 6.5∙106 1.8∙107 1.15∙107 **** 
 
Table 31 Comparison of the phagocytic index of control C (without Intratect) with the samples after Intratect addition (see 
Figure 27). Statistical analyses were performed using a one-way ANOVA and a Bonferroni test. Significance is shown as p-value: 
*** p ≤ 0.001 and **** p ≤ 0.0001. 
Phagocytic index 
control C 
Intratect 
concentration 
Phagocytic index 
Intratect samples 
Difference (Intratect 
sample – control C)  
Significance 
(p-value)  
1. 5∙107 11.2 mg/mL 1.4∙107 1∙106 ns 
8.4 mg/mL 1.4∙107 1∙106 ns 
5.6 mg/mL 1. 5∙107 no difference ns 
2.8 mg/mL 1.4∙107 1∙106 ns 
0.56 mg/mL 1.6∙107 1∙106 ns 
0.28 mg/mL 1.9∙107 4∙106 **** 
0.056 mg/mL 2.3∙107 8∙106 **** 
0.028 mg/mL 2.3∙107 8∙106 **** 
0.0056 mg/mL 1.8∙107 3∙106 *** 
  
   
References   79 
References 
 
1. Chaplin, D. 1. Overview of the human immune response. Journal of Allergy and Clinical Immunology 
117, 430–435 (2006). 
2. Chaplin, D. Overview of the immune response. Journal of Allergy and Clinical Immunology 125, 3–
23 (2010). 
3. Thompson, A. E. The Immune System. Jama 313, 1686 (2015). 
4. McComb, S., Thiriot, A., Krishnan, L. & Stark, F. Introduction to the Immune System. in 
Immunoproteomics (eds. Fulton, K. M. & Twine, S. M.) vol. 1061 1–20 (Humana Press, 2013). 
5. Simon, A. K., Hollander, G. A. & McMichael, A. Evolution of the immune system in humans from 
infancy to old age. Proc. R. Soc. B. 282, 20143085 (2015). 
6. Sarma, J. V. & Ward, P. A. The complement system. Cell Tissue Res 343, 227–235 (2011). 
7. Walport, M. J. Advances in Immunology: Complement (First of Two Parts). New England Journal 
of Medicine 344, 1058–1066 (2001). 
8. Szebeni, J. The Complement System: Novel Roles in Health and Disease. (Kluwer Academic Publishers, 
2004). 
9. Kirschfink, M. Controlling the complement system in inflammation. Immunopharmacology 38, 51–
62 (1997). 
10. Kirschfink, M. & Mollnes, T. E. Modern Complement Analysis. Clinical and Vaccine Immunology 10, 
982–989 (2003). 
11. Basta, M. Ambivalent effect of immunoglobulins on the complement system: Activation versus 
inhibition. Molecular Immunology 45, 4073–4079 (2008). 
12. Janeway, C. J., Travers, P. & Walport, M. The complement system and innate immunity. in 
Immunobiology: The Immune System in Health and Disease. (ed. Janeway, C. J.) (Garland Science, 
2001). 
13. Dunkelberger, J. R. & Song, W.-C. Complement and its role in innate and adaptive immune 
responses. Cell Res 20, 34–50 (2010). 
14. Mortensen, S. A. et al. Structure and activation of C1, the complex initiating the classical pathway 
of the complement cascade. Proc Natl Acad Sci USA 114, 986–991 (2017). 
15. Ritchie, G. E. et al. Glycosylation and the Complement System. Chem. Rev. 102, 305–320 (2002). 
16. Roos, A. et al. Human IgA Activates the Complement System Via the Mannan-Binding Lectin 
Pathway. J Immunol 167, 2861–2868 (2001). 
17. Basta, M. Activation and Inhibition of Complement by Immunoglobulins. in The Complement System 
(ed. Szebeni, J.) 517–529 (Kluwer Academic Publishers, 2004). 
18. Wallis, R., Mitchell, D. A., Schmid, R., Schwaeble, W. J. & Keeble, A. H. Paths reunited: Initiation 
of the classical and lectin pathways of complement activation. Immunobiology 215, 1–11 (2010). 
19. Thurman, J. M. & Holers, V. M. The Central Role of the Alternative Complement Pathway in Human 
Disease. J Immunol 176, 1305–1310 (2006). 
20. Hiemstra, P. S., Gorter, A., Stuurman, M. E., Van Es, L. A. & Daha, M. R. Activation of the alternative 
pathway of complement by human serum IgA. Eur. J. Immunol. 17, 321–326 (1987). 
21. Trouw, L. A., Pickering, M. C. & Blom, A. M. The complement system as a potential therapeutic 
target in rheumatic disease. Nat Rev Rheumatol 13, 538–547 (2017). 
  
 
 
80 References 
22. Frank, M. M. & Fries, L. F. The role of complement in inflammation and phagocytosis. Immunology 
Today 12, 322–326 (1991). 
23. Merle, N. S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V. & Roumenina, L. T. 
Complement System Part II: Role in Immunity. Front. Immunol. 6, 257 (2015). 
24. Basta, M. et al. F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector 
function of immunoglobulins. Nat Med 9, 431–438 (2003). 
25. Ember, J. A. & Hugli, T. E. Complement factors and their receptors. Immunopharmacology 38, 3–
15 (1997). 
26. Pio, R., Ajona, D. & Lambris, J. D. Complement inhibition in cancer therapy. Seminars in 
Immunology 25, 54–64 (2013). 
27. Markiewski, M. M. & Lambris, J. D. The Role of Complement in Inflammatory Diseases From Behind 
the Scenes into the Spotlight. The American Journal of Pathology 171, 715–727 (2007). 
28. Burg, M. et al. IFN-gamma up-regulates the human C5a receptor (CD88) in myeloblastic U937 cells 
and related cell lines. 155, 4419–4426 (1995). 
29. Ohta, R. et al. Serum concentrations of complement anaphylatoxins and proinflammatory 
mediators in patients with 2009 H1N1 influenza: Anaphylatoxins in the new influenza. 
Microbiology and Immunology 55, 191–198 (2011). 
30. Coulthard, L. G. & Woodruff, T. M. Is the Complement Activation Product C3a a Proinflammatory 
Molecule? Re-evaluating the Evidence and the Myth. J.I. 194, 3542–3548 (2015). 
31. Wu, M. C. L. et al. The receptor for complement component C3a mediates protection from intestinal 
ischemia-reperfusion injuries by inhibiting neutrophil mobilization. Proc Natl Acad Sci USA 110, 
9439–9444 (2013). 
32. Ricklin, D. & Lambris, J. D. Complement in Immune and Inflammatory Disorders: 
Pathophysiological Mechanisms. J.I. 190, 3831–3838 (2013). 
33. Rubio-Perez, J. M. & Morillas-Ruiz, J. M. A Review: Inflammatory Process in Alzheimer’s Disease, 
Role of Cytokines. The Scientific World Journal 2012, 1–15 (2012). 
34. Ballanti, E. et al. Role of the complement system in rheumatoid arthritis and psoriatic arthritis: 
Relationship with anti-TNF inhibitors. Autoimmunity Reviews 10, 617–623 (2011). 
35. Schmidt, C. Q., Lambris, J. D. & Ricklin, D. Protection of host cells by complement regulators. 
Immunol Rev 274, 152–171 (2016). 
36. Noris, M. & Remuzzi, G. Overview of Complement Activation and Regulation. Seminars in 
Nephrology 33, 479–492 (2013). 
37. Chonn, A., Hertig, S. & Frencht, L. E. Clusterin, the Human Apolipoprotein and Complement 
Inhibitor, Binds to Complement C7, CSP, and the b Domain of C9’. 151, 2159–2165 (1993). 
38. Merle, N. S., Church, S. E., Fremeaux-Bacchi, V. & Roumenina, L. T. Complement System Part I - 
Molecular Mechanisms of Activation and Regulation. Front. Immunol. 6, 262 (2015). 
39. Ricklin, D., Reis, E. S. & Lambris, J. D. Complement in disease: a defence system turning offensive. 
Nat Rev Nephrol 12, 383–401 (2016). 
40. Ricklin, D. & Lambris, J. D. Complement-targeted therapeutics. Nat Biotechnol 25, 1265–1275 
(2007). 
41. Schroeder, H. W. & Cavacini, L. Structure and function of immunoglobulins. Journal of Allergy and 
Clinical Immunology 125, 41–52 (2010). 
42. Justiz Vaillant, A. & Ramphul, K. Immunoglobulin. StatPearls Publishing (2020). 
   
References   81 
43. Palma, J., Tokarz-Deptuła, B., Deptuła, J. & Deptuła, W. Natural antibodies – facts known and 
unknown. cejoi 43, 466–475 (2018). 
44. Burton, D. R. Antibody: the flexible adaptor molecule. Elsevier Science Publishers Ltd 2, 64–69 
(1990). 
45. Janeway, C. Immunobiology: The immune system in health and disease. (Garland Publ., 2001). 
46. Vidarsson, G., Dekkers, G. & Rispens, T. IgG Subclasses and Allotypes: From Structure to Effector 
Functions. Front. Immunol. 5, 1–17 (2014). 
47. Kapur, R., Einarsdottir, H. K. & Vidarsson, G. IgG-effector functions: “The Good, The Bad and The 
Ugly”. Immunology Letters 160, 139–144 (2014). 
48. van Erp, E. A., Luytjes, W., Ferwerda, G. & van Kasteren, P. B. Fc-Mediated Antibody Effector 
Functions During Respiratory Syncytial Virus Infection and Disease. Front. Immunol. 10, 548 
(2019). 
49. Ferrante, A., Beard, L. & Feldman, R. IgG subclass distribution of antibodies to bacterial and viral 
antigens. The Pediatric Infectious Disease Journal 9, 516–524 (1990). 
50. van Helden, P. M. W. et al. IgG subclasses of anti-FVIII antibodies during immune tolerance 
induction in patients with hemophilia A: Anti-factor VIII IgG Subclasses During ITI. British Journal 
of Haematology 142, 644–652 (2008). 
51. Woof, J. M. & Kerr, M. A. The function of immunoglobulin A in immunity. J. Pathol. 208, 270–282 
(2006). 
52. Woof, J. M. & Russell, M. W. Structure and function relationships in IgA. Mucosal Immunol 4, 590–
597 (2011). 
53. Snoeck, V., Peters, I. R. & Cox, E. The IgA system: a comparison of structure and function in 
different species. Vet. Res. 37, 455–467 (2006). 
54. Mantis, N. J., Rol, N. & Corthésy, B. Secretory IgA’s complex roles in immunity and mucosal 
homeostasis in the gut. Mucosal Immunol 4, 603–611 (2011). 
55. Hansen, I. S., Baeten, D. L. P. & den Dunnen, J. The inflammatory function of human IgA. Cell. Mol. 
Life Sci. 76, 1041–1055 (2019). 
56. de Sousa-Pereira, P. & Woof, J. M. IgA: Structure, Function, and Developability. Antibodies 8, 57 
(2019). 
57. Lopez, E., Shattock, R. J., Kent, S. J. & Chung, A. W. The Multifaceted Nature of Immunoglobulin 
A and Its Complex Role in HIV. AIDS Research and Human Retroviruses 34, 727–738 (2018). 
58. Russell, M. W., Reinholdt, J. & Kilian, M. Anti-inflammatory activity of human IgA antibodies and 
their Fabα fragments: inhibition of IgG-mediated complement activation. Eur. J. Immunol. 19, 
2243–2249 (1989). 
59. Petrušić, V. et al. Hexameric immunoglobulin M in humans: Desired or unwanted? Medical 
Hypotheses 77, 959–961 (2011). 
60. Racine, R. & Winslow, G. M. IgM in microbial infections: Taken for granted? Immunology Letters 
125, 79–85 (2009). 
61. Boes, M. Role of natural and immune IgM antibodies in immune responses. Molecular Immunology 
37, 1141–1149 (2000). 
62. Kubagawa, H. et al. Identity of the elusive IgM Fc receptor (FcμR) in humans. Journal of 
Experimental Medicine 206, 2779–2793 (2009). 
63. Kubagawa, H. et al. Functional Roles of the IgM Fc Receptor in the Immune System. Front. Immunol. 
10, 945 (2019). 
  
 
 
82 References 
64. Meryk, A. et al. Fcμ receptor as a Costimulatory Molecule for T Cells. Cell Reports 26, 2681–2691 
(2019). 
65. Liu, J. et al. Role of the IgM Fc Receptor in Immunity and Tolerance. Front. Immunol. 10, 529 
(2019). 
66. Brandtzaeg, P. & Prydz, H. Direct evidence for an integrated function of J chain and secretory 
component in epithelial transport of immunoglobulins. Nature 311, 71–73 (1984). 
67. Lu, L. L., Suscovich, T. J., Fortune, S. M. & Alter, G. Beyond binding: antibody effector functions in 
infectious diseases. Nat Rev Immunol 18, 46–61 (2018). 
68. Mayadas, T. N., Cullere, X. & Lowell, C. A. The Multifaceted Functions of Neutrophils. Annu. Rev. 
Pathol. Mech. Dis. 9, 181–218 (2014). 
69. Rosales, C. Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types? Front. 
Physiol. 9, 113 (2018). 
70. Rosales, C. & Uribe-Querol, E. Neutrophil Activation by Antibody Receptors. in Neutrophils (ed. 
Khajah, M.) (IntechOpen, 2019). 
71. Pham, C. T. N. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol 
6, 541–550 (2006). 
72. Fuchs, T. A. et al. Novel cell death program leads to neutrophil extracellular traps. Journal of Cell 
Biology 176, 231–241 (2007). 
73. Tamassia, N. et al. Cytokine production by human neutrophils: Revisiting the “dark side of the 
moon”. Eur J Clin Invest 48, e12952 (2018). 
74. Forthal, D. Functions of Antibodies. Microbiol Spectr. 2, 1–17 (2014). 
75. VanBlargan, L. A., Goo, L. & Pierson, T. C. Deconstructing the Antiviral Neutralizing-Antibody 
Response: Implications for Vaccine Development and Immunity. Microbiol. Mol. Biol. Rev. 80, 989–
1010 (2016). 
76. Khan, M. N. & Pichichero, M. E. Vaccine candidates PhtD and PhtE of Streptococcus pneumoniae 
are adhesins that elicit functional antibodies in humans. Vaccine 30, 2900–2907 (2012). 
77. Cartron, G., Watier, H., Golay, J. & Solal-Celigny, P. From the bench to the bedside: ways to 
improve rituximab efficacy. Blood 104, 2635–2642 (2004). 
78. Zhou, X., Hu, W. & Qin, X. The Role of Complement in the Mechanism of Action of Rituximab for 
B‐Cell Lymphoma: Implications for Therapy. The Oncol 13, 954–966 (2008). 
79. Baig, N. A. et al. Complement dependent cytotoxicity in chronic lymphocytic leukemia: 
ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant 
to activated complement. Leukemia & Lymphoma 53, 2218–2227 (2012). 
80. Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J. D. Complement: a key system for immune 
surveillance and homeostasis. Nat Immunol 11, 785–797 (2010). 
81. Bohanakashtan, O. Cell signals transduced by complement. Molecular Immunology 41, 583–597 
(2004). 
82. Bellosillo, B. et al. Complement-mediated cell death induced by rituximab in B-cell 
lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving 
the generation of reactive oxygen species. Blood 98, 2771–2777 (2001). 
83. Al-Youssef, N. L., Ghobadloo, S. M. & Berezovski, M. V. Inhibition of complement dependent 
cytotoxicity by anti-CD20 aptamers. RSC Adv. 6, 12435–12438 (2016). 
84. Rosales, C. & Uribe-Querol, E. Phagocytosis: A Fundamental Process in Immunity. BioMed Research 
International 2017, 1–18 (2017). 
   
References   83 
85. Stuart, L. M. & Ezekowitz, R. A. B. Phagocytosis. Immunity 22, 539–550 (2005). 
86. Blach-Olszewska, Z. & Leszek, J. Mechanisms of over-activated innate immune system regulation 
in autoimmune and neurodegenerative disorders. Neuropsychiatric Disease and Treatment 3, 365–
372 (2007). 
87. Chen, L. et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 
9, 7204–7218 (2018). 
88. Brady, L. J. Antibody-Mediated Immunomodulation: a Strategy To Improve Host Responses against 
Microbial Antigens. IAI 73, 671–678 (2005). 
89. Bayry, J. et al. Immunomodulation of Autoimmunity by Intravenous Immunoglobulin through 
Interaction with Immune Networks. Vox Sanguinis 83, 49–52 (2002). 
90. Imbach, P. 30 years of immunomodulation by intravenous immunoglobulin. Immunotherapy 4, 
651–654 (2012). 
91. Sewell, W. A. C. & Jolles, S. Immunomodulatory action of intravenous immunoglobulin. 
Immunology 107, 387–393 (2002). 
92. Nimmerjahn, F. & Ravetch, J. V. Anti-Inflammatory Actions of Intravenous Immunoglobulin. Annu. 
Rev. Immunol. 26, 513–533 (2008). 
93. Prins, C., Gelfand, W. & French, L. E. Intravenous Immunoglobulin: Properties, Mode of Action and 
Practical Use in Dermatology. Acta Derm Venereol 87, 206–218 (2007). 
94. Basta, M., Illa, I. & Dalakas, M. C. Increased in vitro uptake of the complement C3b in the serum 
of patients with Guillain–Barr6 syndrome, myasthenia gravis and dermatomyositis. 71, 227–22 
(1996). 
95. Basta, M., Langlois, P., Marques, M., Frank, M. M. & Fries, L. F. High-dose intravenous 
immunoglobulin modifies complement-mediated in vivo clearance. Blood 74, 326–333 (1989). 
96. Basta, M. et al. F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector 
function of immunoglobulins. Nat Med 9, 431–438 (2003). 
97. Roos, A. et al. Specific Inhibition of the Classical Complement Pathway by C1q-Binding Peptides. J 
Immunol 167, 7052–7059 (2001). 
98. Roos, A., Rieben, R., Faber-Krol, M. C. & Daha, M. R. IgM-enriched human intravenous 
immunoglobulin strongly inhibits complement-dependent porcine cell cytotoxicity mediated by 
human xenoreactive antibodies. Xenotransplantation 10, 596–605 (2003). 
99. Rieben, R. et al. Immunoglobulin M–Enriched Human Intravenous Immunoglobulin Prevents 
Complement Activation In Vitro and In Vivo in a Rat Model of Acute Inflammation. Blood 93, 942–
951 (1999). 
100. Spycher, M. et al. In vitro comparison of the complement-scavenging capacity of different 
intravenous immunoglobulin preparations. Vox Sanguinis 97, 348–354 (2009). 
101. Frank, M. M., Basta, M. & Fries, L. F. The effects of intravenous immune globulin on complement-
dependent immune damage of cells and tissues. Clinical Immunology and Immunopathology 62, 82–
86 (1992). 
102. Miletic, V. D., Hester, C. G. & Frank, M. M. Regulation of Complement Activity by Immunoglobulin. 
The Journal of Immunology 156, 749–757 (1996). 
103. Mollnes, T. E. et al. Inhibition of Complement-Mediated Red Cell Lysis by Immunoglobulins is 
Dependent on the IG Isotype and its Cl Binding Properties. Scand J Immunol 41, 449–456 (1995). 
  
 
 
84 References 
104. Arumugam, T. V. et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental 
stroke by preventing complement-mediated neuronal cell death. Proceedings of the National 
Academy of Sciences 104, 14104–14109 (2007). 
105. Esen, F. et al. Neuroprotective effects of intravenous immunoglobulin are mediated through 
inhibition of complement activation and apoptosis in a rat model of sepsis. ICMx 5, 1 (2017). 
106. Troeger, C. et al. Estimates of the global, regional, and national morbidity, mortality, and 
aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global 
Burden of Disease Study 2015. The Lancet Infectious Diseases 17, 1133–1161 (2017). 
107. Lanata, C. & Black, R. Acute Lower Respiratory Infections. in Nutrition and Health in Developing 
Countries (Humana Press, 2008). 
108. Mahashur, A. Management of lower respiratory tract infection in outpatient settings: Focus on 
clarithromycin. Lung India 35, 143–149 (2018). 
109. Mizgerd, J. P. Acute Lower Respiratory Tract Infection. N Engl J Med 358, 716–727 (2008). 
110. Wang, H. et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific 
mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of 
Disease Study 2015. The Lancet 388, 1459–1544 (2016). 
111. Jain, S. et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N 
Engl J Med 373, 415–427 (2015). 
112. Wunderink, R. G. & Waterer, G. Advances in the causes and management of community acquired 
pneumonia in adults. BMJ 358, j2471 (2017). 
113. Morgan, A. & Glossop, A. Severe community-acquired pneumonia. BJA Education 16, 167–172 
(2016). 
114. Morris, A. C. Management of pneumonia in intensive care. J Emerg Crit Care Med 2, 101–101 
(2018). 
115. Steel, H. C., Cockeran, R., Anderson, R. & Feldman, C. Overview of Community-Acquired 
Pneumonia and the Role of Inflammatory Mechanisms in the Immunopathogenesis of Severe 
Pneumococcal Disease. Mediators of Inflammation 2013, 1–18 (2013). 
116. Siljan, W. W. et al. Cytokine responses, microbial aetiology and short-term outcome in community-
acquired pneumonia. Eur J Clin Invest 48, e12865 (2018). 
117. Peiris, J. S. M., Guan, Y. & Yuen, K. Y. Severe acute respiratory syndrome. Nat Med 10, 88–97 
(2004). 
118. Giamarellos-Bourboulis, E. J. et al. Kinetics of circulating immunoglobulin M in sepsis: relationship 
with final outcome. Crit Care 17, R247 (2013). 
119. Pandya, P. H. & Wilkes, D. S. Complement System in Lung Disease. Am J Respir Cell Mol Biol 51, 
467–473 (2014). 
120. Müller-Redetzky, H., Lienau, J., Suttorp, N. & Witzenrath, M. Therapeutic strategies in pneumonia: 
going beyond antibiotics. Eur Respir Rev 24, 516–524 (2015). 
121. Song, Y. et al. XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-
Acquired Pneumonia: A Randomized Controlled Trial. Critical Care Medicine 47, 735–743 (2019). 
122. Ferrer, M. et al. Severe community-acquired pneumonia: Characteristics and prognostic factors in 
ventilated and non-ventilated patients. PLoS ONE 13, e0191721 (2018). 
123. Müller-Redetzky, H. et al. Neutralizing Complement C5a Protects Mice with Pneumococcal 
Pulmonary Sepsis. Anesthesiology 132, 795–807 (2020). 
   
References   85 
124. Kreymann, K. G., de Heer, G., Nierhaus, A. & Kluge, S. Use of polyclonal immunoglobulins as 
adjunctive therapy for sepsis or septic shock*: Critical Care Medicine 35, 2677–2685 (2007). 
125. Harapan, H. et al. Coronavirus disease 2019 (COVID-19): A literature review. Journal of Infection 
and Public Health 13, 667–673 (2020). 
126. Gorbalenya, A. E. et al. Severe acute respiratory syndrome-related coronavirus: The species and its 
viruses – a statement of the Coronavirus Study Group. bioRxiv Published ahead of print, (2020). 
127. Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus outbreak of global health 
concern. The Lancet 395, 470–473 (2020). 
128. Chauhan, S. Comprehensive review of coronavirus disease 2019 (COVID-19). Biomedical Journal 
Published ahead of print, (2020). 
129. Singhal, T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 87, 281–286 
(2020). 
130. Drosten, C. et al. Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory 
Syndrome. N Engl J Med 348, 1967–1976 (2003). 
131. Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E. & Fouchier, R. A. M. 
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. N Engl J Med 367, 
1814–1820 (2012). 
132. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. 
The Lancet 395, 497–506 (2020). 
133. Salje, H. et al. Estimating the burden of SARS-CoV-2 in France. Science 369, 208–211 (2020). 
134. Dhama, K. et al. Coronavirus Disease 2019–COVID-19. Clinical Microbiology Reviews 33, e00028-
20 (2020). 
135. Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 
395, 1033–1034 (2020). 
136. Matricardi, P. M., Dal Negro, R. W. & Nisini, R. The first, holistic immunological model of COVID‐
19: Implications for prevention, diagnosis, and public health measures. Pediatr Allergy Immunol 31, 
454–470 (2020). 
137. Song, P., Li, W., Xie, J., Hou, Y. & You, C. Cytokine storm induced by SARS-CoV-2. Clinica Chimica 
Acta 509, 280–287 (2020). 
138. Gralinski, L. E. et al. Complement Activation Contributes to Severe Acute Respiratory Syndrome 
Coronavirus Pathogenesis. mBio 9, e01753-18 (2018). 
139. Gao, T. et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated 
complement over-activation. medRxiv Published ahead of print, (2020). 
140. Cugno, M. et al. Complement activation in patients with COVID-19: A novel therapeutic target. 
Journal of Allergy and Clinical Immunology 146, 215–217 (2020). 
141. Magro, C. et al. Complement associated microvascular injury and thrombosis in the pathogenesis 
of severe COVID-19 infection: A report of five cases. Translational Research 220, 1–13 (2020). 
142. Ritis, K. et al. A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity 
to Coagulation Pathways. J Immunol 177, 4794–4802 (2006). 
143. Øvstebø, R. et al. Microparticle-associated tissue factor activity is reduced by inhibition of the 
complement protein 5 in Neisseria meningitidis -exposed whole blood. Innate Immun 20, 552–560 
(2014). 
  
 
 
86 References 
144. Tang, N., Li, D., Wang, X. & Sun, Z. Abnormal coagulation parameters are associated with poor 
prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18, 844–847 (2020). 
145. Cao, W. et al. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating 
Patients With Coronavirus Disease 2019. Open Forum Infectious Diseases 7, ofaa102 (2020). 
146. Lanza, M. et al. Successful intravenous immunoglobulin treatment in severe COVID-19 pneumonia. 
IDCases 21, e00794 (2020). 
147. Mastaglio, S. et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. 
Clinical Immunology 215, 108450 (2020). 
148. Sakoulas, G. et al. Intravenous Immunoglobulin (IVIG) Significantly Reduces Respiratory Morbidity 
in COVID-19 Pneumonia: A Prospective Randomized Trial. medRxiv Published ahead of print, 
(2020). 
149. Laursen, I. A. et al. Development, Manufacturing and Characterization of a Highly Purified, Liquid 
Immunoglobulin G Preparation from Human Plasma. Transfus Med Hemother 41, 205–212 (2014). 
150. Späth, P. J., Schneider, C. & von Gunten, S. Clinical Use and Therapeutic Potential of IVIG/SCIG, 
Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations. Arch. Immunol. 
Ther. Exp. 65, 215–231 (2017). 
151. Shah, S. Pharmacy considerations for the use of IGIV therapy. American Journal of Health-System 
Pharmacy 62, 5–11 (2005). 
152. Gelfand, E. W. Differences between IGIV products: Impact on clinical outcome. International 
Immunopharmacology 6, 592–599 (2006). 
153. Siegel, J. Safety considerations in IGIV utilization. International Immunopharmacology 6, 523–527 
(2006). 
154. Kempf, C., Stucki, M. & Boschetti, N. Pathogen inactivation and removal procedures used in the 
production of intravenous immunoglobulins. Biologicals 35, 35–42 (2007). 
155. Ballow, M. The IgG molecule as a biological immune response modifier: Mechanisms of action of 
intravenous immune serum globulin in autoimmune and inflammatory disorders. Journal of Allergy 
and Clinical Immunology 127, 315–323 (2011). 
156. Dwyer, J. Manipulating the immune system with immune globulin. New England Journal of Medicine 
326, 107–114 (1992). 
157. Debre, M., Bonnet, M., Fridman, W. & Carosella, E. Infusion of Fc-gamma fragments for treatment 
of children with acute immune thrombocytopenic purpura. The Lancet 342, 945–949 (1993). 
158. Kreuz, W. et al. A multi-centre study of efficacy and safety of Intratect®, a novel intravenous 
immunoglobulin preparation: A multi-centre study on Intratect. Clinical & Experimental 
Immunology 161, 512–517 (2010). 
159. Colovic, M., Dimitrijevic, M., Sonnenburg, C. & Suvajdzic, N. Clinical efficacy and safety of a novel 
intravenous immunoglobulin preparation in adult chronic ITP. Hematol J. 4, 358–362 (2003). 
160. Bauhofer, A., Dietrich, R. L. J. & Schmeidl, R. Safety monitoring of the intravenous immunoglobulin 
preparation Intratect® in primary and secondary immunodeficiencies: a prospective non-
interventional study. CP 53, 21–30 (2015). 
161. Ehrenstein, M. R. & Notley, C. A. The importance of natural IgM: scavenger, protector and 
regulator. Nat Rev Immunol 10, 778–786 (2010). 
162. Schwab, I. & Nimmerjahn, F. Intravenous immunoglobulin therapy: how does IgG modulate the 
immune system? Nat Rev Immunol 13, 176–189 (2013). 
   
References   87 
163. Welte, T. et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in 
patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-
blind, multicenter, phase II trial (CIGMA study). Intensive Care Med 44, 438–448 (2018). 
164. Sproston, N. R. & Ashworth, J. J. Role of C-Reactive Protein at Sites of Inflammation and Infection. 
Front. Immunol. 9, 754 (2018). 
165. Duerr, C. et al. The novel polyclonal Ab preparation trimodulin attenuates ex vivo endotoxin-
induced immune reactions in early hyperinflammation. Innate Immun 25, 374–388 (2019). 
166. Rieben, R. Preclinical study with Prof. Rieben. Data not published. (2008). 
167. Nolte, M. T., Pirofsky, B. & Gerritz, G. A. Intravenous immunoglobulin therapy for antibody 
deficiency. 36, 237–243 (1979). 
168. Soderstrom, T., Soderstrom, R. & Enskog, A. Immunoglobulin subclasses and prophylactic use of 
immunoglobulin in immunoglobulin g subclass deficiency. 68, 1426–1429 (1991). 
169. Tuomanen, E. I., Austrian, R. & Masure, H. R. Pathogenesis of Pneumococcal Infection. The New 
England Journal Of Medicine 332, 1280–1284 (1995). 
170. Klein, G., Giovanella, B., Westman, A., Stehlin, J. & Mumford, D. An EBV-genome-negative cell line 
established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and 
permanent conversion into EBV-positive sublines by in vitro infection. Intervirology 5, 319–34 
(1975). 
171. Benjamin, D. et al. Immunoglobulin secretion by cell lines derived from African and American 
undifferentiated lymphomas of Burkitt’s and non-Burkitt’s type. J Immunol 129, 1336–1342 (1982). 
172. Dorvignit, D. et al. Expression and biological characterization of an anti-CD20 biosimilar candidate 
antibody: A case study. mAbs 4, 488–496 (2012). 
173. Gillissen, M. A. et al. The modified FACS calcein AM retention assay: A high throughput flow 
cytometer based method to measure cytotoxicity. Journal of Immunological Methods 434, 16–23 
(2016). 
174. Flavell, D. J. et al. The anti-CD20 antibody rituximab augments the immunospecific therapeutic 
effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma. Br J 
Haematol 134, 157–170 (2006). 
175. Collins, S. J., Gallo, R. C. & Gallagher, R. E. Continuous growth and differentiation of human 
myeloid leukaemic cells in suspension culture. Nature 270, 347–349 (1977). 
176. Breitman, T. R., Selonick, S. E. & Collins, S. J. Induction of differentiation of the human 
promyelocytic leukemia cell line (HL-60) by retinoic acid. Proceedings of the National Academy of 
Sciences 77, 2936–2940 (1980). 
177. Collins, S. J., Ruscetti, F. W., Gallagher, R. E. & Gallo, R. C. Terminal differentiation of human 
promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. 
Proceedings of the National Academy of Sciences 75, 2458–2462 (1978). 
178. Nakayasu, M., Hecker, E. & Sugimura, T. Induction of differentiation in human promyelocytic 
leukemia cells by tumor promoters. J Cancer Res Clin Oncol 103, 17–29 (1982). 
179. Birnie, G. D. The HL60 cell line: A model system for studying human myeloid cell differentiation. 
Br. J. Cancer 58, 41–45 (1988). 
180. Berg, R. The indigenous gastrointestinal microflora. Trends in Microbiology 4, 430–435 (1996). 
181. Bentley, R. & Meganathan, R. Biosynthesis of vitamin K (menaquinone) in bacteria. Microbiological 
Reviews 46, 241–280 (1982). 
  
 
 
88 References 
182. Sears, H. J., Brownlee, I. & Uchiyama, J. K. Persistence Of Individual Strains Of Escherichia Coli In 
The Intestinal Tract Of Man. Journal of Bacteriology 59, 293–301 (1950). 
183. Kaper, J. B., Nataro, J. P. & Mobley, H. L. T. Pathogenic Escherichia coli. Nat Rev Microbiol 2, 123–
140 (2004). 
184. Tenaillon, O., Skurnik, D., Picard, B. & Denamur, E. The population genetics of commensal 
Escherichia coli. Nat Rev Microbiol 8, 207–217 (2010). 
185. Hardwick, J. Blood processing. ISBT Science Series 3, 148–176 (2008). 
186. Leeman, M., Choi, J., Hansson, S., Storm, M. U. & Nilsson, L. Proteins and antibodies in serum, 
plasma, and whole blood—size characterization using asymmetrical flow field-flow fractionation 
(AF4). Anal Bioanal Chem 410, 4867–4873 (2018). 
187. Sadagopan, N. P. et al. Investigation of EDTA anticoagulant in plasma to improve the throughput 
of liquid chromatography/tandem mass spectrometric assays. Rapid Commun. Mass Spectrom. 17, 
1065–1070 (2003). 
188. Vercauteren, K. O. A., Lambrecht, S. & Delanghe, J. Preanalytical classical and alternative 
complement pathway activity loss. Biochem. med. (Online) 29, 498–505 (2019). 
189. Fearon, D. T. & Austen, K. F. Activation of the alternative complement pathway due to resistance 
of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc. Natl. 
Acad. Sci. USA 74, 1683–1687 (1977). 
190. Di Carlo, F. J. & Fiore, J. V. On the Composition of Zymosan. Science 127, 756–757 (1958). 
191. Bornstein, G. G. et al. Development of a new fully human anti-CD20 monoclonal antibody for the 
treatment of B-cell malignancies. Invest New Drugs 28, 561–574 (2010). 
192. Carner, K. et al. Depletion of B Cells In Vivo by a Chimeric MouseHuman Monoclonal Antibody 
toCD20. Blood 83, 435–445 (1994). 
193. Nahm, M. H. & Burton, R. L. Protocol for opsonophagocytic killing assay for antibodies against 
Group B Streptococcus (UAB GBS OPA). (2016). 
194. von Behring & Kitasato. Ueber das Zustandekommen der Diphtherie-immunität und der Tetanus-
immunität bei Thieren. Deutsche Medicinische Wochenschrift 16, 1113–1114 (1890). 
195. Hooper, J. A. The history and evolution of immunoglobulin products and their clinical indications. 
LymphoSign Journal 2, 181–194 (2015). 
196. Kaveri, S. V. et al. Intravenous immunoglobulin and immune response: IVIg and immune response. 
Clin Exp Immunol 178, 94–96 (2014). 
197. Cedzyński, M., Thielens, N. M., Mollnes, T. E. & Vorup-Jensen, T. Editorial: The Role of 
Complement in Health and Disease. Front. Immunol. 10, 1869 (2019). 
198. Basta, M., Fries, L. F. & Frank, M. M. High Doses of Intravenous Ig Inhibit In Vitro Uptake of C4 
Fragments Onto Sensitized Erythrocytes. Blood 77, 376–380 (1991). 
199. Kasperska-Zajac, A. et al. Increased serum complement C3 and C4 concentrations and their relation 
to severity of chronic spontaneous urticaria and CRP concentration. J Inflamm 10, 22 (2013). 
200. Sharp, T. H. et al. Insights into IgM-mediated complement activation based on in situ structures of 
IgM-C1-C4b. Proc Natl Acad Sci USA 116, 11900–11905 (2019). 
201. Frank, M. & Fries, L. F. Complement. in Fundamental Immunology 686–687 (Raven Press, 1989). 
202. Frank, M. M., Miletic, V. D. & Jiang, H. Immunoglobulin in the Control of Complement Action. IR 
22, 137–146 (2000). 
   
References   89 
203. Güven, E. et al. Non-specific binding in solid phase immunoassays for autoantibodies correlates 
with inflammation markers. Journal of Immunological Methods 403, 26–36 (2014). 
204. Näreoja, T., Määttänen, A., Peltonen, J., Hänninen, P. E. & Härmä, H. Impact of surface defects and 
denaturation of capture surface proteins on nonspecific binding in immunoassays using antibody-
coated polystyrene nanoparticle labels. Journal of Immunological Methods 347, 24–30 (2009). 
205. Péterfi, Z. & Kocsis, B. Comparison of Blocking Agents for an Elisa for Lps. Journal of Immunoassay 
21, 341–354 (2000). 
206. Xiao, Y. & Isaacs, S. N. Enzyme-linked immunosorbent assay (ELISA) and blocking with bovine 
serum albumin (BSA)—not all BSAs are alike. Journal of Immunological Methods 384, 148–151 
(2012). 
207. Klos, A. et al. The role of the anaphylatoxins in health and disease. Molecular Immunology 46, 2753–
2766 (2009). 
208. Tate, J. & Ward, G. Interferences in Immunoassay. Clin Biochem Rev 25, 105–120 (2004). 
209. Nezlin, R., Freywald, A. & Oppermann, M. Proteins separated from human IgG molecules. Molecular 
Immunology 30, 935–940 (1993). 
210. Wang, B. et al. Regulation of antibody-mediated complement-dependent cytotoxicity by 
modulating the intrinsic affinity and binding valency of IgG for target antigen. mAbs 12, e1690959 
(2020). 
211. Rogers, L. M., Veeramani, S. & Weiner, G. J. Complement in monoclonal antibody therapy of 
cancer. Immunol Res 59, 203–210 (2014). 
212. Jilani, I. et al. Transient down-modulation of CD20 by rituximab in patients with chronic 
lymphocytic leukemia. Blood 102, 3514–3520 (2003). 
213. Hiraga, J. et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with 
rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 
113, 4885–4893 (2009). 
214. D’Auria, F. et al. Modulation of CD20 antigen expression after rituximab treatment: A retrospective 
study in patients with chronic lymphocytic leukemia. Clinical Therapeutics 32, 1911–1916 (2010). 
215. Pickartz, T. Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-
CD20 monoclonal antibody rituximab. Experimental Hematology 29, 1410–1416 (2001). 
216. Klein, C. et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship 
to functional properties. mAbs 5, 22–33 (2013). 
217. Peschke, B., Keller, C. W., Weber, P., Quast, I. & Lünemann, J. D. Fc-Galactosylation of Human 
Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent 
Cytotoxicity. Front. Immunol. 8, 646 (2017). 
218. Strasser, J. et al. Unraveling the Macromolecular Pathways of IgG Oligomerization and 
Complement Activation on Antigenic Surfaces. Nano Lett. 19, 4787–4796 (2019). 
219. Sledgei, C. R. & Bing, H. Binding Properties of the Human Complement Protein Clq. The Journal Of 
Biological Chemistry 248, 2818–2823 (1973). 
220. Scitiess, J. T. T. & Engel, J. Antigen-independent activation of the first component of complement 
C1 by chemically crosslinkend rabbit IgG-oligomers. FEBS Letters 112, 152–154 (1980). 
221. Diebolder, C. A. et al. Complement Is Activated by IgG Hexamers Assembled at the Cell Surface. 
Science 343, 1260–1263 (2014). 
222. Newman, S. & Mikus, L. Deposition Of C3b And iC3b Onto Particulate Activators Of The Human 
Complement System. J. ExP. MED 161, 1414–1431 (1985). 
  
 
 
90 References 
223. Rieben, R. et al. Immunoglobulin M–Enriched Human Intravenous Immunoglobulin Prevents 
Complement Activation In Vitro and In Vivo in a Rat Model of Acute Inflammation. Blood 93, 942–
951 (1999). 
224. Schroff, R. W., Foon, K. A., Beatty, S. M., Oldham, R. K. & Morgan, A. C. Human Anti-Murine 
Immunoglobulin Responses in Patients Receiving Monoclonal Antibody Therapy. Cancer Research 
45, 879–885 (1985). 
225. Hosono, M. et al. Human/mouse chimeric antibodies show low reactivity with human anti-murine 
antibodies (HAMA). Br J Cancer 65, 197–200 (1992). 
226. Hwang, W. Y. K. & Foote, J. Immunogenicity of engineered antibodies. Methods 36, 3–10 (2005). 
227. Andersson, J., Ekdahl, K. N., Larsson, R., Nilsson, U. R. & Nilsson, B. C3 Adsorbed to a Polymer 
Surface Can Form an Initiating Alternative Pathway Convertase. J Immunol 168, 5786–5791 
(2002). 
228. Hed, J., Johansson, M. & Lindroth, M. Complement activation according to the alternate pathway 
by glass and plastic surfaces and its role in neutrophil adhesion. Immunology Letters 8, 295–299 
(1984). 
229. Müller-Redetzky, H., Lienau, J., Suttorp, N. & Witzenrath, M. Therapeutic strategies in pneumonia: 
going beyond antibiotics. Eur Respir Rev 24, 516–524 (2015). 
230. Calbo, E., Alsina, M., Rodriguez-Carballeira, M., Lite, J. & Garau, J. The impact of time on the 
systemic inflammatory response in pneumococcal pneumonia. European Respiratory Journal 35, 
614–618 (2010). 
231. Tian, W. et al. Predictors of mortality in hospitalized COVID‐19 patients: A systematic review and 
meta‐analysis. J Med Virol 92, 1875–1883 (2020). 
232. Centurión, O. A., Scavenius, K. E., García, L. B., Torales, J. M. & Miño, L. M. Potential mechanisms 
of cardiac injury and common pathways of inflammation in patients with COVID-19. Crit Pathw 
Cardiol. Published ahead of print, (2020). 
233. Jose, R. J. & Manuel, A. COVID-19 cytokine storm: the interplay between inflammation and 
coagulation. The Lancet Respiratory Medicine 8, 46–47 (2020). 
234. Giudice, V. et al. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-
2-Related Acute Respiratory Distress Syndrome: A Controlled Study. Front. Pharmacol. 11, 857 
(2020). 
235. Lam, L. M. et al. Erythrocytes Reveal Complement Activation in Patients with COVID-19. medRxiv 
Published ahead of print, (2020). 
236. Diurno, F. et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life 
ASL Napoli 2 Nord experience. European Review for Medical and Pharmacological Sciences 24, 4040–
4047 (2020). 
237. Lee, J. W. et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to 
complement inhibitors: the 301 study. Blood 133, 530–539 (2019). 
238. CHINA National Health Commission. Diagnosis and Treatment of Pneumonia Infected by Novel 
Coronavirus (Trial Version 7). Chinese Medical Journal 133, 1087–1095 (2020). 
239. Li, T. Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 
(SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital 
(V2.0): Working Group of 2019 Novel Coronavirus, Peking Union Medical College Hospital. 
Emerging Microbes & Infections 9, 582–585 (2020). 
240. Worley, M. J. et al. Neutrophils mediate HIV-specific antibody-dependent phagocytosis and ADCC. 
Journal of Immunological Methods 457, 41–52 (2018). 
   
References   91 
241. Trayner, I. D. et al. Changes in antigen expression on differentiating HL60 cells treated with 
dimethylsulphoxide, all-trans retinoic acid, h1,25-dihydroxyvitamin D3 or 12-O-tetradecanoyl 
phorbol-13-acetate. Leukemia Research 22, 537–547 (1998). 
242. Verbrugge, A. Differential expression of leukocyte-associated Ig-like receptor-1 during neutrophil 
differentiation and activation. Journal of Leukocyte Biology 79, 828–836 (2006). 
243. Fleck, R. A., Romero-Steiner, S. & Nahm, M. H. Use of HL-60 Cell Line To Measure Opsonic Capacity 
of Pneumococcal Antibodies. CVI 12, 19–27 (2005). 
244. Fabbrini, M. et al. A new flow-cytometry-based opsonophagocytosis assay for the rapid 
measurement of functional antibody levels against Group B Streptococcus. Journal of 
Immunological Methods 378, 11–19 (2012). 
245. Romero-Steiner, S. et al. Standardization of an opsonophagocytic assay for the measurement of 
functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. 
Clinical and diagnostic laboratory immunology 4, 415–422 (1997). 
246. Chang, H., Oh, P., Ingber, D. & Huang, S. Multistable and multistep dynamics in neutrophil 
differentiation. BMC Cell Biol 7, 11 (2006). 
247. Golay, J. et al. Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN 
activation. Blood 133, 1395–1405 (2019). 
248. Nuutila, J. et al. Quantitative analysis of complement receptors, CR1 (CD35) and CR3 (CD11b), on 
neutrophils improves distinction between bacterial and viral infections in febrile patients: 
Comparison with standard clinical laboratory data. Journal of Immunological Methods 315, 191–
201 (2006). 
249. Boonlayangoor, P., Telischi, M., Boonlayangoor, S. & Sinclair, T. Cryopreservation of human 
granulocytes: study ofgranulocyte function and ultrastructure. Blood 56, 237–245 (1980). 
250. Yaseen, R. et al. Antimicrobial activity of HL-60 cells compared to primary blood-derived 
neutrophils against Staphylococcus aureus. J Negat Results BioMed 16, 2 (2017). 
251. Burton, R. L. & Nahm, M. H. Development and Validation of a Fourfold Multiplexed Opsonization 
Assay (MOPA4) for Pneumococcal Antibodies. CVI 13, 1004–1009 (2006). 
252. Abbanat, D. et al. Development and Qualification of an Opsonophagocytic Killing Assay To Assess 
Immunogenicity of a Bioconjugated Escherichia coli Vaccine. Clin. Vaccine Immunol. 24, e00123-
17 (2017). 
253. Burton, R. L. & Nahm, M. H. Development of a Fourfold Multiplexed Opsonophagocytosis Assay 
for Pneumococcal Antibodies against Additional Serotypes and Discovery of Serological Subtypes 
in Streptococcus pneumoniae Serotype 20. Clin. Vaccine Immunol. 19, 835–841 (2012). 
254. Okamoto, M. et al. Toll-like Receptors (TLRs) are expressed by myeloid leukaemia cell lines, but 
fail to trigger differentiation in response to the respective TLR ligands. British Journal of 
Haematology 147, 585–587 (2009). 
255. Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nat 
Immunol 5, 987–995 (2004). 
256. Hayashi, F., Means, T. K. & Luster, A. D. Toll-like receptors stimulate human neutrophil function. 
Blood 102, 2660–2669 (2003). 
257. Sabroe, I., Dower, S. K. & Whyte, M. K. B. The Role of Toll-Like Receptors in the Regulation of 
Neutrophil Migration, Activation, and Apoptosis. Clinical Infectious Diseases 41, 421–426 (2005). 
258. Beutler, B. Tlr4: central component of the sole mammalian LPS sensor. Current Opinion in 
Immunology 12, 20–26 (2000). 
  
 
 
92 References 
259. Chow, J. C., Young, D. W., Golenbock, D. T., Christ, W. J. & Gusovsky, F. Toll-like Receptor-4 
Mediates Lipopolysaccharide-induced Signal Transduction. J. Biol. Chem. 274, 10689–10692 
(1999). 
260. Brouwer, N. et al. Mannose-Binding Lectin (MBL) Facilitates Opsonophagocytosis of Yeasts but Not 
of Bacteria despite MBL Binding. J Immunol 180, 4124–4132 (2008). 
261. Perobelli, S. M. et al. Plasticity of neutrophils reveals modulatory capacity. Braz J Med Biol Res 48, 
665–675 (2015). 
262. Mladenov, R. et al. The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid 
leukemia: Targeting and Elimination of Malignant Myeloid Cells. Int. J. Cancer 137, 2729–2738 
(2015). 
263. Aleyd, E. et al. IgA Enhances NETosis and Release of Neutrophil Extracellular Traps by 
Polymorphonuclear Cells via Fcα Receptor I. J.I. 192, 2374–2383 (2014). 
264. Lutz, H., Stammler, P., Jelezarova, E., Nater, M. & Spath, P. High doses of immunoglobulin G 
attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage 
of C3b in C3bn- IgG complexes. Blood 88, 184–193 (1996). 
265. Durandy, A. et al. Intravenous immunoglobulins - understanding properties and mechanisms. 
Clinical & Experimental Immunology 158, 2–13 (2009). 
266. Molecular Probes. BioParticles Fluorescent Particles and Opsonizing Reagents (product 
information). (2001). 
267. Leemans, J. C., Heikens, M., van Kessel, K. P. M., Florquin, S. & van der Poll, T. Lipoteichoic Acid 
and Peptidoglycan from Staphylococcus aureus Synergistically Induce Neutrophil Influx into the 
Lungs of Mice. CVI 10, 950–953 (2003). 
268. Wang, J. E. et al. Peptidoglycan and Lipoteichoic Acid from Staphylococcus aureus Induce Tumor 
Necrosis Factor Alpha, Interleukin 6 (IL-6), and IL-10 Production in Both T Cells and Monocytes in 
a Human Whole Blood Model. Infect. Immun. 68, 3965–3970 (2000). 
269. Fournier, B. The function of TLR2 during staphylococcal diseases. Front. Cell. Inf. Microbio. 2, 167 
(2013). 
270. Gelfand, E. W. Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases. N Engl J 
Med 367, 2015–2025 (2012). 
271. Galeotti, C., Kaveri, S. V. & Bayry, J. IVIG-mediated effector functions in autoimmune and 
inflammatory diseases. International Immunology 29, 491–498 (2017). 
272. Shock, A., Humphreys, D. & Nimmerjahn, F. Dissecting the mechanism of action of intravenous 
immunoglobulin in human autoimmune disease: lessons from therapeutic modalities targeting Fcγ 
receptors. Journal of Allergy and Clinical Immunology 146, 492–500 (2020). 
273. Nagelkerke, S. Q. et al. Inhibition of FcgR-mediated phagocytosis by IVIg is independent of IgG-Fc 
sialylation and FcgRIIb in human macrophages. Blood 124, 3709–3718 (2014). 
274. Nagelkerke, S. Q. & Kuijpers, T. W. Immunomodulation by IVIg and the Role of Fc-Gamma 
Receptors: Classic Mechanisms of Action after all? Front. Immunol. 5, 674 (2015). 
275. Walpen, A. J., Laumonier, T., Aebi, C., Mohacsi, P. J. & Rieben, R. Immunoglobulin M-enriched 
intravenous immunoglobulin inhibits classical pathway complement activation, but not bactericidal 
activity of human serum. Xenotransplantation 11, 141–148 (2004). 
276. Wagner, E., Platt, J. L. & Frank, M. M. High Dose Intravenous Immunoglobulin Does Not Affect 
Complement-Bacteria Interactions. The Journal of Immunology 160, 1936–1943 (1998). 
   
References   93 
277. Gilbert, I. Dissociation in an Encapsulated Staphylococcus. Journal of Bacteriology 21, 157–160 
(1931). 
278. O’Riordan, K. & Lee, J. C. Staphylococcus aureus Capsular Polysaccharides. CMR 17, 218–234 
(2004). 
279. Hageman, J. C. et al. Severe Community-acquired Pneumonia Due to Staphylococcus aureus , 2003–
04 Influenza Season. Emerg. Infect. Dis. 12, 894–899 (2006). 
280. Self, W. H. et al. Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical 
Characteristics, and Outcomes. Clin Infect Dis. 63, 300–309 (2016). 
281. de la Torre, M. C. et al. Serum levels of immunoglobulins and severity of community-acquired 
pneumonia. BMJ Open Resp Res 3, e000152 (2016). 
282. Bermejo-Martín, J. F. et al. Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing 
survival in sepsis. J Intern Med 276, 404–412 (2014). 
283. Rice, T. W. et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in 
the United States*: Critical Care Medicine 40, 1487–1498 (2012). 
284. Zahariadis, G. et al. Risk of Ruling out Severe Acute Respiratory Syndrome by Ruling in another 
Diagnosis: Variable Incidence of Atypical Bacteria Coinfection Based on Diagnostic Assays. 
Canadian Respiratory Journal 13, 17–22 (2006). 
285. Arabi, Y. M. et al. Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter 
Retrospective Cohort Study. Critical Care Medicine 45, 1683–1695 (2017). 
286. Lansbury, L., Lim, B., Baskaran, V. & Lim, W. S. Co-infections in people with COVID-19: a systematic 
review and meta-analysis. Journal of Infection 81, 266–275 (2020). 
287. Crotty, M. P. et al. Investigation of subsequent and co-infections associated with SARS-CoV-2 
(COVID-19) in hospitalized patients. medRxiv Published ahead of print, (2020). 
288. Chen, X. et al. Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in 
areas adjacent to Hubei, China: a double-center observational study. medRxiv Published ahead of 
print, (2020). 
289. Xing, Q., Li, G., Xing, Y. & Chen, T. Precautions are Needed for COVID-19 Patients with Coinfection 
of Common Respiratory Pathogens. medRxiv Online ahead of print, 24 (2020). 
290. Chen, J., Wu, H., Yu, Y. & Tang, N. Pulmonary alveolar regeneration in adult COVID-19 patients. 
Cell Res 30, 708–710 (2020). 
291. Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in 
Wuhan, China: a retrospective cohort study. The Lancet 395, 1054–1062 (2020). 
292. Shao, W. et al. Epithelial cells are a source of natural IgM that contribute to innate immune 
responses. The International Journal of Biochemistry & Cell Biology 73, 19–29 (2016). 
 
   
List of abbreviations   95 
List of abbreviations 
 
ADCC Antibody-dependent cell-mediated cytotoxicity 
ADCP Antibody-dependent cellular phagocytosis 
ANOVA Analysis of variance 
APC Allophycocyanin 
ARDS Acute respiratory distress syndrome  
ATCC American Type Culture Collection 
BCR B-cell receptor 
C1INH C1 inhibitor 
CAP Community-acquired pneumonia 
CDC Complement-dependent cytotoxicity 
CFH Complement factor H 
CFI Complement factor I 
CFU Colony-forming units  
CH Constant domain heavy chain 
CIDP Chronic inflammatory demyelinating polyneuropathy 
CL Constant domain light chain 
COVID-19 Coronavirus disease 2019 
CR1 Complement receptor 1 
CR3 Complement receptor 3 
CRP C-reactive protein 
DMF Dimethylformamide  
DMSO Dimethyl sulfoxide  
D-PBS Dulbecco’s PBS 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
e.g. Exempli gratia 
FACS Fluorescence-activated cell sorter 
FB Formulation buffer 
FBS Fetal bovine serum 
FcµR Fcµ receptor  
FcαRI Fcα receptor I 
FcƴR Fcƴ receptor 
FcƴRIIB Fcƴ receptor II B 
FITC Fluorescein isothiocyanate 
FSC Forward scatter 
  
 
 
96 List of abbreviations 
GVB++ Gelatin Veronal Buffer with Mg2+ and Ca2+ 
h Hour 
HACA Human anti-chimeric antibodies 
HAMA Human anti-murine antibodies 
HBSS Hanks’ Balanced Salt Solution 
hi Heat-inactivated 
HRP Horseradish peroxidase 
ICU Intensive care unit 
Ig Immunoglobulin 
IgA Immunoglobulin A 
IgG Immunoglobulin G 
IgM Immunoglobulin M 
IL-1β Interleukin-1β 
IL-6 Interleukin-6 
IV Intravenous 
IVIg Intravenous immunoglobulin  
kDa Kilo Dalton 
LB Lysogeny broth 
LPS Lipopolysaccharide  
LRI Lower respiratory tract infections 
LTA Lipoteichoic acid 
MAC Membrane attack complex 
MASP MBL-associated serine proteases 
MBL Mannose-binding lectin 
MERS Middle East respiratory syndrome 
min Minute 
MMN Multifocal motor neuropathy 
MoA Mode of Action 
MW Marker Molecular weight marker 
N Nucleocapsid  
NADPH Nicotinamide adenine dinucleotide phosphate 
NET Neutrophil extracellular traps  
NHS Normal human serum 
NHS minus Normal human serum depleted of IgG and IgM 
NK cell Natural killer cell 
OB Opsonization buffer  
   
List of abbreviations   97 
OD Optical density 
OPA Opsonophagocytosis assay 
PAMP Pathogen-associated molecular patterns 
PBS Phosphate-buffered saline  
PE Phycoerythrin 
PI Propidiumiodid  
PID Primary immunodeficiency 
pIgR Polymeric Ig receptor  
PMN Polymorphonuclear  
PMT Photomultiplier tube  
RBC Red blood cell 
ROS Reactive oxygen species 
RT Room temperature 
S. aureus Staphylococcus aureus 
SARS Severe acute respiratory syndrome  
SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 
sCAP Severe community-acquired pneumonia  
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM Standard error of the mean 
SID Secondary immunodeficiency 
sIgA Secretory IgA 
SSC Sideward scatter 
TBS-T Tris-buffered saline with tween 20 
TLR Toll-like receptor  
TMB Tetramethylbenzidine substrate 
TNF Tumor necrosis factor 
TPA 12-O-tetradecanoylphorbol-13-acetate 
U Round bottom  
VH Variable domain heavy chain 
VL Variable domain light chain 
w/o Without  
 
 
   
List of figures   99 
List of figures 
 
Figure 1 Overview of the complement cascade. The complement system can be activated via the classical, 
lectin and alternative pathway. The binding of C1q to its ligands, such as immune complexes, 
triggers classical pathway activation. The lectin pathway is activated by the binding of MBL ficolins 
or collectins to a pathogen. Activation of the alternative pathway occurs spontaneously and is 
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activation that is cleaved into the opsin C3b and the anaphylatoxin C3a. C5 convertases lead to the 
formation of C5a as well as C5b. The latter generates together with C6-9 the MAC, which in turn 
forms pores into the membrane and lyses the target cells21. CR = complement-receptor; FI = factor 
I; MAC = membrane attack complex; MASP = MBL-associated serine proteases; MBL = mannose-
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binding occurs and carboxyl terminal constant regions, where effector functions are triggered (Fc-
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heavy chain is composited of one variable region (VH) and three constant regions (CH1-3). The Fab 
and the Fc domain are linked by a flexible hinge-region with disulfide bonds. Light and heavy chains 
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Figure 3 Antibody mediated functions to destroy pathogens. Antibodies exhibit direct and indirect 
mechanisms to mediate the destruction and clearance of invading microorganisms. (i) Direct 
binding and neutralization prevents the infection of the cell by pathogens. (ii) CDC induces the 
formation of the MAC and leads to the lysis of bacteria. (iii) Opsonization and phagocytosis induces 
the ingestion of a microorganism covered with specific opsonins on its surface (antibodies and 
complement factors) by an activated phagocytic cell. (iv) ADCC occurs when the Fc part of an 
antibody is bound by Fc receptors on an effector cell, which induces the lysis of a pathogen48. ...... 8 
 
Figure 4 Purification of blood components by centrifugation of whole blood. Due to their different 
gravities, plasma, white blood cells and platelets as well as RBCs can be separated after 
centrifugation of whole blood. In comparison to plasma, serum is devoid of fibrinogens as well as 
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Figure 5 Overview of the CH50 test. Sheep RBCs coated with anti-sheep RBC antibodies are incubated 
with the diluted serum or plasma samples at 37 °C. The classical pathway is triggered by binding of 
C1q to the anti-sheep RBC antibodies and the generation of the MAC leads to the lysis of the target 
cells in samples with active complement. After measuring free hemoglobin in the supernatant, the 
dilution of the sample to obtain 50% lysis of the sheep RBCs is calculated. .................................. 26 
 
Figure 6 Detection of remaining C3b or C4b after trimodulin addition. A 96 well flat (F) bottom plate is 
coated with aggregated IgG and incubated overnight at 2-8 °C. After washing, different dilutions of 
trimodulin and Intratect (used as IVIg control) are mixed with EDTA-plasma, distributed to the wells 
and the residual opsonins are detected with a goat anti-rabbit antibody, conjugated to a HRP. The 
ELISA was adjusted to the protocol described by Rieben et al. 99. ................................................. 27 
 
Figure 7 Detection of C5a bound to trimodulin. A 96 well F-bottom plate was coated with different 
dilutions of trimodulin in carbonate bicarbonate buffer, blocked with BSA and incubated with 350 
ng/mL purified C5a. After washing with TBS-T, bound C5a was detected with a primary rabbit anti-
human C5a antibody and a secondary goat anti-rabbit antibody, conjugated to HRP. .................. 29 
 
Figure 8 Schematic overview of the anaphylatoxin ELISA, using a zymosan-coated microplate. A 96 well 
F-bottom plate was coated with 20 µg/mL zymosan in carbonate bicarbonate buffer (plate 1). EDTA-
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plasma was incubated on plate 1 to activate the complement system and generate the 
anaphylatoxins. The activated supernatant was transferred to a second plate coated with an anti-
human IgG+IgA+IgM antibody and mixed with different dilutions of trimodulin or Intratect (plate 
2). After that, an anti-human C3a or C5a coated plate of a C3a or C5a ELISA kit was used to detect 
the unbound anaphylatoxins with specific antibodies (plate 3) in a spectralphotometer. ............. 30 
 
Figure 9 Schematic overview of a CDC assay. (a) Ramos cells that express CD20 on their surface can be 
used as target cells in the CDC assay. (b) The chimeric monoclonal antibody Rituximab binds CD20 
and the subsequent incubation with normal human serum (NHS) leads to the activation of the 
complement cascade by binding of C1q to the Fc domain of Rituximab. This triggers the formation 
of the MAC, which forms pores into the membrane and causes the lysis of the Ramos cells. (c) By 
the addition of trimodulin, activated complement components could be inhibited, leading to a 
reduced complement deposition and cell lysis. ............................................................................ 31 
 
Figure 10 Trimodulin inhibits the detection of C3b concentration-dependently. (a) A 96 well F bottom 
plate was coated with 0.1 µg/mL aggregated IgG (Intratect). After washing with TBS-T washing 
buffer, different dilutions of three batches trimodulin (blue) and Intratect (green; used as IVIg 
control) were distributed to the plate and mixed with 100-fold pre-diluted EDTA-plasma. After 
incubation for 1 h at 37 °C, an anti-human C3c antibody that is able to detect C3b and iC3b as well 
as a secondary goat anti-rabbit antibody (conjugated to HRP) were added. Finally, the plate was 
measured in an ELISA reader. Error bars indicate the standard error of the mean (SEM). Data 
represent results from six independent experiments performed in duplicates. (b) The highest used 
trimodulin and Intratect concentrations were compared with each other as well as with FB only 
(without (w/o) the products). Error bars indicate the SEM. Data represent results from six 
independent experiments performed in duplicates. The statistical analyses were performed using a 
Kruskal-Wallis test. Significance is shown as p-value: * p ≤ 0.05 and **** p ≤ 0.0001. ................ 42 
 
Figure 11 Trimodulin inhibits the detection of C4b concentration-dependently. (a) A 96 well F bottom 
plate was coated with 0.1 µg/mL aggregated IgG (Intratect). After washing with TBS-T washing 
buffer, different dilutions of three batches trimodulin (blue) and Intratect (green; used as IVIg 
control) were distributed to the plate and were mixed with 100-fold pre-diluted EDTA-plasma. After 
incubation for 1 h at 37 °C, an anti-human C4c antibody that is able to detect C4b and iC4b as well 
as a secondary goat anti-rabbit antibody (conjugated to HRP) were added. Finally, the plate was 
measured in an ELISA reader. Error bars indicate the standard error of the mean (SEM). Data 
represent results from six independent experiments performed in duplicates. (b) The highest used 
trimodulin and Intratect concentrations were compared with each other as well as with FB only 
(without (w/o) the products). Error bars indicate the SEM. Data represent results from six 
independent experiments performed in duplicates. The statistical analyses were performed using a 
Kruskal-Wallis test. Significance is shown as p-value: **** p ≤ 0.0001. ....................................... 43 
 
Figure 12 Analysis of the IgM-C3b interaction using a fluid phase ELISA. The supernatant of the opsonin 
ELISA (see chapter 4.4.1) was transferred to a second plate coated with an anti-human C3c antibody 
and the binding of IgM to C3b was detected with a primary mouse anti-human IgM antibody and a 
secondary rabbit anti-mouse IgG antibody conjugated to HRP. In order to exclude unspecific binding 
of trimodulin (B588036) to the anti-C3c coating, trimodulin was incubated with GVB++ instead of 
EDTA-plasma. After incubation of the plate for 1 h at 37 °C and the addition of the specific 
antibodies, the plate was measured in an ELISA reader. Error bars indicate the SEM. Data represents 
results from three independent experiments performed in duplicates. ......................................... 44 
 
Figure 13 SDS-PAGE and Western blot of the opsonin ELISA supernatant. An opsonin ELISA was 
performed as described in 4.4.1 and the supernatant was used for a subsequent SDS-PAGE and 
Western Blot analysis. As molecular weight (MW) marker the All Blue Prestained Protein Standard 
was added to lane 1 and 12. Lane 2 contained the negative control for C3b detection (12.5 mg/mL 
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trimodulin + GVB++). The positive controls for C3b detection (EDTA-plasma + GVB++ as well as 
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Figure 14 Results of the anaphylatoxin ELISA using a trimodulin-coated plate. A 96 well F bottom plate 
was coated with 100 µL serially diluted trimodulin (B588036) and was incubated overnight at 2-8 
°C. Carbonate bicarbonate buffer served as control for the specific binding of C5a to trimodulin. 
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used as control for the unspecific binding of the primary anti-C5a antibody to trimodulin. The plate 
was incubated for 1 h at 37 °C, washed and after addition of the primary as well as secondary goat 
antibodies measured in an ELISA reader. Error bars indicate the SD. Data represent results from two 
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was coated with zymosan and another 96 well F bottom plate with an anti-human IgG/IgA/IgM 
antibody mix in carbonate bicarbonate buffer and incubated overnight at 2-8 °C. After washing, 
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specific anti-human C5a antibody (b) and measured in an ELISA reader at 450/690 nm. Error bars 
indicate the SEM. Data represent results from three independent experiments performed in 
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Figure 16 CD20 expression on human Ramos cells. (a) Ramos cells (5∙106 cells/mL) were seeded to a 
V-bottom 96 well plate, diluted in assay buffer and stained with an anti-CD20 antibody and the 
appropriate isotype control. The expression of CD20 was measured in a flow cytometer. The filled 
grey area indicates the unstained Ramos cells, the dotted black line the isotype control and the red 
line the CD20 expression of the untreated cells. The data are representative for three independent 
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well as anti-CD20 antibody and measured in a flow cytometer. Error bars indicate the SD. Data 
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(b) Intratect was pre-incubated with NHS and mixed with 20 µg/mL Rituximab as well as 50 µL 
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by PI staining in a flow cytometer. Error bars indicate the SD. Data represent results from three 
independent experiments performed in duplicates. Statistical analyses were performed using a one-
way ANOVA and a Bonferroni test. Significance is shown as p-value: ** p ≤ 0.01. See Table 22 and 
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Figure 22 Phenotype characterization of differentiated HL-60 cells. After differentiation, HL-60 cells 
were incubated with anti-CD16, anti-CD32, anti-CD64, anti-CD11b, anti-CD35 and anti-CD71 
antibodies. As control, undifferentiated cells were used and the specific isotype controls were added 
to the wells. The expression of the surface receptors was measured in a flow cytometer. The filled 
grey area indicates the unstained HL-60 cells, the dotted black line the particular isotype control 
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Figure 23 Titration of IgG/IgM depleted serum for use in the OPA. Initially, OB was prepared and 20 µL 
transferred to the appropriate wells of a 96 well U-bottom plate. 3 µL of trimodulin FB was added 
to the wells. Differentiated as well as undifferentiated HL-60 cells were counted and resuspended 
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incubation, 50 µL of the HL-60 cell and NHS minus mix was distributed to the 96 well plate and 
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